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ABSTRACT 
THE ROLE OF PTSD AND SHAME 
IN METHADONE TREATMENT 
MAY 1999 
LEE PADDY, B.A., MIDDLEBURY COLLEGE 
M.A., LESLEY COLLEGE 
ED.D., UNIVERSITY OF MASSACHUSETTS, AMHERST 
Directed by: Professor John W. Wideman 
The purpose of this dissertation is to examine the role internalized shame 
and Post Traumatic Stress Disorder (PTSD) play in the treatment outcomes of 
people in methadone programs. Clients at two methadone treatment sites were 
surveyed with Cook’s Shame Scale and the MMPI PK and PS sub-scales for 
PTSD. Over 63%-ten times that found in the general population and two and a 
half times the frequency found in other chemically dependent populations— 
tested for PTSD, which is often passed over as a generalized anxiety disorder. 
The study showed that the symptoms of PTSD, internalized shame and low self¬ 
esteem are highly intercorrelated in this population. The study also showed that 
there is a strong relationship between PTSD test scores, methadone dose 
levels, and the frequency of drug use. P values of <.001 between internalized 
shame and PTSD scores suggest a relationship exists between shame in the 
context of PTSD and the frequency of drug use. 
VI. 
Secondary findings suggest that there is a correlation between sexual 
abuse, age of first drug use, shame and PTSD scores. Internalized shame, 
PTSD PS Scale scores and race also showed some trends. These findings, 
along with research on the biochemical effects of not only chemical dependency, 
but also of trauma and internalized shame support the understanding that PTSD 
and internalized shame do play a role in affecting treatment outcomes. 
Research in related fields describe biochemical feedback loops created 
by responses to trauma and the biochemistry of chemical dependency. These 
feedback loops are perpetuated and exacerbated by continued drug use and 
untreated trauma symptomology. The resultant biochemical deficiencies can be 
stabilized and replenished through time when direct interventions are made on 
the physical, behavioral and emotional levels of treatment. Methadone, while 
helping to decrease the use of heroin, may actually contribute to furthering the 
progression of chemical dependency and block treatment of PTSD by covering 
symptoms which when addressed could lessen or resolve and improve treatment 
outcomes. 
Further studies, which find ways to examine and measure these different 
aspects of trauma, internalized shame and PTSD need to be designed to 
understand more clearly how these conditions affect various outcome variables. 
A variety of therapeutic modalities which focus on overall wellness and recovery 
can be used and tested to design comprehensive treatment. Hopefully, this 
study will begin to build a bridge between conventional methadone treatment - 
which uses behavioral modification and drug replacement therapies - with the 
exciting new findings in neurobiochemistry. 
VII. 
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CHAPTER I 
INTRODUCTION 
According to the 1998 National Triennial Report (Leland, 1998), there are 
over 600,000 people addicted to heroin in this country. This report states that 
the heroin industry, a $7 billion-plus retail market in the United States, is offering 
a more powerful, cheaper and safer product due to the doubling in global 
production over the past year. By rough government estimates, U.S. heroin 
consumption has doubled since the mid-‘80s to about 10 to 15 metric tons per 
year. The amount of crime and disease related to heroin use is high. Over the 
past two and a half decades, methadone clinics have been set up and run by 
state and federal funding as a primary means of addressing the problem and 
treating this polysubstance dependent population. 
Individuals who have not been able to cut down or stop their drug use on 
their own come to a clinic addicted to heroin and other street drugs. Addicts are 
given a methadone, an alternative opiate, which can be controlled. Clients are 
then expected to attend therapy and support groups to help them make changes 
in their lives and behaviors. Urine samples are screened randomly to monitor 
the use of heroin and other street drugs. The methadone doses are determined 
by whether or not clients are using street drugs and by their success in making 
prescribed changes in their lives. In many cases, when lifestyle and therapeutic 
changes are made, the addicted persons should eventually be weaned off of 
methadone. 
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In the meantime, maintenance reduces the use of needles and the risk of 
spreading disease, while also reducing crime related to heroin trafficking. An 
individual is allowed to stay on methadone provided he or she stops his/her use 
of heroin and eventually stops using all street drugs. The next step is to wean 
off of methadone, However, in actuality, only a small percentage of clients, 
approximately ten percent, are able to stop street drug use and are weaned off 
of methadone (Joe, G. W., 1994). What accounts for this low percentage? 
Staff members at a local methadone clinic which was used as the 
research site in this study describe three distinguishable groups of client 
participation at the clinic: 1) those who come to the clinic and stop or decrease 
their use of heroin, but continue to use street drugs and don’t make significant 
life changes; 2) those who are able to stop heroin use and street drugs, make 
some life changes, but are not able to get off methadone; and 3) those who are 
able, through time, to successfully get off all drugs, including methadone, after 
making necessary life changes. 
Since all of the clients receive the same treatment, several questions 
arise. Why are some clients able to stop their street drug use and make life 
changes while others do not? What factors contribute to the success or failure 
of progress in treatment? Treatment for this population continues to pose a 
challenge to the mental health profession. To prepare for this research project 
literature was surveyed to determine which factors might account for some of the 
differences in response to methadone treatment. 
Factors that Effect Treatment Outcomes 
A review of the literature presents divergent thought within the fields of 
psychology, chemical depenency, methadone treatment and trauma recovery 
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concerning symptoms and diagnosis in the methadone population. As a means 
of exploring factors that significantly effect treatment outcomes, the literature 
review focuses on studies which include an examination of other mental health 
diagnoses and their associated symptoms. Interestingly, these varied schools of 
thought use the same symptoms to determine an array of different diagnoses. In 
general, different diagnoses require different approaches to treatment. 
Many of the studies reviewed cite depression and character disorders 
such as Borderline, Narcissistic and Antisocial Personality Disorders as 
significant factors correlating with chemical dependency. Other studies show 
that the majority of people who suffer from chemical dependency are also 
survivors of childhood trauma, battering, and the trauma inherent in the heroin 
drug use lifestyle. As a result, clients often meet the criteria for a Post Traumatic 
Stress diagnosis (PTSD). Several studies establish comorbidity with PTSD and 
chemical dependency within the methadone population. 
Though a trauma survivor's condition has a course of progression as well 
as a recognized course of healing, various studies show that only a small 
percent of methadone clients are treated specifically for post traumatic stress. It 
is this researcher’s belief that this condition affects the progression of treatment. 
Untreated PTSD, and many of its debilitating symptoms could account for the 
low percentage of people who are not able to successfully wean off methadone. 
Another trend in the research studies shows that the majority of 
individuals who are diagnosed with Borderline Personality Disorder are survivors 
of emotional, physical and/or sexual abuse and profound neglect in childhood. 
There appear to be several ways to assess the effects of childhood abuse. Chil¬ 
dren often experience neglect and abuse when growing up with one or more 
chemically dependent parents. In addition, if such a child begins to drink or 
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uses other substances as an adolescent, the effects of addictive substances and 
dependency biochemically create many of the symptoms and behaviors which 
are associated with character disorders and PTSD. Therefore, when clients 
present themselves as survivors of physical and sexual abuse and are 
chemically dependent, the symptoms of both conditions often mask, parallel, and 
mirror one another. Clarification around these varied diagnoses and shared 
symptoms will facilitate a difference in treatment and treatment planning. 
For example, anxiety is a major feature of both chemical dependency and 
PTSD and can be difficult to distinguish. In treatment, when a client reports 
experiencing increased anxiety, it may be a result of the change in body 
chemistry as the client goes through withdrawal. A newly abstinent client is no 
longer armored by denial and has not yet developed healthy coping skills to 
manage his or her new emotionally raw and vulnerable state without the 
chemicals. This state can be anxiety producing. Even after detoxification, it can 
take months and even years to replenish and stabilize brain chemistry. 
Deficiencies in the adrenal and opiate system can also contribute to anxiety. 
Facing unresolved feelings and issues without defenses alone is anxiety 
provoking. Facing issues with deficient neurochemistry and skills can be 
overwhelming. 
In addition, in the recovery process for chemical dependency, the body 
goes through heightened emotional and physical stresses at expected intervals. 
The symptom of anxiety is one of the ways the disease seemingly pushes the 
client and creates a need to pick up his or her drug of choice to allay the 
distress, client’s body craving the chemical he or she is no longer consuming. 
Anxiety often both signals the beginning of relapse and actually both signals and 
increases the risk of a client relapsing into drug use. At this point, the anxiety 
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needs to be addressed as a symptom in a relapse cycle. Once the client 
recognizes anxiety symptom in this context, he or she can address it by in¬ 
creasing the rigor of his/her recovery program, thus, breaking the relapse 
pattern. 
At the same time, anxiety may signal the emergence of trauma material as 
a result of the client no longer numbing or medicating the memory, feeling or 
pain of past trauma. Addressing the memory or feeling directly can reduce the 
anxiety. Naming its source can also change an individual’s options around 
managing the anxiety. In addition, the symptom won’t be mistaken for the 
anxiety associated with relapsing. The individuals can learn to manage their 
feelings and memories instead of responding to their ill ease with alcohol or 
other chemical substances and compulsions. Anxiety which is the result of 
surfacing material needs to be handled differently from anxiety which needs to 
be addressed as a signal of relapse. Identifying and working with these 
conditions and distinguishing between them could change treatment protocol 
and treatment outcomes at methadone clinics. Diagnosis as a major tenet of 
treatment directly effects expected outcomes. 
Shame is shown to be another notably central experience in both 
chemical dependency and the posttraumatic stress syndrome (PTSD). In this 
study the use of the word shame, or the phrases toxic or internalized shame 
refer to chronic shame, which will be measured and discussed in this study. The 
literature supports the finding that toxic shame in the methadone population is 
prevalent. Literature also supports the need to further study the impact that 
trauma and internalized shame have on clients and treatment. 
Two authors, whose work will be covered in the literature review, have 
helped to clarify how internalized shame is a central experience. In his work on 
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shame and affect theory, Donald Nathanson challenges the use of Borderline, 
Narcissistic, Antisocial and other drive theory diagnoses. He invites 
practitioners to re-examine the basic premises of drive theory, noting that drive 
theory is not consistent with physiology and current research findings in 
neurobiology. Nathanson demonstrates how toxic shame, as a powerful primary 
affect drives experience and expression and plays a key role in reframing and 
understanding progress and impasse in therapy. 
Bessel Van der Kolk's work on trauma shows how the effects of trauma, 
its neurobiochemistry and the resulting symptoms support the premises of affect 
theory but do not support the premises of drive theory.illustrate this Van der 
Kolk’s work points to a discrepancy between drive theory and physiology. His 
work also clarifies how internalized shame, as a major component of both PTSD 
and chemical dependency and PTSD thus becomes another important factor to 
consider in reviewing success rates in methadone programs. 
While literature on chemical dependency cites toxic shame as one of its 
basic tenets (Hazelton, 1986), and chronic shame is referred to in much of the 
literature on trauma and recovery (Herman, 1992; Gelinas, 1983; and Miller, 
1994), the interplay between these two conditions of chemical dependency and 
PTSD and their shared feature of shame factors was not found in the literature. 
While the factors of internalized shame and PTSD are cited in several studies no 
quantitative research has been done to look at the interplay of these variables 
and treatment outcomes. It is the experience of this researcher that the factors 
of internalized shame and PTSD play a major role in treatment. In my own 
practice, this researched has observed that these factors seem to effect the 
clients’ abilities to manage affect, make changes and stay drug free. The 
question of whether or not PTSD and internalized shame play a specific role in 
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treatment outcomes of methadone clients is explored in this study by looking for 
possible correlations among these variables. 
Hypothesis 
It is this authors’ hypothesis that posttraumatic stress symptoms and 
symptoms of internalized shame will correlate with one another and that these 
factors will correlate with levels of participation and outcomes in treatment. 
Internalized shame has been described as a self-annihilating and debilitating 
experience. It is understood as the core experience behind chemical 
dependency and other compulsions. It most likely plays a role in treatment. In 
addition, because the likelihood of trauma is so prevalent in chemically 
dependent populations, either as a result of experiences on the street or in 
childhood, this researcher believes that if it remains untreated it will impact on 
the client’s ability to succeed. In the subsequent chapters a more involved 
presentation of the literature, the methodology, results and discussion follows. 
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CHAPTER II 
LITERATURE REVIEW 
In the first section on methadone treatment, a. brief history of the goals 
and efficacy of methadone treatment is presented., Section two reviews studies 
that attempt to establish a single profile description of a heroin addict. These 
sketches are followed by research and theories in psychology that describe the 
addict as a character disordered person. In the next section, research that 
offers an alternative diagnosis of post-traumatic stress disorder is presented., 
Symptoms which are used to substantiate psychopathology in the addict are 
reframed in the context of chemical dependency and trauma theory as 
understandable and treatable symptoms and behaviors. 
In section four, studies on the prevalence of PTSD in chemically 
dependent populations are presented to establish comorbidity. Section five 
expands upon the idea of comorbidity and looks at multiple diagnoses and the 
importance of recognizing internalized shame as a conditions that need to be 
addressed in treatment. A presentation of the underlying neurochemistry of 
trauma is given in section six, along with a review of affect theory and the impact 
of internalized shame on the methadone population. These presentations 
support the hypothesis that there are several interdependent factors that play a 
role in the experience of individuals who come into methadone treatment. 
Together, an understanding of these perspectives form the theoretical 
foundation for this study. 
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Methadone Treatment 
Methadone Maintenance Treatment has survived many years of criticism 
and change as a result of philosophical and ideological controversy in the fields 
of chemical dependency treatment, behavioral science, disease control and 
systems work. Nevertheless, methadone has recently gained favor by 
demonstrating its effectiveness in reducing the spread of acquired immune 
deficiency syndrome and reducing crime. The various program structures and 
significant difference in outcomes, however, continue to feed the ongoing 
controversy. 
Several researchers, (Strain, Stitzer, Liebson, & Bigelow, 1993), found 
that methadone clients who participate on a consistent basis show improvement 
in pro-social behaviors and a decrease in drug use. Symptoms of depression 
and anxiety are also found to decrease within weeks of starting methadone 
treatment. 
There are many clients who continue to use methadone, but only 
intermittently while maintaining street drug addictions. Numerous others 
withdraw from methadone maintenance programs altogether and deteriorate as 
the progression of their chemical dependency continues without interruption. In 
a 12-year follow-up study on 181 methadone maintenance treatment clients, 
Marsh, Joe, Simpson, and Lehman (1990) reported that there was less than a 
50% probability of clients remaining abstinent for three years, even under the 
best conditions. In a major study by Hubbard, Marsden, Rachal, Harwood, 
Cavanaugh and Ginzburg (1983), which included 2,660 addicts it was noted that 
15% of clients leave treatment within a year and almost all of the clients who left 
the program relapsed., except for those who transferred. 
9 
In view of these diverse outcomes, it becomes important to study what 
factors contribute to the success and failure of methadone treatment response. 
Hubbard et al.(1983), in their study, known as the Treatment Outcome 
Prospective Study (TOPS), noted that length of time in treatment was the most 
important predictor of correlated with improvement, which was measured by the 
decreased use of street drugs. Severity of previous drug use, measured by 
length of use and the amount, the class of drugs and the frequency of their use 
did not affect outcomes in treatment. However, while those who did not continue 
to drink improved at higher rates than those who continued to use alcohol or 
marijuana during treatment.were addicted to several substances did affect 
outcome. McLellan (1983) notes that while many studies have looked at 
diagnoses and personality profiles, they fail to show any consistent results. 
Studies have however, shown correlations between some environmental factors. 
Marital status, age, income and employment, correlate with better 
outcomes, length of drug abuse history and amount of drug use affect methadone 
treatment outcome. McLellan (1983) notes that while many studies have looked 
at diagnoses and personality profiles, they fail to show any consistent results. 
In addition, another study by NIDA studies showed that different therapies 
and services offered as a part of treatment affect outcomes. Woody (1983) 
surveyed NIDA studies and found that subjects receiving psychotherapy have 
better retention and improved performance over those who receive only 
standard clinic counseling. Standard counseling in most programs focuses on 
external issues such as behaviors as opposed to internal or intrapsychic 
processes. Those who had frequent therapy had better outcomes. In Hall's 
review of NIDA studies (1983), while looking for treatment factors he found that 
psychodynamic and cognitive therapies improved retention and rates of progress 
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while other forms of therapy did not. These reviews offer some information 
about variables and their effects on outcomes. Other studies note that there is a 
reduction in the intensity of symptoms of depression, anxiety and psychotic 
behaviors when methadone or other medications are administered in treatment. 
However, there has been no research done on how the direct treatment of PTSD 
in therapy might affect treatment outcomes in the methadone population. 
Much of the research available is around these different focuses on 
program design rather than the effects of specific therapies. While long term 
methadone maintenance has the goal of decreasing harm and the shorter term 
programs which focus on abstinence and rehabilitation (Caplehom and Batey, 
1992). Comments by Dutch author Reuter (1994) suggest that there may be a 
trade-off between treatment access and efficacy. "Patients may become stuck at 
the low threshold level, where they receive services that improve their quality of 
life but do not have to make the major behavioral changes required by more 
rehabilitative regimes." 
Although outcome statistics are not available in these studies, that review 
outcome factors, the studies show that various kinds of treatment affect 
outcomes differently. These two approaches of long and short term care 
represent two opposing arguments in the debate on methadone treatment: Is it 
better to maintain clients long term on methadone, medicate their symptoms and 
improve their quality of life by getting them away from heroin and crime? Or 
does methadone perpetuate the disease of chemical dependency by substituting 
one drug for another and thus prohibit intrapsychic healing by suppressing 
traumatic material? Or are there irreversible brain chemistry deficiencies, as 
Zweben and others would argue that need to be medicated and methadone 
offers that long term solution? Or does the methadone so suppress opiate 
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production that the brain cannot repair? The answers may lie somewhere in the 
middle. One purpose of this study is to explore the continuum of outcomes and 
how they are affected by co-existing conditions. This study also reviews 
research which explains neurochemistry and how it is affected by chemical 
dependency and trauma. 
An Addiction Profile 
In the 1970’s and early 1980’s there was an effort to “discover” the 
“addictive personality”. Research focused on identifying character traits and 
personal histories that contribute to a sketch or profile of heroin addicts. For 
example, Bailey, Sheri, Hsieh and Smith <1994) divided their narcotics 
population of 354 into four groupings; winners, striving addicts, enduring addicts, 
and those who were incarcerated. In their follow up study after twenty four years 
they found that members of the first group referred to as the ‘winner’ had 
generally negative familial experiences, higher rates of sexual molestation, and 
that they were least happy in childhood. In the second group, ‘the strivers’, were 
characterized by their usually tea-totalling church-going parents. In the third 
group, the ‘enduring’ addicts were mostly from lower socioeconomic families, 
commonly accessed methadone treatment and avoided incarceration while 
persisting in narcotic addiction and crime. The fourth group of addicts were 
incarcerated and described as having the most parental caring along with the 
most severe punishment. Many studies similar to this provide information, but 
do not give more insight into intrapsychic dynamics or symptoms and possible 
correlations between these dynamics and rates of recovery. 
Another attempt to obtain a profile on the heroin addict maintained on 
methadone involved a study where 458 subjects were given the Symptoms 
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Checklist Scale (Drake, Swift and Hall, 1994). Skinner's Modal Profile Analysis 
was utilized to review variants in the four determined categories of paranoid, 
somatic, hostile and anxious-depressed. The subjects' scores on the Symptoms 
Checklist were high in all of these mentioned areas. The authors of this study 
provide help in understanding affect, but no correlation to outcome is provided. 
Research that attempts to define the characteristics of an addicted person 
is so varied that it makes it difficult to find a single profile of a successful or 
non-successful client. Other composite studies (Attia, 1989; Mulinski, 1989; 
Kaufman, 1989, Zweben, 1991, 1997; Blume, 1993), Joe, Simpson, Hubbard 
(1991), Woody, McLellan, Luborsky, O'Brien (1990, 1988) which look at 
comorbid or secondary diagnoses, cite symptoms of major depression, 
somatization, psychotic symptoms, posttraumatic stress symptoms and character 
disorders as prominent features in the methadone community. To get a better 
understanding of these symptoms it is helpful to look at how the disciplines of 
psychoanalysis, chemical dependency, trauma and neurobiology view these 
symptoms. It is important to understand how these varied disciplines use these 
symptoms to formulate varied diagnoses and treatment considerations. 
Psychopathology and the Addict 
Psychoanalysis adopts the view that substance abuse disorders and their 
neuropsychological correlates cannot be easily separated from personality and 
psychopathology variables (Millet, 1990). Early psychoanalytic formulations 
equate opiate use with unfulfilled or pathological drive states. These states are 
related to sex and aggression, an inability to cope with pervasive negative 
emotions including depression and anxiety, basic ego and superego 
deficiencies, and general immaturity or childhood fixations (Sutker and Archer, 
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1984). Miller and Glover (1932, 1956) hypothesized that drug addiction was a 
defense against sadistic or aggressive impulses and was used by prepsychotic 
people. Fenichel (1945) thought that addicts were passive, narcissistic 
individuals who used drugs to satisfy oral fixations. 
Khantzian (1990) a proponent of affect regulation as the central issue in 
addictions, writes that addicts seek relief more than they seek euphoria. In his 
work with heroin addicts and the methadone population, he focuses on heroin 
addicts' lifelong difficulties with feelings and impulses associated with 
aggression and the dysphoric feelings associated with anger, rage, and 
restlessness which are temporarily relieved by heroin and other opiates. He 
proposes that methadone works due to its sustained use over time and the 
reported relief it offers from angry and dysphoric feelings. Khantzian explains 
addicts' erratic behaviors as rageful outbursts of rage and defiance, isolation 
and self-reliance, passivity and despair as defenses used to cover dependency 
needs. He notes that addicts' lifelong struggles with rage and aggression most 
often date back to environmental influences, such as family, where they were 
subject to physical and emotional abuse, brutality, violence and neglect. 
Khantzian supports the idea that opiates offer relief from the dysphoria 
associated with anger, rage, and related restlessness. Opiates seem to calm, 
relax and soothe drug users when they become agitated. The opiates seem to 
counteract the 'regressed', disorganized and dysphoric ego states, helping 
addicts to feel and become temporarily more integrated and able to cope with 
life. This equilibrium, however, is usually precarious due to clients’ the lack of 
skills and self-structures present to cope with painful feelings associated with 
rage and aggression. 
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Krystal and Kemberg (1992) also recognize that addicts have difficulty 
managing their affect. They believe that this difficulty stems from a 
developmental deficit, focus on the addict’s difficulty with affect stemming from 
an undeveloped deficit which is the result of inadequate parenting. According to 
the theory, known as object relations, any disruption in a relationship; with a 
parent or caregiver may create this deficit. Neglect, and physical, verbal and 
sexual abuses create a disconnection in development. The difficulty in affect 
regulation stems from this disruption in relationship, which is known as object 
relations theory. A child struggling to be responded to or one who gives up and 
withdraws, does not learn how to negotiate successful relationships. Blocked or 
dismissed, emotions that could be used for successful relating, become 
thwarted. The child’s experiences of distress, despair, fear and rage become 
intolerable. Often these children and adults are not able to identify their 
feelings, because feelings are painful or repressed. 
If the child lives in an environment where there is abuse and threats, 
feelings are over ridden by the child's automatic fight or flight response. 
Individuals are not able to identify their feelings when they are lumped into a 
stress response. Kemberg states that the rage and aggression which are often 
observed in people who are addicted to substances actually embodies the fear 
of returning to the experience or feelings of the original trauma. This fear, rage 
and aggression are most prominent in relationships. The person who grows up 
with these deficits in their experiences often finds people who continue to treat 
them in ways similar to their parent and/or they project onto people who are 
close to them, unable to distinguish between their inner and outer experiences. 
Kemberg describes addicts as “a specie of borderline with ambivalence about 
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relationships". Addictive substances are used to modify and manage these 
experiences and deficits. 
In addition to developmental/environmental factors, psychodynamic 
theory looks at several intrapsychic and relational dynamics which predispose 
individuals for chemically dependency. A predisposition to drug dependency 
may include problems with intimacy as a result of 'narcissistic wounding'. As a 
result of this type of wound the individual often fears involving one's own 
aggression in relationships with others. This fear is amplified by an intolerance 
of rejection or disappointment in relationships. Chemical substances are used 
then to manage anger and closeness. 
The wounded individual experiences other issues around intimacy, which 
include an inability to turn to others for comfort or to find comfort in others. 
Issues around competition, achievement, autonomy and especially issues 
around the maintenance of self-esteem. These features are examples of 
narcissistic disturbances that predispose individuals to drug addiction, according 
to psychodynamic theory. 
McLellan (1983), notes that while many studies have looked at diagnoses 
and personality profiles, they fail to show any consistent results. Other fields of 
study view these same characteristics and behaviors not as character disorders, 
but as understandable and treatable outcomes of physical and sexual abuse and 
neglect. 
Gender differences may also play a significant role in the understanding 
of these variables and constructs. Though anger and aggression are prominent 
in both genders in the methadone population, women reportedly experience 
more suicidal and self-abusive behaviors while men act outwardly. In trauma 
literature, aggression is one of the prominent characteristics in male survivors of 
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abuse. These descriptions and behaviors can also be explained in part by Van 
der Kolk's work (1992) on the biochemical effects of trauma and are reviewed in 
a later following section. 
In this section, some degree of trauma is a component of the theories and 
diagnoses presented to describe people who are predisposed to chemical 
dependency. The following section combines the information we have about 
methadone treatment programs with information about co-existing diagnoses to 
establish the comorbidity of PTSD in the methadone population. 
Comorbiditv 
Much research has been done to substantiate the prevalence of PTSD in 
substance abusing populations (Triffleman, Marmar, Delucchi, Ronfeldt, 1993; 
Saxe, Van-der-Kolk, Berkowitz, 1993; Brown and Wolfe, 1994). In one study by 
Dansky (1996), a quarter of the sample of 48 male and 36 females interviewed 
had significant PTSD comorbidity and correspondingly high rates of inpatient 
substance abuse treatment (Dansky, 1996). In another study, 77% of male 
veteran substance abuse inpatients had been exposed to severe childhood 
trauma disorder and 58% had lifetime PTSD (Helzer, 1988). To make this more 
specific to the opioid treatment community, research done by Wilson (1993) on 
one hundred patients being admitted for trauma treatment, 100% of the patients 
reported polysubstance use. Ninety four percent of these polysubstance 
abusers were using alcohol, cocaine and opiates as their drugs of choice. 
Hien and Levin (1994) demonstrated that both childhood and adult abuse 
correlates with depression and polysubstance abuse. Findings from their pilot 
study describe a high prevalence of trauma and PTSD in methadone patients. A 
lifetime history of PTSD, in addition to a concurrent depression, was uncovered 
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for 80% of the women and 63% of the men. The presence of depression in Hien 
and Levin's sample can be explained by the body's stress response to repeated 
abuse in childhood and a repeated stress response in adulthood. This can also 
be explained by the fact that chemical dependency affects brain chemistry and 
creates a deficiency of the neurotransmitters serotonin and dopamine, two 
substances which can create a biochemical depression (Genazzani, 1982). 
Brady, Killeen, Saladin and Dansky, (1994), explored the relationship between 
posttraumatic stress disorder and substance abuse. Thirty subjects with twenty- 
five controls showed that women with PTSD were more likely to have been 
victims of sexual and physical abuse, particularly childhood abuse. They had 
significantly higher scores on the Addiction Severity Index, were more likely to 
have comorbid affective disorders, and were less likely to comply with aftercare. 
In another study, the number of lifetime substance dependence disorders 
was strongly positively associated with childhood trauma exposure (Triffleman, 
Marmar, Delucchi, Ronfeldt, 1995). In addition, when subjects with PTSD were 
tested for quality of life status these researchers was found that subjects with 
PTSD had the worst functioning on all of the measures examined, except for 
those related to social life. 
Lifetime substance dependent individuals experienced higher rates of 
suicide attempts, psychiatric hospitalization, substance abuse, depression and 
dissociation (Warshaw, Fierman, Pratt and Hunt, 1993). It is surmised that 
untreated trauma related disorders and symptomatology may be a factor 
hindering treatment response and leads to treatment complications when 
unattended ((Hien and Levin, 1994; Bollerud, 1990;). Therefore, screening for 
trauma may have important prognostic and treatment implications. 
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Several articles present guidelines for addressing coexisting 
psychological disorders in the treatment of addicts (Zweben, 1991; 1991; Joe, 
Simpson, and Hubbard, 1991; Woody, McLellan, Luborsky, and O'Brien, 1990, 
1988; Nebelkopf, 1989; and Kleber, 1989). Maremmani, Zolesi, Agueci, and 
Castrogiovanni (1993) attempted to verify the impact of psychopathological 
symptoms on stabilization dosage during methadone maintenance treatment. 
Results indicated that higher methadone doses were necessary for those 
subjects who presented symptoms of somatization depression, phobic anxiety, 
paranoid ideation, psychoticism and aggression. Khantzian's work (1984) also 
supports the idea that sustained methadone treatment relieves many of the 
symptoms listed above. 
If these same symptoms are the result of childhood abuse and other 
traumas and can be treated by other means, increased dosages of methadone 
would be counter-productive (Herman, 1993; Gelinas, 1989; Miller, 1995). In 
turn, the same symptoms describe the experiences of addicts in the later stages 
of their disease progression. Increased medication may speed up the 
progression of the disease. Therefore, while some studies support the argument 
for higher doses of methadone to reduce symptoms, they may actually misguide 
the field of methadone treatment. 
If research in the fields of trauma and addictions present arguments for 
being able to treat these symptoms by other means, methadone treatment 
programs need to consider these perspectives. Various psychiatric symptoms 
have been noted to continue until three years after discontinuance of excessive 
doses of benzodiazepines, (Twerski, 1989). Many people in the methadone 
programs have a history of using benzodiazepines. 
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In another piece of research in the field of addictions, Wallace (1985), 
states that the function of the cells destroyed by alcohol are not taken over by 
neighboring cells until an individual has abstained from addictive substances for 
five years or more. Genazzani’s work (1982), cites two years as a time frame for 
replenishing and stabilizing brain chemistry once the use of addictive 
substances is stopped. In the methadone population, a high percentage clients 
have and continue to use alcohol and other substances. Perhaps this 
phenomenon needs to be addressed as well. What role is PTSD playing in 
clients continued use of substances? 
Presenting symptoms can be used to formulate and substantiate various 
mental health conditions and needs in treatment. Without thorough multiple 
diagnoses, a fragmented diagnosis can lead to a worsening of the patient’s 
condition. On the other hand, if symptoms can be treated in therapy in the 
context of PTSD and resolved, clients can find some relief from their 
excruciatingly painful inner lives. The importance of a comprehensive diagnosis 
cannot be emphasized enough, lack applicability because they look only at 
symptoms and do not consider ways in which these symptoms can be used to 
formulate and substantiate various mental health conditions and needs in 
treatment. In the following section an argument for multiple diagnoses is 
presented. 
Multiple Diagnoses in Methadone Clients 
According to the American Psychiatric Association (1994), clients who 
meet the criteria for chemical dependency and those who meet the criteria for 
PTSD also meet the diagnostic criteria for a number of other DSM-IV disorders. 
In a review of studies on comorbidity and PTSD, Keane and Wolfe (1990), 
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presented a study which revealed that clients diagnosed with PTSD averaged 
3.5 Axis I lifetime diagnoses with alcohol dependence (65%), social phobia 
(50%), drug dependence (40%), major depression (35%), and schizophrenia 
(35%). When examining the criteria for schizophrenia cited in the Diagnostic 
Interview Schedule more closely, behaviors include many of the same symptoms 
as those cited for PTSD. Symptoms of flashbacks, unusual smell, and auditory 
phenomena are symptoms which trauma survivors also report. Thus, it is 
essential to carefully evaluate these symptoms to determine which diagnosis 
and treatment protocol is appropriate for individuals in methadone treatment. 
Kendell (1991) describes the ideal diagnostic classification system as one 
in which all categories would be both mutually exclusive and jointly exhaustive. 
Unfortunately, this level of sophistication just does not exist. Matching 
symptoms with diagnostic criteria is only one level of diagnosing. In addition to 
meeting diagnostic criteria, clinical observations, histories, treatment responses 
and clinical course play a role in formulating a diagnosis and treatment plan. 
Cross-sectional versus longitudinal data gathering methods as well as variability 
in reporting by patients and observers does affect diagnostic outcome. 
Specifically in the case of methadone clients, the reporting of information is often 
skewed by drug affected memory. In addition, many behaviors and symptoms 
are a direct result of chemical abuse and progression. Therefore, careful and 
systematic comprehensive evaluations and diagnoses need to be a priority with 
methadone clients. The symptoms of chemical dependency, trauma, PTSD and 
internalized shame appear to parallel, mirror and mask one another so that 
careful diagnosis and facilitation are essential for appropriate and successful 
treatment. A look at current research in neurochemistry can help to explain why 
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the symptoms of these conditions look alike. They stem from similar 
neurochemical patterns. 
Neurochemistrv and Physiology in Diagnosis 
Research on the physiological effects of childhood abuses and neglect 
help to explain how various emotional responses and behaviors evolve. The 
research also helps in the understanding of coping behaviors and symptoms 
which characterize adults who are trauma survivors and/or chemically 
dependent. 
As early as Darwin in 1872 and Sartre’s writings in 1948, shame was 
described as both a cognitive incapacity and a paralyzing experience. Kardiner 
(1941) was the first to observe emotional constriction and limited range of 
expression in many people with PTSD. He notes that instead of responding with 
emotion, clients would respond physically to certain stimuli as if there were a 
continuing threat of annihilation. Struck by the physiological hyperactivity, 
Kardiner suggested that the autonomic nervous system of people with PTSD 
appears to keep them in a hyper alert reactive state, prepared for action. 
Field (1985) postulated that an unresponsive or abusive early 
environment could stimulate the emergence of hyper-arousal states that have 
long-term effects on the child’s ability to modulate anxiety and aggression. Van 
der Kolk (1987) shows how disruptions of attachment during infancy can lead to 
lasting neurobiological changes, which create the conditions and symptoms of a 
hyper-alert state. 
According to Van der Kolk, lack of parental response to separation 
typically results in a biphasic protest/despair response that may be correlated 
with hyperactivity or under activity of neurotransmitter systems. In humans, 
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damage related to protest might lead to panic attacks in adulthood, while 
excessive exposure to despair in infancy may give rise to cyclical depressions in 
adults. A lack of synchrony between mother and child may result in impaired 
modulation of physiological arousal. Disruptions of the attachment bond may 
cause extremes of under and over arousal, which can result in lasting 
psychobiological changes. Norepinephrine, dopamine, serotonin, and the 
endogenous opioid and endocrine systems are all involved in the protest/despair 
response. This suggests the potential for great complexity and variety in 
resulting clinical syndromes (Van der Kolk, 1987). 
Van der Kolk’s work (1987) on inescapable pain shows how the adrenal 
system becomes depleted and hypersensitive when children or adults are 
exposed to threats, violence, or sexual violation. Fear and anger trigger the 
production and release of adrenaline so that an individual can react quickly to 
danger. In response to the environmental trigger, the brain secretes opioids to 
soothe and calm the system the adrenaline stimulates. In order to cope with 
stress, autonomic stress reactions need to be adequate. However, where this 
mechanism has been disturbed by physical or sexual trauma, the system 
becomes suppressed or deficient, even depleted. Kardiner (1941), Krystal 
(1994), and Strian (1978) found that survivors of physical and sexual abuse 
continue to respond intensely to minor stress and stimuli in their daily lives. 
Fight or flight responses to daily events are characterized by hypervigilence, 
perhaps suspicion or paranoia when exaggerated, high anxiety, aggression, and 
fear. After exposure to severe and prolonged abuse, re-exposure to traumatic 
situations stimulate an endogenous opioid response (van der Kolk, 1987). 
However when opioids become deficient or depleted through time, the individual 
experiences difficulty calming down and modulating affect. 
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In addition to acting as anti-depressants opiates have properties that also 
tranquilize, thus reducing rage, aggression, paranoia and feelings of inadequacy 
(Vereby, 1978). If the body is depleted of opioids, symptoms of arousal will 
prevail while the individual experiences feeling a lack of control and difficulty 
modulating feelings. 
Opioids have historically been used in clinics to treat depression. People 
also self medicate with alcohol and other drugs to address their depressive 
symptoms. In the metabolic process of these addictive substances opiate-like 
substances are produced and serve temporarily to lessen symptoms of 
depression and anxiety. Van der Kolk found that naturally occurring opiates are 
also released by the body in response to physical pain, when there is strenuous 
exercise such as running a marathon or working out, or as part of compulsive 
activity, like gambling or taking physical risks. The desire or need to experience 
the opioid response helps to explain why survivors of trauma and addicts 
continue to be involved in risk taking, self-destructive, or compulsive behaviors 
which stimulate this 'needed' substance (Blaszczynski, 1984). In conventional 
diagnostic language, the individual would be described as self-abusive, 
compulsive, addictive or displaying borderline behaviors. 
Reversibility of resulting psychobiological damage is dependent upon the 
stage of development in which the trauma occurred, its severity and duration. In 
addition, individual coping strengths and personal supports in the environment 
contribute to a child’s ability to survive abuse and plays a role in the recovery or 
healing process in adult life. Therefore, diagnosing hyperactivity, depression, 
aggression, and difficulty with impulse control without understanding the context 
and nature of childhood trauma can have an effect on the outcome of treatment. 
Similarly, diagnosing symptoms of PTSD and chemical dependency without 
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understanding the nature and impact of childhood and accumulative trauma may 
jeopardize or fragment the treatment and in some cases prolong treatment 
(Miller, 1994). If these conditions are not understood or diagnosed there is also 
the risk that clients may drop out and not return to treatment. 
Internalized Shame and Trauma 
Since there are several ways to view symptoms and behaviors, being 
trained to discern it is important to be trained in discerning the distinctions 
between symptoms that stem from chemical dependency and those that 
represent expression of the experiences of trauma is important. A review of 
drive and affect theories along with recent understandings of how biochemistry 
and physiology are affected by trauma will help to explain how childhood 
experiences affect development. An understanding of how an individual’s affect 
and biochemistry are changed by trauma can help practitioners and clients to 
discern between symptoms that are the result of trauma and those that are a 
component of chemical dependency. 
In this section, Freud’s drive theory is reviewed as a basis of 
understanding leading psychologists, Kohut’s and Kemberg’s own variations on 
the sources of client difficulty with affect regulation. Nathanson, another 
psychologist, whose work is referred to in both chemical dependency and trauma 
research offers an alternative theory about affect, which challenges the precepts 
of drive theory. He refers to Wurmser, Lewis, and Tomkins”’ works to describe 
and establish the etiology of his theory on affect, which aligns with 
psychoanalysis and neurobiology. He then, expands upon this theory to explain 
how the affect of shame as an aspect of trauma, becomes a powerful debilitating 
aspect of self when it is internalized. Nathanson’s work establishes the basis of 
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this study’s inquiry into the existence of and the effects of trauma and 
internalized shame in the methadone population. 
Freud viewed trauma as anything that interferes with the normal 
sequence of maturation through psychosexual development. Affect theory views 
trauma as anything that produces negative effects of such density that it comes 
to have its own representation in memory and governs a whole series of internal 
scripts. This experience triggers affect and acts as a magnifier of the group of 
physical and emotional memories with which it becomes associated. 
Kemberg (1975) and Kohut's work elaborate Freud's assumption that 
drives and affects are mutually interconvertible. Kemberg (1990) extends this 
idea and suggests that during various phases of psychosexual development, 
drives are assembled like building blocks from affect. Excesses in any emotion 
are the result of drive energy being blocked and the original structures being 
misformed. 
According to drive theory, affect is modulated in the context of our 
interactions with others. Therefore, Kemberg traces any clinical problem 
involving affect to failures in object relations. Individuals who have insufficient 
relationships throughout their development, build defective pathways for the 
expression of various drives resulting in inappropriate expressions. For 
example, when people are diagnosed with Borderline Personality Disorder it is 
understood by object relations theory that their internal constructs for expression 
are misformed by their parent-child relationships. These expressions are 
described as outbursts of rage, misinterpretations of comments and aggressive 
reactivity. Adults who grow up with this type of insufficient parenting also they 
often demonstrate compulsivity in areas of spending, gambling, sex and other 
activities. They often are chemically dependent or have problems with 
26 
substances like food, stimulants and other drugs. Their experience of difficulty 
in modulating emotions is the result of the original deficiency or damage 
experienced in their relationships with their parents according to Kemberg. Drug 
use and compulsivity are viewed as attempts to modulate affect. 
While Kohut (1972) also accepts Freud's drive theory, he focuses on the 
development of the self or what he refers to frequently as narcissistic 
development instead of focusing on disturbances in object relations and defense 
structures. To understand drug addiction, he looks at defects in the ways 
caregivers react to the infant's internal states. Drug use becomes a way to cope 
the emotions which are reactions to the parental defects. 
Work by Nathanson (1992), however, offers an alternative theory about 
affect and challenges the precepts of drive theory, which has been a prominent 
theory in the field of psychoanalysis for the past two decades. Nathanson refers 
to Silvan Tomkin’s work (1992) with affect theory. His work shows how drive 
theory does not correspond with newly understood research in neurochemistry. 
Tomkin’s theory places innate emotional aggregates in a primary role in the 
developent of the individual, instead of continuing to view them as by-products of 
drives. He states that our emotions are not hard wired. Unlike our mammalian 
cousins our emotions and expression unfold gradually as we become who we 
are. His work illustrates how affect and physiology influence one another and 
create a physical and emotional feedback loop. 
Nathanson explains that affect is a consistent physiological experience. 
Striated muscles are described as running the affect 'programs'. Each affect has 
its own biological pattern of action responding at various sites of action 
throughout the body. For example, the affect of mild and gradual enjoyment 
presents a feeling of contentment and the experience of laughter when it is 
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sudden, produces a smile, drawn lips, bright and shining eyes and a generalized 
feeling of relaxation. Based on biology and physiology, affects are programmed 
to produce a set of expressions and responses when triggered, such as 
increased heartbeat, perspiration, etc. Shame is described as an auxiliary 
affect, which is so powerful it can interfere with perception, drive and affect when 
it is triggered. Nathanson’s work points to our misunderstandings about shame 
psychology and a wider cultural misunderstanding about shame. His 
contribution to the fields of chemical dependency and trauma around the affect 
of shame has been ground breaking. 
In his work, shame is described as a built in inhibitor of positive affect 
Tomkins states that the affects of interest and enjoyment are positive, while 
surprise and startle are affects that remain neutral to clear the central nervous 
system for a quick response. Shame is identified as an auxiliary affect to 
interest and enjoyment. It is triggered by anything that impedes or interferes 
with enjoyment or interest. “Every instance of shame is a moment of painful 
incapacity." The younger the child, the more powerful will be the interference 
with the sense of self. 
Any impediment to positive affects triggers what Tomkins (1992) calls 
shame or humiliation, with the eyes averted, cheeks flushed and the neck and 
upper body slumped. These expressions of affect are visible in the infant whose 
caretakers have been inconsistent, unresponsive, harsh, negating or otherwise 
abusive. The expressions are consistent throughout life and can be recognized 
in treatment as well. Often a survivor of severe trauma or a person who is 
chemically dependent and new in recovery will slump in his or her chair, head 
bent downward, unable to make eye contact. Or a client will describe or 
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demonstrate strong negative affects which are described as defense reactions to 
shame feelings. 
Nathanson refers to the work of two other contemporary psychoanalytic 
scholars, Helen Block Lewis and Leon Wurmser (1981) who focus their research 
on what they call 'field dependence". This work explains an etiology of 
internalized shame and establishes the importance of shame in therapeutic 
work. Wurmser, in his book The Mask of Shame (1981) presents what he 
categorizes as a 'shame family' of emotions: shame, embarrassment, ridicule, 
put downs, contempt, mortification, and humiliation. According to the theories of 
Lewis and Wurmser, these physical and cognitive responses along with the 
other stigmata of shame can be chemically recreated when compounds such as 
opiates or dopamine are administered or over-stimulated. This introduction of 
compounds results in interrupting pathways for the synthesis of vital 
neurotransmitters. The interruption of the synthesis of these neurotransmitters, 
they believe, contributes to the biology of the shame effect and describes a type 
of physical and emotional feedback loop 
Wurmser and Block describe shame as a feeling of self-annihilation, 
which is a form of internal punishment imposed by the superego. Upon reviewing 
transcripts of analytic sessions, Block noted that shame could be correlated with 
an otherwise inexplicable worsening of symptoms of panic, self abuse, suicide, 
withdrawal and resistance. Block found that these symptoms were prominent in 
clients who were characterized as exhibiting borderline or narcissistic behaviors. 
Many of these behaviors are viewed as the expression of or defenses against 
feeling shame. The worsening of symptoms was viewed as a signal that a 
experience of internalized toxic shame was being triggered. The constriction of 
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the self was visible and the symptoms showed that the experience was 
excruciatingly painful and self negating and even self destructive. 
Nathanson (1994) invites the reader to view the entire landscape of 
borderline and narcissistic illnesses from the vantage point of the affect theory 
developed by Silvan Tomkins. Nathanson shows how affect theory aligns 
psychoanalysis with neurobiology. He views affect as a psychic energy or power 
that drives the intrapsychic system, rather than viewing it as a by-product of a 
misguided drive. He states that affect is innate and that its function is to amplify 
or make conscious anything with which it is assembled. 
He believes that we are not bom hard-wired with emotions like our cousin 
mammals. Our emotions evolve as we grow and unfold. Without affect, 
memory, perception and cognition, hunger and sexual arousal would be neutral 
experiences. Without affect, these experiences and drives would be very 
different. Affect is no longer viewed as subordinate to drives. Instead, he shows 
how the opposite is true. Instead, affect is viewed as the innate expression of 
the Self and carries a biography of the individual’s experience of expressing 
each of the nine affects which are identified in this theory. 
Affect and emotion are viewed not as matters of "brain" and "mind" but 
rather as biology and biography. Emotion refers to the ways we leam to 
experience or handle an affect over a lifetime. An individual's expression of 
emotion is viewed as the biography of their affect. 
Tomkins (1987) states that shame becomes internalized when it is 
magnified in frequency, duration and intensity. Internalized shame produces an 
awareness of an incompetent self, defective and unworthy. Kaufman describes 
it as “the affect of inferiority”. No affect is so central to the development of 
identity. None is closer to the experience of Self. “Shame is felt as an inner 
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torment”. Internalized shame is a wound made from inside, dividing us from both 
ourselves and others. It is described as the “the breaking of the interpersonal 
bridge” (Kaufman, 1989). 
Kaufman (1989) introduced the terms ‘internalized shame’, and “shame 
based identity”, and has also described these life long experiences of shame as 
“chronic" and as “toxic shame”. Once shame becomes internalized it forms a 
major aspect of one’s identity and the shame affect becomes autonomous and 
can be triggered without an interpersonal event. Understanding internalized 
shame is important because the behaviors and symptoms which are 
characteristic of a borderline diagnosis also describe a trauma survivor's 
experience. 
Defenses used to avoid or to cope with the painful experience of, (in this 
case) internalized shame, range from ignoring information that would lead to a 
reduction in self image, to attack reactions, suicide, paralyzing isolation, 
avoidance, impulsivity, compulsivity and periods of dysphoria. These same 
experiences and behaviors describe both borderline personality characteristics 
and the experiences described by survivors of trauma. The affect of 
distress-anguish also follows chronic feelings of emptiness experienced by 
addicts. John Bradshaw (1988) refers to the source of this emptiness as ‘toxic 
shame’. He explains that this is the experience which fuels chemical 
dependency and compulsive behaviors. 
When a shame based client begins to have feelings of shame, 
uncomfortable or intense feelings of anger or dysphoria may begin to surface. 
Compulsive or risk taking behaviors may follow in an attempt to suppress these 
overwhelming feelings. These behaviors provide distraction but they also 
stimulate the production of opiates and dopamine through an adrenal, hormonal 
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and neurotransmitter feedback loop. These substances, temporarily soothe 
system, however, just as it is with addictive chemicals, the system is further 
depleted by this activity and the individual is stuck in a cycle of shame feelings, 
compulsivity, depletion, and a return to shame. 
In trauma literature, internalized or toxic shame is described as part of a 
feedback system. It is described as an experience of intolerable feelings, where 
the individual often feels they cannot bear to exist. This often is described as 
feelings of self annihilation when sensory memories are triggered or an 
encounter is experienced as shaming. Since it is not tolerable to remain in this 
feeling state, a trauma survivor will do anything to stop the experience: cover, 
numb, distract, fight, flee or freeze. Clients at methadone clinics, a population 
with a prevalence of a history of trauma, often express that they experience 
behaviors and feeling states, which are not unlike those described in the 
previous paragraphs. Since there are several ways to view symptoms and 
behaviors it is important to be trained in discerning the distinctions in the ways 
these conditions of chemical dependency and trauma parallel, mirror and mask 
one another. 
Summary 
This review of literature demonstrates that there are several ways to 
frame the symptoms, which are present in a chemically dependent population. 
Nathanson and Van der Kolk’s work on trauma and shame present alternative 
ways to consider behaviors and symptoms which were previously framed as 
character and affect disorders in psychodynamic and drive theory. The review 
also supports the fact that PTSD is prevalent in methadone and other treatment 
programs where chemical dependency is identified, thus establishing a probable 
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CHAPTER II! 
METHODS 
Research Question 
Will levels of PTSD and internalized shame correlate with treatment 
outcomes? It is this author's hypothesis that post traumatic stress symptoms 
and symptoms of internalized shame will likely correlate with one another and 
will also correlate with levels of participation and with outcomes in treatment. 
Purpose 
Chemically dependent people and patients diagnosed as having PTSD 
are recognized as sharing common characteristics and utilize similar defense 
mechanisms (Koretzkey and Rosenoer, 1987). Due to the high incidence of co¬ 
morbidity of chemical dependency and PTSD in the methadone population, it is 
important to understand how internalized shame and posttraumatic stress are 
correlated with each other and with treatment outcomes. It is hoped that the 
correlation analysis performed in this study will create ways to more 
comprehensively and successfully address the needs of the methadone 
population when focusing on implications for treatment 
Desion 
To determine the correlations between shame, PTSD and treatment 
outcome variables, which reflect levels of participation in methadone treatment, 
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the author of this study surveyed 120 clients from a local methadone population. 
Two valid and reliable scales, the Internalized Shame Scale (ISS), and the 
Minnesota Multiphasic Personality Inventory (MMPI) Post Traumatic Stress 
Subscale were used to measure levels of shame symptoms and levels of 
posttraumatic stress. 
The Internalized Shame Scale (ISS), designed by David R. Cook in 1987 
was used to identify the symptoms and prevalence of internalized shame in the 
chosen sample. The scale was not derived from any specific theory but was 
constructed as a result of experience in the field. 
For the purpose of this study, internalized shame is to be understood as a 
developmental process in which the experience of shame affect becomes linked 
to the development of the self. It creates a personality style in which shame 
emotions play a prominent part. This framework of internalized shame is derived 
from Silvan Tomkins’ affect theory which was further expanded upon and 
interpreted by Nathanson (1993). Internalized shame is so uncomfortable that it 
can cause a lingering sense of wariness and an unwillingness to trust positive 
affect. The constellation of feelings triggered by shame are those associated 
with incompetence, inferiority, defectiveness, unworthiness, threats of exposure, 
emptiness, alienation and self contempt. 
Items on the ISS were drawn from this phenomenology of feelings and 
emotions. The language used in the wording of the items reflects a high degree 
of negative affect intensity. Internalized shame is defined operationally by a 
high score on the ISS resulting from frequent triggering of shame in 
circumstances or situations that intensify or magnify the shame feelings. 
Cook (1989) reviewed the work of Perlman (1958) and Beall (1972) and 
the original 103 items that they pooled to measure shame. The items were 
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divided into descriptions of situations in which one might feel shame or guilt and 
descriptions of traits or characteristics (e.g., “I keep secrets and worry that they 
might be discovered.”). By reviewing scales which were developed from this 
original pool to measure guilt and shame, Cook determined that the “trait” 
approach to measuring shame or guilt gets at the more enduring or chronic 
results of frequent shame experiences over developmental time. In addition to 
greater reliability, the “trait shame” measure appears to have more clinical 
relevance. Cook reviewed other data (Harder, 1990; Shreve, 1987; Kugler and 
Jones, 1992) which support the greater relevance of shame over guilt to almost 
all forms of psychopathology. He states that high levels of “internalized shame” 
can be shown to be related to a number of different defense or symptom patterns 
that make the scale relevant to clinical use. The scale is also useful for studying 
the psychological impact of frequently induced shame feelings in individuals. It 
was developed into a single factor test in which the core experience being 
measured cannot be adequately divided into other independent factors. Other 
studies using the ISS have supported the single factor approach. High item-total 
correlations have reinforced the single factor approach. 
The original 48-item scale, which included items from Kaufman, Lewis 
and Wurmser’s phenomenological descriptions of shame feelings, was reduced 
to 24 items without losing any internal consistency. The reliabilities were based 
on both a clinical and a non-clinical sample. Efforts to measure various types or 
aspects of “trait shame" have consistently intercorrelated with each other and 
correlated highly with more general measures. The scale was administered to 
clinical and non-clinical populations ranging from 14 to 70 years of age. Items 
that did not contribute to scale reliability were dropped to reduce the scale to 24 
items without losing any internal consistency. 
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comorbidity. Untreated, clients in other studies are shown to comply less and 
drop out.. 
Methadone researchers currently recommend higher doses of methadone 
for clients who experience symptoms relating to co-existing conditions. Studies 
suggest that some of the symptoms being medicated are actually the result of 
chemical dependency progression. Studies also suggest that some of the 
symptoms are heightened responses to the experience of shame. According to 
Wurmser, physical and cognitive responses to toxic shame can actually be 
chemically recreated when other chemicals interrupt the pathways for the 
production of needed neurotransmitters. This leads to the consideration that 
chemical dependency and possibly methadone treatment may perpetuate 
symptoms of shame and PTSD, which hinder progress in treatment. Herman, 
Gelinas and Miller, as authorities on trauma recovery state that higher doses of 
medications are counter productive. Medications and methadone actually cover 
symptoms which can be treated and may actually prolong treatment. 
While studies establish comorbidity, they do not establish a correlation 
between coexisting conditions and outcomes. The need to substantiate a 
measurable correlation between PTSD and internalized shame presented one 
goal, which needed to be addressed in the design of this study. A second goal 
was to look for a correlation between PTSD, internalized shame and outcomes in 
treatment. Such a correlation would show that the coexisting conditions of 
PTSD, internalized shame and chemical dependency need to be carefully 
considered and treated in methadone and other chemically dependent 
populations. The next chapter explains the methodology used in the research 
design and states the research question which was tested in the study. 
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In a study by Akashi (1994) the Brief Symptom Checklist was 
administered along with the ISS. Data confirmed the pervasive role shame 
emotions play in the diagnoses of a clinical population. Correlations ranged 
from .45 to .74, all significant at <.01. The highest correlations were with the 
scales that measured Interpersonal Sensitivity, Depression and Psychoticism. 
The Interpersonal Sensitivity dimension “focuses on feelings of personal 
inadequacy and inferiority, particularly in comparisons with others. Self- 
deprecation, feelings of uneasiness, and marked discomfort during interpersonal 
interactions are characteristic manifestations of internalized shame. 
Items on the Psychoticism scale are “indicative of a withdrawn, isolated, 
schizoid life style”. The ISS correlates highly with the “interpersonal alienation” 
and withdrawal, which is typical of many shame-bound individuals. Druschel ran 
a study (1993) on a high risk groups of adolescents to look at the relationship 
between shame and suicide probability. Firestone ran a study (1991) on the 
correlations between internalized shame and a voice scale for self-destructive 
behavior. Together, they suggest that high levels of internalized shame 
represent a level of self-worthlessness and self-disgust that suggests suicide 
potential. 
The ISS identifies a constellation of feelings that belong to the family of 
shame emotions. “The shame items on the ISS are a sample of the most 
internally consistent statements that tap into the central sense of incompetence 
or inferiority that represents the core of the internalized shame experience, 
(Cook, 1989). Respondents indicate the frequency with which they experience 
this internalized shame. 
The test, in its final form is a Lickert scale with thirty items. It was 
constructed to measure the extent (based on a frequency scale) to which 
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respondents experience internalized shame. It is a self-report instrument 
containing thirty negatively and positively worded items. 
A single shame scale was derived from the twenty-four negatively worded 
items. The remaining number of items are positively worded and are not used in 
calculating the shame scale. Their purpose is "to lessen the tendency for a 
response set to develop when all items are worded in the same direction" (Cook, 
1993, p.3). The Internalized Shame Scale has a reliability coefficient of .95 and 
.96. 
A subscale of the Shame Scale—the Self-Esteem Scale, is also used in 
this study. The items were taken from the Rosenberg Self-Esteem Scale 
(Rosenberg, 1965). Cook states the correlation between the ISS total score and 
the six positive items is around .70, which demonstrates the overlapping use of 
the items in the scales. The score for the test range from 0-24 with scores of 18 
or higher is indicative of positive self-esteem and scores falling below 18 
indicate negative or low self-esteem. Cook states that, in general, if the ISS 
score is 50 or higher the SE score will be under 18. 
The MMPI subscale for PTSD was administered to determine the 
prevalence of post traumatic stress disorder and related symptoms. Keane, 
Mallory, and Fairbank (1984) developed this scale as a psychometric indicator of 
the post-traumatic stress syndrome. The scale was designed to distinguish 
PTSD cases from a psychiatric control group at a rate of 82%. This percentage 
was obtained by using a cut-off score of 30 in the 49-item scale. Other studies 
report positive use of the scale, although reporting lower diagnostic hit rates. 
Kenderdine, Phillips and Scurfield (1992) compared the scores of 
veterans with PTSD with and without substance abuse with those of veterans 
with substance abuse only on the MMPI-PTSD sub-scale. Results support the 
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ability of the test to distinguish between groups of subjects with PTSD and those 
with substance abuse only. These findings support the validity of a distinct 
PTSD syndrome cluster, versus the measurement of generalized distress 
common to several diagnostic categories. 
High scores on the PK scale indicate individuals who: 1) report intense 
emotional distress, 2) report symptoms of anxiety and sleep disturbance, 3) feel 
guilty and depressed, 4) may be experiencing unwanted and disturbing thoughts, 
5) fear loss of emotional and cognitive control, and 6) feel misunderstood and 
mistreated. 
Sampling 
A random sample was chosen from a private behavioral methadone 
treatment program with five locations in Massachusetts and Connecticut.. One 
hundred twenty subjects who had been in treatment at least six months were 
randomly selected from the population of eight hundred. Counselors were asked 
to select ten clients, whose progress ranged from poor to successful, to be 
surveyed for PTSD and internalized shame. The sample consisted of males and 
females between the ages of 18-60, living in the inner city, urban or rural areas. 
The clinic's population is approximately forty percent Caucasian and forty 
percent Latino. Most of the remaining 20% are African American, Native 
American or of mixed racial descent. Approximately 60% of the clients are male 
and 40% female. Clients range in age from 18 to 62 years of age. All subjects 
are chemically addicted and polysubstance dependent. 
A multi-disciplined team staffs the program. The team consists of a 
medical staff of three part time physicians, three part time medical assistants, 
and a nursing staff of supervising RNs and part-time LPN’s who are responsible 
39 
for daily dosing. Case managers, who do individual counseling with 
approximately forty clients each hold a Bachelor’s or a Master’s degree. Several 
case managers are bi-lingual and bi-cultural. Supervision for case managers is 
provided weekly on an individual and group basis by an independently licensed 
social worker. 
At the time of intake, rules are explained to the clients and contracts are 
signed. Progress is defined by whether or not the client reaches the goals, 
which are described in their initial meeting. Clients are expected to abstain from 
street drug use. Routine random urines are administered. If drugs other than 
methadone are found in the urine it is considered to be dirty. A refusal to have 
urine tested is also considered to indicate that the individual is using street 
drugs. 
Attendance at all weekly or bi-weekly counseling sessions is required. 
Sessions are conducted for 15-60 minutes dependent upon the individual” ability 
and interest to engage in counseling. Clients are expected to receive their daily 
dosing at specific hours. If they are not able to be consistent with their dosing, 
they are released from the program. They must also abstain from illegal activity. 
Clients must also observe all clinic rules as stated in the manual they receive 
upon intake 
The treatment is structured in a multi-tiered model, offering privilege and 
freedom for accomplishing specific goals. When these goals are met clients are 
given the privilege of taking home doses of methadone for three days at a time. 
Clients with take home privileges are expected to attend one or two of the 
groups that are offered by the program. A group on feelings is offered along 
with women and men’s groups, relationship, anger management, HIV and 
parenting groups. 
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Data Coliection and Analysis 
The human subjects review committee reviewed and approved the 
project, and clients’ confidentiality was guaranteed. Consent forms were signed 
and client confidentiality was guaranteed before data was gathered. The 
process of setting up research in any methadone clinic is a lengthy process due 
to regulations which are imposed on methadone clinics, by the DEA and other 
Federal legislation in response to the distribution of methadone, which is a 
narcotic. In addition, many of the clients themselves exhibit some paranoid 
tendencies due to the progressed later stage of the disease of chemical 
dependency and possible illegal involvements. 
Counselors tend to be taxed and vicariously traumatized by the high 
levels of trauma they encounter in their work with the methadone population. It 
was important to be aware of these factors when interfacing with the counselors 
and program. After the surveys were completed, demographics and urine 
checks were gathered on each client to provide necessary background data. 
Participants were given the Shame Scale and the MMPI-PTSD sub-scale 
surveys during their bimonthly visits to the methadone clinic. The scales were 
completed during the visit and returned to the tester. In some cases where 
literacy was a problem, the case manager assisted in reading the question to the 
client. After the surveys were completed, demographics and urine checks were 
gathered on each client to provide necessary background data. 
In the pilot study, some counselors stated that their clients asked them to 
explain the questions. When this occurred, staff found that the survey questions 
brought up information about suicidality and other symptoms, which the 
counselors felt they needed to address. In the final study the counselors were 
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reminded to limit their involvement to distributing the test and asking clients to 
respond as best as they were able. Given that one of the common features of 
chemical dependency is alexythymia or the inability to identify feelings, it was 
explained that answering several questions, which ask about feelings would be 
difficult. While this limitation is recognized, this feature is factored into the 
design of the surveys. 
Demographics and drug use histories were obtained from the standard 
admissions interview used by the Department of Public Health. The described 
scales and interview were used to identify demographic variables. A univariate 
analysis and several analytic regressions served to determine whether or not the 
PTSD and Shame variables were correlated with each other and with treatment 
outcomes. A stepwise regression was run to determine whether or not shame 
and PTSD are predictors for the outcome variable of relapses. There were also, 
several secondary findings as a result of statistical analyses, which will be 
presented in the following chapter. 
Significance 
A better understanding about chemical dependency and the combined 
struggles many methadone clients experience as survivors of trauma make it 
possible to better support clients in treatment, thus affecting outcomes. 
Clinicians can be trained to differentiate among symptoms and to help clients 
stabilize when their efforts in recovery become overwhelming. There could be a 
much clearer understanding of the recovery process for each condition. The 
distinctions between PTSD and other diagnoses will also help to focus treatment 
and will likely affect participation in programs. 
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Limitations 
One limitation is that only PTSD and shame are explored in this study. 
There may be other significant factors that play an important role in treatment 
participation. This study does not prove, but only suggests that treatment for 
PTSD and internalized shame will generate more positive outcomes. Studies 
that can measure a change in symptoms when these issues are addressed 
would provide effective follow up to this study. Further studies using populations 
where individuals are dependent on other chemicals or who demonstrate other 
compulsive behaviors would provide a more comprehensive picture of how 
internalized shame and PTSD play a significant role in the progress and 
treatment of addictions and compulsivity. 
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CHAPTER IV 
RESULTS 
The first section of this chapter focuses on a brief discussion of the 
demographic characteristics of the methadone subjects. The second section 
addresses each of the hypotheses of the study by reviewing test scores and 
correlation results and statistics. The next section presents a discussion of the 
secondary findings and how they provide additional insights into the significance 
of the test scores and their significance in the methadone population. 
Summary of Demographic Characteristics 
Overall, the demographics represent a range of characteristics (Appendix 
B). When regressions were run tests showed that there was no single 
demographic indicator that correlated with survey scores or treatment outcome 
variables. Sex, age, race, employment status, family construction and previous 
treatment did not play a significant role in affecting test outcomes. There were 
no correlations between PTSD, internalized shame or self-esteem scores and 
any demographic indicators. Secondary findings, however, showed some trends 
with race and sexual abuse. Gender and choice of drug also showed some 
significant correlations to treatment outcome variables and will be presented 
later in the third section. 
The group that was surveyed in this study ranged in age from 24 to 63 
years of age. A minimum of six months in treatment was required to participate 
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in this study and treatment ranged from six months to over seven and a half 
years. Treatment ranges from receiving methadone doses and meeting with a 
case manager/counselor once a week to participating in groups and individual 
therapy. Sixty percent of the population had received previous methadone 
treatment. Fifty two percent had been in a detox program. Twenty percent had 
been in a residential program. Twelve percent had received previous outpatient 
treatment. Ninety six percent of the population had received no prior treatment 
for mental health issues. Given the prevalence of PTSD and other symptoms 
this statistic is noteworthy. 
Fifty one percent of the participants did not complete high school, 49% 
did. Of those who did not graduate, nearly a third completed ninth grade and a 
third stopped their education at an earlier grade and one third dropped out in 
tenth or eleventh grade. A little over a third of those who graduated, 18% or the 
total population went on to college. Five of these individuals (4% of the total) 
completed college. 
Eleven percent started their drug use at age eleven or younger. Forty five 
percent of the participants started to use drugs at age fourteen or younger. 
Another 37% percent started to use drugs between ages fifteen and twenty. 
These figures total to 72% of the clients starting drug use before the age of 
eighteen and 87% started before age twenty.Three percent started after the age 
of thirty. 
Fifty three percent of the participants were male and 47% were female. 
Eighteen percent identified themselves racially as Caucasian, 16% as Afro- 
American, 55% as Latino and 11% as ‘Other1, which was a category comprised 
of Asians and Native Americans. 
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Fifty two percent never married, 48% had married and 24% are now 
divorced or separated. Ninety percent are not employed. Nine percent are 
employed, 4% full-time. Ninety four percent of the participants live on less than 
$5,000 per year. Eighty nine percent receive public assistance. Approximately 
three quarters (90 members) of the population have children. Twenty two 
percent live alone., 17%with their younger children and 26% with a child over 
the age of eighteen. 
The Study 
In order to investigate a comprehensive picture of how internalized shame 
and post traumatic stress might correlate with methadone treatment outcomes, 
several analyses needed to be run. Initially, a smaller group of clients was 
surveyed to assess the proposed methodology. In the pilot study, a trend 
between shame test scores and the percentage of relapses was observed, along 
with strong correlations between the different scales. 
Initially, the incidence rates of PTSD and internalized shame in this 
methadone population needed to be determined, before looking at relationships 
between internalized shame, and posttraumatic stress, correlate with and 
methadone treatment outcome variables.and with each other. The table below 
shows these frequencies.In the general population, PTSD exists at a rate of 2- 
5%. In the population that was tested, 60-62% of the clients scored in the range 
for posttraumatic stress. 
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Table 1. Frequency of PTSD and Shame in the Methadone Population 
Scale Percentages 
PK Scale for PTSD 
PTSD 63% 
No PTSD 
PS Scale for PTSD 
37% 
PTSD 
in the 75th percentile 24% 
in the 85th percentile 38% 
62% in total tested for significant PTSD 
No PTSD 38% 
Shame Scale 
Significant Shame 17% 
Severe Shame 26% 
43% in total 
No Shame 57% 
Low Self-Esteem 74% 
Sixty two percent of the population demonstrated had scores which 
indicated that clients experience significant PTSD according to the Minnesota 
Multi-Phasic Inventory PK subscale. This percentage is 10-12 times greater 
than the percentage of PTSD found in the general population and 2 !4 times 
greater than that found in other chemically dependent populations. 
The PK and PS subscales for PTSD share 26 items in common. As would 
be expected, they are highly correlated, r=.939 and the P value + <.001. The 
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analyses in this study statistically validates the reliability of these two scales. 
The PK scale has been used in the field of research for some time, while the PS 
Scale is newer and is still being tested. Both established the fact that PTSD 
occurs at a high rate in this study population. Out of a possible total score of 46 
on the PK Scale, 17 positive responses determined the cut off score for men and 
a score of 18 positive responses was the cut off for women. On the PS Scale, 
out of a possible total of 60, 23 was the cut off for males and 26 was the cut off 
for females. The PS scale identified 60% of the population as experiencing 
PTSD: 22% in the 75th percentile and 38% in the 85th percentile. These figures 
substantiate the prevalence of PTSD in this population. 
In the final survey, 42% Out of a possible score of 96 on the Internalized 
Shame Scale, a score of 50 indicated significant levels of internalized shame. A 
score of 60 or above indicated that the individual was experiencing severe 
shame. Forty two percent (50) clients scored in the range for internalized shame 
and 25% (30) scored in the range for severe shame. The shame subscale for 
self esteem indicated that 74% (89) of the population demonstrated that they 
experience low self esteem, while 26% (31) did not. These percentages show 
that internalized shame and low self esteem are also prevalent in this 
population. 
Initial runs on correlations (Appendix E, Tables I and II) showed 
relationships In the initial tests run on correlations (Appendix E, Tables I and II), 
correlations between test scores, outcome variables and other factors, which 
were measured were the focus of this study. Shame, Self-Esteem (Self E) and 
PTSD (PK Scale and the PS Scale) scores were highly correlated with each 
other. Internalized shame scores correlated highly with PTSD test scores (PS 
Scale and the IS Scale, r=.719, P value = <.01 and PK Scale and the IS Scale, 
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r= 701, P value = <.01), S and self esteem scores correlated negatively with 
both internalized shame and PTSD (Shame, r=-327, P value= < 0.01, PS Scale, 
r=-.210, P value .024 and PS Scale, r= -.231, P value = .013). These 
correlations show that as PTSD scores increase, self-esteem decreases, as 
would be expected. See Appendix E, I to view the correlation table. 
The outcome variables for methadone treatment were (Time) length of 
time in treatment measured by months, (Dose) current dose of methadone 
measured in milligrams and (Drug Use) measured by the frequency of the 
number of dirty urines in the past six months. A dirty urine is found to have any 
number of street drugs in it when tested and indicates that the client is not 
adhering to program expectations. Some interesting correlations were 
demonstrated amongst the outcome variables. There were significant 
correlations between the frequency of drug use and the current dose of 
methadone and between current methadone dose and time in treatment, but not 
between drug use frequency and length of time in treatment.. A client’s drug use 
frequency was not determined by the length of time in treatment. However, 
methadone dose level could be determined by time in treatment. For example, 
when a regression equation obtained by analyzing the correlation between an 
individual’s methadone dose and length of time in treatment was used, the 
client’s dosage or length of time in treatment could be determined. In the case 
of a client who was in treatment for 36 months the methadone dose was 
accurately determined to be around 75 mg. 
When looking for correlations between test scores and outcome variables 
only the only outcome variable that correlated with test scores was the frequency 
of drug use variable. PK Scale and shame scores were correlated with the 
frequency of drug use with P values of .054 and .043 respectively and r values 
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of .178 and .190. The P values were also significant for the frequency of drug 
use and methadone dose with r =0.207, and P value = 0.025. Correlations were 
also significant and between current methadone dose and several of the drugs 
that were found in dirty urines. The specific drugs and values are as follows: 
opiates, r=0.277, P value <.01: benzodiazapines, r=0.196, P value=0.034 and 
barbiturates, r=0.226, P value= 0.014. were the drugs of choice (Appendix E, 
Table IV). 
Methadone dosages and time in treatment were evenly distributed 
(Appendix F, Tables 1 and 2), however,but the frequency of drug use was not 
(Appendix F, Table 3). Initially, this variable was divided into four categories of 
frequency, however, after running several stepwise regressions along with a 
review of client profiles it was determined that frequency of drug use as a 
dichotomous variable was consistant with observed trends and created a 
stronger and cleaner statistical analysis. 
When profiles on groups of clients categorized by their frequency of drug 
use were reviewed, it was found that those who were using drugs < 20% of the 
time showed no significant score, for PTSD, while those who used street drugs 
>20% of the time had scores in the high range for PTSD symptoms. Subjects in 
the study were then divided into one of two categories: those whose frequency 
of drug use ranged from 0-20% and those who used street drugs at a frequency 
of 21 -100% of the time. 
Next, t-tests were run with the categorized frequency of drug use variable 
and variables that were significant in the original correlations were used as 
dependent variables. PTSD scales, along with the current methadone dose 
variable were significantly differentiated by the frequency of drug use 
groups..Internalized shame, age of first drug use and time in treatment were not, 
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however, significantly differentiated. Below, Table 2 shows the results of these 
t-tests values for categorized frequencies, test scales and methadone dose 
levels. (See Appendix H, Tables I. A-D for full analyses). 
Table 2. T-tests for Categorized Frequency of Drug Use and Other Variables 
Dependent 
Source Variable N Mean Std. DevStd. Error Pr > t Variable 
Drug Use PK Scale 0 35 26.14 14.58 2.46 0.050 
1 83 31.98 14.30 1.57 
Drug Use PS Scale 0 35 18.86 11.46 1.94 0.014 
1 83 24.65 11.22 1.23 
Drug Use Shame 0 34 36.03 28.12 4.82 0.093 
1 80 45.38 22.98 2.57 
Drug Use Dose 0 35 58.08 22.25 3.76 0.013 
1 82 70.06 25.93 2.86 
Drug Use Time 0 35 22.8 10.7 1.8 .57 
1 83 21.4 15.5 1.7 
Drug Use Age of 0 35 16.86 6.06 1.0 .24 
1 st Use 1 82 15.49 4.82 0.53 
These first, second and fourth variables, PK and PS scale scores and 
dose levels are statistically significant and were determined to be possible 
factors in predicting frequency of drug use. Length of time in treatment and first 
age of drug use were not significant and were eliminated from the model. 
Internalized shame initially, had such a strong correlation with the test scores 
that it was surprising to find that it was not significant in the two way views. 
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Based on the results of the T-tests, PK scale and the methadone dose 
variable were chosen as possible predictors of drug use frequency. Results of 
the stepwise regression which was run to determine the importance of each 
variable are listed in the table below. 
Table 3. Stepwise Regression 
Variable Number Score Pr> 
Step Entered In Chi Square Chi Square 
1 PK Scale 1 6.8322 0.0090 
2 Curmeth 2 4.0796 0.0434 
Wald 
OddsConfidence Limits 
Variable Unit Ratio Lower Upper 
Curmeth 1.000 1.019 1.000 1.038 
PK Scale 1.000 1.049 1.010 1.090 
The PK Scale and dose came in as significant factors in this regression. Odds 
ratios were low so these variables are not viewed as predictors of drug use 
frequency. The regression, does however, show that there is a strong statistical 
relationship between PTSD, methadone dose and frequency of drug use with 
PTSD having a more important important relationship with drug use frequency 
than dose. The Pr value for PTSD was .009, compared with .043 for dose. 
As a result of the strong correlation and overlap between PK and PS 
scales (r = 0.939, Pvalue = <.001), PS Scale results were nearly the same as the 
PK Scale in determining PTSD in the population. The scale also correlated with 
the drug use variable when it was categorized. Therefore, both scales can be 
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used to show that there is a strong interrelationship between PTSD and the 
frequency of drug use variable. When an Anova was run with the PS scale and 
the drug use variable there was a signifcant P value and correlation. 
We can hypothesize that in treatment, if a client is diagnosed with PTSD, 
her/his methadone dose would be in the high range and street drug use would 
be more frequent. Conversely, if a client is in the high dose range or frequently 
uses street drugs it is most likely that he or she also suffers with the condition of 
PTSD. As a result, PTSD and its treatment, may play a role in treatment 
outcomes in the methadone populations and further studies could explore this. 
The sophistication needed to determine whether or not various outcomes could 
be improved by treating PTSD are beyond the scope of this study, however, the 
study presents groundwork for such research. 
Though internalized shame was highly correlated with PTSD, P value< 01, 
in the initial analyses, when t-tests were run the P value for shame was .093 and 
not statistically significant. This was unexpected and does not support the 
original hypothesis of this study. However, an exploration of possible 
explanations for this is warranted. 
The ISS results showed that 43% of this population experiences 
internalized shame. Even though there was a high correlation with PTSD, either 
the frequency was not high enough to be significant or as Cook, cautions 
symptoms may not be reported due to the psychic blocking. In addition, in the 
case of working with this population, symptoms could be medicated with 
methadone or other drugs. 
Another reason that internalized shame would lack significance could be 
explained by its strong correlation with PTSD. It could be hidden within the 
constructs of PTSD and/or covered by the strength of PTSD's relationship to 
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drug use frequency. Again, the sophistication needed to determine this was not 
within the scope of this study. However, as an integral component of chemical 
dependency, PTSD, and other traumas, it would be reasonable to assume that 
because of it’s strong correlation with PTSD, internalized shame would 
predictably play a role in treatment outcomes. Other factors which may play a 
role in minimizing the significance of internalized shame will be discussed in the 
Chapter V discussion. 
A question for further studies could look for change in treatment outcomes 
when internalized shame and PTSD are treated directly. It is this researcher’s 
belief that outcomes would improve if these conditions were treated. In the next 
section, secondary findings provide information which points to some interesting 
trends with sexual abuse, needle use, race, choice of drugs and gender. Future 
studies could include research focused on these trends. 
Secondary Findings 
In this section, findings on other variables that demonstrate statistically 
significant relationships with PTSD, internalized shame and outcome variables 
are presented. First, a discussion pertaining to the incidence of internalized 
shame with PTSD and PTSD when it occurs without internalized shame is 
presented. Next, the findings on the frequency of sexual abuse and needle use 
are presented. A discussion on trends around race and gender follows, along 
with the effects of specific drugs used when street are found in dirty urines. 
Random urines are taken to determine whether or not an individual is using 
street drugs. 
Correlational analyses (Appendix E, Tables I and II) show that high scores 
of PTSD correspond with high scores for shame in 61 % (44) of the seventy three 
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subjects showing significant scores for PTSD. When individual test scores were 
compared, internalized shame and PTSD scores correspond 36% of the time. 
However, there were instances where subjects showed significant PTSD, but 
scores indicated that they were not experiencing significant levels of internalized 
shame in 48% (32) of those tested with the PK Scale. In 17% (7) of the forty-two 
clients that showed a significant score for internalized shame, there was no 
PTSD indicated in the PK Scale testing. When using the PS Scale, there were 
corresponding PTSD and significant internalized shame scores in 59% (44) of 
the cases. There were, however, measures of PTSD where there were no 
corresponding significant internalized shame scores in 44% (31) of the subjects 
using the PS Scale. Sixteen percent (7) of those who had significant shame did 
not show PTSD symptomology. 
Table 4. Chi Square for Shame and PTSD 
Internalized Shame 
0=no PTSD 1=PTSD 2=severe 
PTSD 
i 
0=no 36 19 12 67 
shame 24.42 16.47 26.12 67 
1= 3 9 8 20 
shame 7.29 4.92 7.80 20 
2= 4 1 26 31 
severe 
shame 
11.30 7.62 12.08 31 
All 43 29 46 118 
43 29 46 118 
Chi-Square = 45.927, DF = 4, P-Value = 0.000 
1 cells with expected counts less than 5.0 
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Findings show that in 16-17% of the cases internalized shame does exist 
independently of PTSD in the methadone population. Internalized shame as a 
primary symptom in the disease of chemical dependency may be experienced as 
an aspect of the disease without the presence of PTSD. Another reason shame 
may exist without PTSD could be due to the tendency of methadone or street 
drugs to cover or medicate symptoms of PTSD. Clients would not check the 
symptoms on the surveys. 
Internalized shame is experienced by 46% of the clients who are treated 
with high doses of methadone. Thirty percent of the internalized shame scores 
fall into the severe shame category. In this high dosing group relapse 
percentages are high. Seventy five percent of the clients used street drugs 75% 
of the time. PTSD which exists at a rate of 65% in this group could be correlated 
with the majority of people who are using street drugs. However, these numbers 
show that at least 19% of the clients who experience PTSD do not report 
experiencing significant internalized shame. In fact, a total of 54% of the clients 
in this group do not experience shame. Is the shame medicated? Perhaps the 
shame is lessened as a result of treatment or the results of 12-step recovery. It 
would be interesting to look at the individual surveys of those who scored high 
for the internalized shame but not for PTSD. It is possible that the later stages 
of their disease contributes to this experience of shame. Left untreated, it could 
paralyze It would also be interesting to look at the profiles of the 54% who did 
not demonstrate the experience of shame. 
When PTSD scores are high and internalized shame scores are low it 
may still be the case that it is the methadone or other street drugs that suppress 
the emotion of shame. One reason individuals continue to use drugs is to stop 
feeling their feelings. As a major component of chemical dependency 
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internalized shame surfaces in the times between drug use, when the drug 
levels fall below an accustomed level in the body and in early recovery. Shame 
feelings may be suppressed at certain doses of methadone and surface at lower 
doses. Further study would be necessary to track and measure this occurrence. 
Correlations were significant between sexual abuse, needle use, race and 
test scores. P values in the initial correlations are shown in the table on the next 
page. 
Table 5. Correlations Between Test Scales & Other Variables 
Scales P value 
Shame 
Sexual Abuse 2.48 .020 
Needles 2.13 .034 
PK Scale 
Sexual Abuse 2.05 .053 
The difference in the mean score for those who used needles and those 
who did not is statistically significant. However, both mean scores are below 
shame level scores. What can be said is that those who use needles 
experience more shame symptoms. 
On the following pages, tables 6 and 7 show the relationship between 
sexual abuse and test scores. 
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Table 6. T-test for Shame and Other Variables 
Variable N Mean DF T 
Use of needles 
Did not use 
Used 
53 38 
56 48 
103 -2.14 .035 
In this test the mean difference is statistically significant and the scores show 
that those who do not experience sexual abuse do not experience shame as 
measured by the shame survey. Those who do experience sexual abuse do 
experience significant shame. 
Table 7. T-test for PK Scale and Sexual Abuse 
Variable T DF N P-Value 
Sexual abuse -2.10 50 .040 
None 65 
Abuse 25 
Again there is a significant difference in means between sexual abuse and 
scores for PTSD. Those who have experienced sexual abuse are more likely to 
experience PTSD. 
The presence of physical abuse as a factor did not correlate with 
internalized shame or PTSD scores nor did it correlate with methadone dose 
levels or frequency of drug use. It is not possible to evaluate the significance of 
physical abuse for several reasons. It was not reported in many cases. It also 
58 
was not asked about directly in intakes. Further studies with a focus on 
gathering this data would need to be initiated to report significant data. 
Sexual abuse, however, does have a significant correlation with PTSD 
and internalized shame. This is not surprising and helps to clarify which issues 
need to be explored with clients in methadone treatment programs. 
When t-tests were run for gender and PK and PS Scales no significant 
differences were found. Table 8 demonstrates this. 
Table 8. Test Scores Differentiated by Sex 
Sex Number Mean Median 
PK Scores 
Women 57 22 24 
Men 63 23 21 
PS Scores 
Men 63 31 33 
Women 57 29 29 
Shame Scores 
Men 63 42 44 
Women 53 43 44 
Mean PTSD scores for women and men are close in value where the 
mean scores for shame show a significant difference between genders. Men 
score higher, an indication that they experience more shame, but they do not on 
average score in the range for significant internalized shame any more than 
women do. 
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When profiles were compiled according to gender, they show that more 
women, 67% of the clients versus 33% of the men were being maintained on low 
doses of methadone. Do these women experience less shame and PTSD or are 
they making progress as a result of their treatment? The figures suggest that 
treatment may be experienced differently by women. A high percent of men 
(61 %) were using a high dose of methadone compared to the 19% of women 
who were in that category. This could indicate that men who are in this category 
use street drugs more often. This may occur as a result of their chemical 
dependency, shame, PTSD or other emotional experiences. Perhaps treatment 
does not address the needs of men well enough. 
Race is another variable where trends appear with shame and PTSD and 
are shown in the table below. 
Table 9. Anova for PS Scale and Race 
Shame Mean PS Scale Mean N 
Caucasians 17% 43.2 18% 29.1 20 
Latinos 55% 47.0 57% 33.0 18 
African American 5% 33.2 15% 27.0 66 
Other 10% 32.0 11% 23.0 12 
Race and internalized shame scores and race and PS Scales present a 
pattern or trend with P values of .065 and .067.respectively. Mean scores and 
P-Values show that Latinos and Caucasians experience significantly more 
internalized shame symptoms than do Afro Americans and others. Latinos also 
experience a higher percentage of internalized shame and PTSD. Fifty five 
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percent of Latinos scored in the range for shame. This frequency is markedly 
higher than the 17% frequency for Caucasians and 5% for Afro Americans. On 
the PS Scale 57% of Latinos scored in the range of PTSD, compared with 
Caucasians at 18% and Afro-Americans at 15%. These trends indicate that 
there are cultural differences in the experience of internalized shame and PTSD 
symptoms. In further studies, these distinctions would be important to explore. 
Treatment of the symptoms would vary depending on the cultural context in 
which they are experienced. 
Treatment Outcome Variables and Other Correlations. 
When clients have dirty urines they use specific drugs. Tests were run to 
see whether or not the choice of drug used made a difference in test scores or 
outcomes. While specific drug use did not correlate with PTSD or Shame, there 
were some interesting correlations between specific drug use and treatment 
outcome variables. 
Initially, when correlational analyses were run, as would be expected, 
frequency of drug use correlated with use of specific drugs. When individuals 
use drugs, they use a variety of drugs. The results are listed in TablelO. 
Table 10. Drug Use Frequencies and Other Variables Correlations (Appendix E, 
IV) 
Variables r Value P-Value 
Opiates .543 <.001 
Cocaine .611 <.001 
Benzodiazapines .358 <.001 
Barbiturates .179 .055 
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Chi squares run on cocaine and opiates show that cocaine and opiates are used 
together 100% of the time (Appendix H, IV) a relationship between cocaine and 
opiate us and frequency of drug use. Table 11 shows the relationship between 
drug use frequency and drugs of choice. 
Table 11. T- tests for Drug Use Frequencies and Specific Drugs (Appendix H. 
IV. D-G) 
Mean 
Cocaine 32 
73 
Opiates 32 
73 
Benzo- 50 
diazpines 65 
Barbibturites 54 
61 
T DF P 
-6.39 91 <.001 
-6.39 91 <.001 
-2.14 85 .035 
-0.66 12 .52 
Clients used street drugs at a much higher rate with a combination of 
cocaine and opiates. This can be understood in terms of drug use tendencies. 
Clients frequently use opiates to come down from their cocaine high. Therefore, 
we find higher relapsing rates when both substances are used together. In 
addition, the use of two substances will accelerate the progression of the 
chemical dependency. Increased amounts and frequency of use more rapidly 
deplete and destabilize brain chemistry. When clients relapsed with opiates, the 
mean dose of methadone was found to be higher, thus further diminishing the 
brain’s supply of opiates and other neurotransmitters. As the disease 
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progresses the risk of relapse is greater, due to the change in body chemistry 
and increased dependency on both the physical and emotional levels. 
Interestingly, when the factor of gender with choice of drug use was 
explored, there was a relationship between cocaine use and gender. 
Table 12. Chi Square for Cocaine and Gender 
Variable P-Value Percentage 
Gender 0.057 
30% 
25% 
Women 
Men 
This value indicates that there is a trend for women to relapse more frequently 
on cocaine than men do. The reasons for this difference could be many-fold and 
are not accessible in a study like this. Conjecturing, women are easy targets for 
dealers and their dependency often leads them to relationships where they can 
continue their drug use. When opiate use was tested with gender, there was no 
significant correlation. 
Another significant relationship between factors appeared between the 
age of the first use of drugs and high scores for internalized shame and PTSD. 
The table on the next page shows the r factor and P-value for these variables. 
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Table 13. Correlations for Age of First Drug Use and Scales 
Variable r P-Value 
Self Esteem 0.175 .062 
Shame 0.173 .065 
PS Scale 0.213 .020 
PK Scale 0.251 .006 
These correlations indicate that the higher the scores for PTSD, the younger the 
age of the individual was when they started using alcohol and other drugs. In 
addition, negative correlations with internalized shame and low self esteem 
suggest that the younger a client was when he or she started drug use, the 
higher his or her scores were for internalized shame and low self-esteem. The 
implications of these correlations are several and support the hypothesis that 
many individuals begin using drugs to cope with unbearable feelings such as 
those that are experienced as a result of physical, sexual or emotional abuse. If 
these experiences generate symptoms of depression, anxiety, internalized 
shame, dissociation, nightmares, flashbacks or avoidant behaviors which are 
symptoms of PTSD, it could be understood that drugs may have been used to 
manage or modify these symptoms. 
If the findings in neurobiological research on trauma are applied here, 
drug use can be understood as an attempt to provide the brain with dopamine, 
endorphins, and opiates which are deficient as a result of trauma. Using drugs, 
however, to satisfy the need for certain feelings states or to decrease certain 
64 
feelings actually further diminishes the supply of these various 
neurotransmitters. 
The process by which the drugs create a high, blocks these 
neurotransmitters from being reabsorbed into the brain. They are removed by 
the cerebral fluids and the supply of these substances is diminished. It is at the 
point of dependency that clinicians would diagnose the individual as having two 
conditions that re-enforce one another on the biochemical, emotional and 
behavioral levels, thus masking, mirroring and paralleling one another. 
There was also a correlation between the age of the client when they 
started using their primary drug of choice which was heroin >95% of the time, 
and the frequency of street drug use. The younger the age of the client when the 
primary drug of choice was started, the higher the frequency of dirty urines, 
which measure street drug use. This could be explained in two ways, either the 
length of time of drug use and the progression of the disease of chemical 
dependency makes it difficult to stop using street drugs or there is something 
specific about the way heroin effects the client’s biochemistry through time, 
which contributes to the need to continue use of other street drugs. Or perhaps 
the choice of drug, being predominantly heroin in this population, changes an 
individual’s biochemistry in ways that make it more difficult to stop the use of 
street drugs in treatment. Perhaps the street drugs serve some purpose in 
supplementing a biochemical deficiency. 
Levels of methadone dose also correlated with frequency of drug use 
along with time in treatment and the use of benzodiazapines. Table 13 provides 
the data that explains these relationships. 
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Table 14. T-test for Methadone Dose and Opiate Use 
Variable Percent Dose Mean T DF P-Value 
Opiate Use 
-7.23 67 <.001 
None 43 60.5 mid range 
Used 56 71.5 high 
T-tests were run for percentage of relapses and cocaine with no significance. 
According to this data, those who use opiates on average are being given 
doses of methadone, which are considered to be in the high end of methadone 
dosing. Those individuals who do not use opiates are receiving the 
maintenance level of methadone. This finding implies that the choice of street 
drug correlates with the level of methadone that is required for maintenance. 
Fifty seven percent of the population did use opiates as their drug of choice. 
Thirty two percent of the subjects who had opiates in their urines reported 
having no success in stopping the use of any of their drugs. Eighty percent of 
these 68 clients who used street drugs >50% of the time used opiates. They 
also used cocaine at the same rate. Forty eight percent of the clients who used 
opiates and cocaine reported using needles and 28% reported sexual abuse in 
their histories. There were no significant differences around race, age, sex or 
time in the program. In this study the frequency of using opiates correlates with 
high scores for severe internalized shame. 
Table 15 shows the data for the other significant factors of time, drug use 
frequency and use of benzodiazapines. 
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Table 15. Anovas for Current Methadone Dose and Other Variables 
Variable F P-Value 
Percentage of relapses 2.98 .034 
Time2 3.47 .018 
Benzos 2.04 .009 
Note: Use of benzodiazapines also correlate with higher doses of Methadone. 
These numbers suggest that people on higher doses of methadone tend 
to use street drugs more often, are in treatment for longer periods of time and 
they frequently use benzodiazapines when they use street drugs. Again, is the 
progression of the disease accelerated by polysubstance use which contributes 
to a higher frequency of street drug use and the struggle to maintain on 
methadone without using street drugs or is it the combination of the disease of 
chemical dependency along with internalized shame and PTSD symptomology 
that makes it a struggle to progress in treatment? 
Summary 
Demographic data does not appear to affect scales or outcome variables 
except in some cases of gender, race, sexual abuse, needle use, the age of the 
client when they first started using drugs, and the age of the individual when he 
or she first used his or her primary drug of choice. Correlations for PTSD, 
internalized shame and low self-esteem are high in this methadone population, 
along with the prevalence of PTSD, internalized shame and low self-esteem. 
Statistical analyses suggest that there is a strong inter-relationship between PK 
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scale scores, methadone dose level variables and higher frequencies of street 
drug use in this methadone treatment program. Where PTSD is present, 
methadone doses and drug use are higher. We could then hypothesize that if 
PTSD symptoms were less severe, methadone doses and drug use would 
correspondingly decreased. 
Even though internalized shame was not statistically significant in later 
analyses, it was highly correlated with PTSD in initial tests. We can surmise that 
treatment of internalized shame as an integral component of PTSD would also 
decrease symptoms and treatment outcomes would improve. Further research, 
however, is needed to determine this. 
Internalized shame scores were significantly high for Latinos and 
individuals who were sexually abused. PTSD scores were also significantly high 
for Latinos and individuals who were sexually abused. High percentages of 
internalized shame were also found in groupings of individuals who used 
needles and those who used opiates on the street. PTSD was identified in a 
high percentage of individuals on high doses of methadone as well as those 
who frequently used street drugs. 
Test results provide enough information to suggest that treatment, which 
addresses sexual abuse, culture, internalized shame or PTSD would effect 
outcomes in treatment and improve progress. The next chapter, will continue to 
explore the implications of these findings. 
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CHAPTER V 
DISCUSSION 
Introduction 
In this chapter, a review of the results of the findings are presented to 
create a context for discussing the implications for treatment. The results of this 
study suggest that correlations between PTSD, internalized shame and the 
frequency of drug use support the need to design comprehensive treatment 
approaches which address the conditions of PTSD, internalized shame and 
chemical dependency. In section two a case for looking at the methadone 
population as a population with comorbid PTSD is made with a presentation of 
current research in neurochemistry. Research from the fields of heroin 
addiction, chemical dependency, shame, and trauma illustrate and further 
support the argument for dual diagnoses. Section three presents some current 
findings on brain research which explain why the implications of the research, 
along with the findings in this study, are so important for treatment 
considerations. These implications and the results of the study, along with 
findings in brain research, are used to formulate strategies for treatment for 
treatment in section four. 
In the fifth section a discussion of the limitations of the study is 
presented. The final section reviews ideas for further research, followed by a 
summary. 
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Review of Results 
A review of the results of this study create a context for looking at brain 
research and implications for treatment. The strong interrelationship between 
levels of PTSD, methadone dose levels and street drug use frequency in the 
methadone population suggest that PTSD may play an important role in 
treatment progress. Results also demonstrate that there are high levels of 
PTSD and internalized shame in the methadone population surveyed in this 
study. In addition, the study's analyses support the hypothesis that both PTSD 
scales and internalized shame are highly correlated Sixty three percent of the 
sample of clients being treated at the methadone clinic were in the 65th 
percentile or above for PTSD. This is 9-12 times greater than the 5-7% 
prevalence found in the general population. Even when compared with other 
chemically dependent populations this figure is 2 A times greater. Though 
internalized shame did not prove to be statistically significant when looking at 
treatment outcomes its correlation with PTSD suggests that it is also an 
important factor in treatment. 
Internalized shame is found more often in clients who have PTSD though 
it was found to be present without PTSD. In addition, 79% of the people in 
treatment were identified as having low self-esteem. This is consistent with the 
strength of the original correlations found between self-esteem, internalized 
shame and the PTSD. The original correlations between PTSD, methadone 
dose levels and drug use frequency were substantiated in the regression 
analyses. 
PK scores were found to be statistically significant for predicting the 
frequency of drug use outcome variable. The odds ratio between PTSD and 
drug use frequency is below the 2 value that would make PTSD predictor, 
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however the ratio does indicate that there is a higher chance that the presence 
of PTSD and higher scores on the PK Scale will correspond with an increase in 
street drug use and methadone dose levels. The fact that internalized shame 
did not present itself as a significant factor as it had been hypothesized could 
indicate that PTSD is a stronger predictor of drug use frequency. 
The low odds ratio in the results of the stepwise regression could be 
accounted for by several factors. Some clients are being treated for PTSD in 
therapy outside of the program which would lower the symptom severity of 
PTSD. Counselor contact in the program is limited to 15-20 minute check ins 
and doesn’t provide enough time for therapy. Other symptoms are medicated 
with methadone or medications prescribed by the staff doctors, which again 
lowers scores on PTSD and shame scales. In addition, it is possible that the 
methadone treatment and the required changes in lifestyle do address some of 
the symptoms of PTSD. Creating stability by a change in lifestyle, reducing 
exposure to triggers, and decreasing paranoia by decreasing street drug use all 
contribute to this first step toward safety and could account for a smaller 
correlation with street drug use. 
The fact that test results show a high incidence of PTSD and internalized 
shame in this population does support other research at methadone clinics and 
demonstrates the frequency of co-existing conditions which need to be explored 
and addressed in the methadone treatment. In the next section, research on 
brain chemistry explains how these three conditions of PTSD, internalized 
shame and chemical dependency develop and are chemically perpetuated when 
these conditions go untreated. The research supports the need to address the 
conditions of chemical dependency and PTSD along with internalized shame as 
an integral component of both conditions simultaneously. 
71 
Current Research on Neurochemistrv 
Ideally, after clients begin treatment, they make progress in several ways. 
They decrease their use of street drugs. They start to make lifestyle changes, 
they go to counseling and training, and begin to address health issues. They 
refrain from criminal activities and live a more settled, less violent, more 
responsible lifestyle. After a period of stabilization, some are able to decrease 
their methadone dose and eventually totally stop methadone use. 
Why are some individuals able to progress to a level of being weaned 
from methadone, while others are able to stop their use of street drugs and make 
life changes, but are not able to decrease their methadone use? Why do some 
clients never stop their use of street drugs? Why do some stop street drugs, but 
seem unable to make life changes? The answers appear to be related to the 
interplay between brain chemistry, the underlying symptomatology of PTSD and 
internalized shame, and the resultant lack of skills needed to cope with 
emotional affect and relationships. Results of this study suggest that the 
condition of PTSD and the prevalence of shame play a significant role in the 
progression and outcomes of treatment. It is important to understand how brain 
chemistry plays a role in how clients experience their symptoms and make 
progress in treatment. 
Research in the fields of trauma and neurobiology explain how chemistry 
and physiology are effected by trauma, shame, stress and chemical dependency 
(van der Kolk; 1987, Cook; 1991, Nathanson; 1994, and Genazzani; 1929). 
Current heroin addiction research also focuses on understanding brain 
chemistry. One researcher, Zweban (1998) focuses primarily on what happens 
at opiate receptor cites. She and several other researchers believe that the 
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opiate receptor system is dysfunctional in heroin addicts. Current thought in 
methadone treatment has been informed by the ongoing debates about whether 
or not the brain can function “normally” after prolonged use of heroin. 
Brain research is able to pinpoint the areas of the brain that are effected 
by drug use (Harvard, 1998). There appears to be a circuit that runs between 
the midbrain and the prefrontal region of the cerebral cortex. The prefrontal 
cortex, at one end of this circuit, is the seat of planning and judgement. At the 
other end, the amygdala is described as the factory of emotions. The link or 
circuit is known as the medial forebrain bundle and is described as a rewards 
system, which was originally intended for survival and reproduction. Its function 
is to tell us chemically what to avoid and what to approach (Harvard, 1998). It 
initiates the fight or flight response when one perceives danger. It also releases 
dopamine when the reward for any given activity is greater than expected. This 
system is the focus of Goleman’s work (1997) on emotional intelligence. He 
notes that childhood abuse and neglect damage this system and account for 
difficulties with anxiety, aggression and impulse control. 
Brain research explains why and how brain chemistry can be altered by 
trauma and drug use. The following paragraphs explain how different drugs 
affect the dopamine levels, how trauma affects brain chemistry and how the 
resulting changes in chemistry then effect an individual's ability to manage and 
express various emotions. 
Different drugs take different routes to the forebrain target area (Harvard, 
1998). Cocaine, for example, blocks the reuptake mechanism that reabsorbs 
dopamine into the cells; this increases availability of the dopamine at post- 
synaptic sites. The resulting concentration of dopamine gives addicts their 
“high” experience. Dopamine is the neurotransmitter that is also released when 
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risk taking or compulsive activity is pursued. Amphetamines overstimulate the 
mechanisms that release of dopamine, causing an increase in dopamine. 
Nicotine affects a receptor that plays a role in breaking up the dopamine 
molecule. Like cocaine, opiates decrease the uptake of dopamine by blocking 
receptor sites. The use of cocaine and other addictive substances, actually 
produce opiate like substances. These drugs, along with direct use of opiates 
decrease the brain’s ability to produce its own opiates is naturally. 
When addictive drugs enhance dopamine transmission by blocking re- 
absorption, by overstimulating its production, or by blocking its metabolism, the 
disturbance can cause long lasting changes in the production of dopamine and 
brain function. This occurs when the brain adapts to excesses of opiates or 
opiate-like substances and the natural production of opiates declines. When 
opiates are provided externally dopamine receptors become less numerous and 
sensitive. These adaptations are the result of drug use and can also be the 
result of methadone treatment. Treatment, then, as well as drug use might 
perpetuate the deficiency of dopamine and create a feedback loop in which the 
body’s ability to regenerate and take over the production of dopamine would be 
blocked. 
When addictive substances interrupt the normal activity of this essential 
neurochemistry, endorphins and enkephalins can reverse the interruption. 
Endorphins and enkephalins replace the brain’s morphine-like substances. 
However, several factors, which include stress, trauma, diet, and the use of 
stimulants and depressants can limit the supply and effects of these substances. 
When relapse occurs, it is currently theorized that the cause is endorphin 
deficiency, endorphin excess with a failure to respond, or alteration of the 
feedback mechanism (Kaufman, 1998). Genazzani’s work (1982) actually 
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measured this endorphin deficiency by performing spinal tap fluid analyses in 
recovering chemically dependent people. He found that the endorphin levels 
along with serotonin, dopamine and noradrenaline were deficient. He also found 
that neurotransmitters started to be replenished six months to two years after 
drug use stopped. 
When these deficiencies occur in the client, the biochemical and 
emotional changes result in depression, anxiety, aggression and compulsivity. 
As a result, the client often resorts to street drugs to replace the missing opiates. 
The client might also engage in other compulsive behaviors which stimulate the 
release of dopamine or opiates. 
Research on trauma offers another perspective on assessing brain 
chemistry and relapse stressors. In addition to deficiencies as a result of drug 
use, there may be pre-existing deficiencies in endorphins and opiates as a result 
of the trauma. In the field of trauma research, Van der Kolk (1987) shows that 
as a result of trauma and learned self-defeating patterns, clients experience 
deficient brain and body chemistry that may impede their ability to move forward 
in treatment. As a result of childhood and current trauma, endorphins and the 
enkephalins are deficient in the brain before drug use begins. 
Nathanson and Cook’s research on internalized shame (1986) describes 
how despair in infancy can cause cyclical depressions. When there is an 
unresponsive or abusive environment, the infant reverts to hyper-arousal states, 
requiring an over production of adrenaline and the corresponding 
overstimulation of opiates, which are produced to calm this heightened state. 
Through time, the child has difficulty modulating anxiety and aggression. This 
difficulty can be explained by the deficiency in opiates, created over time by 
these hyper-aroused states and the body’s repeated attempt to soothe. 
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In addition, the absence of a response to the separation phase can create 
a biphasic protest/despair response which creates, in turn, a hyperactive or 
underactive response in children. Children may withdraw and isolate or may 
present with anxiety and exhibit difficulty managing their feelings and/or focusing 
their attention. They often don’t thrive and meet developmental challenges with 
high anxiety and a sense of failure. 
In adults, Nathanson’s descriptions of the symptoms of internalized 
shame also correspond with some of the effects that are the result of hyper and 
underactive responses such as attack reactions, suicide, paralyzing isolation, 
avoidance, impulsivity and dysphoria. Nathanson places these responses to 
internalized shame into four categories which are also prevalent in this 
population. 
The first category is withdrawal, accompanied by helplessness and 
isolation, which are often manifested as depression. The second category is the 
response of avoidance which may be expressed as disavowal or denial, drug 
use, defensive hedonistic activity and going out of the way to distract attention 
from what might bring shame. The third category and response is self-attack. It 
is an attempt to experience shame under one’s own sense of control by self- 
shaming, self- criticism, and anger toward self. Shyness, deference, conformity 
and masochism are personality patterns associated with this response. In the 
fourth category, the cognitive aspect of shame, makes a sense of inferiority 
conscious and becomes unbearable. When this occurs, the individual will attack 
others with criticism, ridicule, and contempt. Externalization, blame and 
paranoia are common features of this defense. Addressed, these four 
responses can be managed. Untreated, they continue to destabilize the client 
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and perpetuate the cycle of shame along with associated biochemical 
deficiencies. 
The biochemistry effected by disruptions in the attachment bond, 
contributes to the experience of internalized shame and include the 
neurotransmitters dopamine and serotonin, as well as opioids, norepinephrine 
and other endocrine hormones. Van der Kolk notes that these same 
biochemicals are depleted in individuals who experience post traumatic stress or 
those who fall somewhere along the trauma complex continuum as a result of 
physical or sexual abuse or neglect. 
Genazzani’s work, as noted in the paragraphs above, shows that the 
same neurotransmitters are deficient in chemical dependency. These parallels 
on the biochemical level support an understanding of how the symptoms might 
parallel, mirror or mask one another. The research argues for a dual or multi¬ 
diagnostic approach to methadone treatment. It shows that both conditions are 
significant and interrelated on the biochemical and affect levels. Both require 
the attention of trained personnel. The next section will further discuss the 
implications of these findings for treatment. 
Implications for Treatment 
Shame exists in the conditions of both PTSD and chemical dependency. 
When an individual is stabilized without drugs or when drugs or medications no 
longer cover the symptoms of PTSD and/or internalized shame, cycles of shame 
may become more apparent. Internalized shame and trauma symptoms will 
surface naturally as a matter of course unless the individual is able to numb or 
suppress these experiences on their own without drugs. Cycles of internalized 
shame and trauma can also be initiated by the treatment process itself. Any 
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treatment that shames can trigger toxic shame or other experiences related to 
original trauma. It is then, important to train counselors to be conscious of how 
they might shame or trigger shame reactions. In addition, creating an 
atmosphere for discussing shame experiences and modelling self-forgiveness 
would be optimum. 
Internalized shame will likely be present in various phases of treatment as 
a result of both trauma and chemical dependency. When internalized shame is 
triggered for a trauma survivor, it is described as a feeling of self-annihilation. In 
an attempt to stop this experience, a trauma survivor will do anything to cover or 
numb these feelings. This reaction parallels the addict’s tendency to cover or 
numb uncomfortable feelings with drugs or other compulsive behaviors. 
Addressed directly, clients learn to name their feelings and learn howto manage 
them differently. They also can begin to distinguish between feelings brought up 
by trauma and those relating to their chemical dependency 
People who are both chemically dependent and survivors of trauma 
experience a destabilizing and often unbearable roller coaster of emotions. The 
affect experience of distress-anguish often follows chronic feelings of emptiness. 
Bradshaw (1988) also calls this emptiness “toxic” shame. It is the experience of 
being abandoned as a child by parents who neglect developmental needs or 
abuse physically or emotionally. Chemically dependent clients experience an 
array of these shame based feelings when drug use is decreased. They often 
seek activities which stimulate the release of dopamine to soothe the system 
biochemically. Individuals also attempt to distract themselves from the feelings 
of “toxic” shame with other compulsions such as relationships, gambling, sex, 
intellectualizing, and perfectionism. They often act out from their shame with 
anger, unable to tolerate the feelings of self-loathing. They blame others for 
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their feelings and discomfort, and are unable to recognize these patterns of 
behavior without the help of a trained practitioner. 
When drugs are decreased, PTSD symptoms of depression, phobic 
anxiety, paranoia, aggression, somatization and ‘psychotic’ features such as 
dissociated states and intrusive thoughts or memories often surface and can 
easily compound the feeling states of internalized shame and trauma that are 
common to chemical dependency. Unnamed and unaddressed, these feelings 
and experiences can keep chemically dependent clients and trauma survivors 
locked into endless cycles of distress, despair and relapse. 
If affect modulation is not treated and enhanced, the adrenal fight or flight 
response will continue to biochemically stress the system, thus perpetuating the 
opiate, dopamine, serotonin, and endorphin deficiencies. This feedback loop 
often frustrates therapy and may be misidentified as a setback, regression, or 
resistance. Knowledge about brain chemistry and feedback loops which are run 
by stimulants, stress and compulsivity, can help the clinician discern and in turn 
help the client understand his or her experiences. Clients can then identify 
activities and behaviors that either feed this cycle or help to rebuild brain 
chemistry. In addition, clients can learn skills which help them to manage their 
feelings and make life changes. 
Several modalities and therapies exist which help to support this process. 
Bio-feedback has been helpful in teaching people how to regulate their 
responses to various stimuli. When MIT researched meditation, it was found to 
help the brain organize and modulate desired brain wave activity. Hypnosis may 
offer healing. Nathanson(1988) suggests that the techniques used in hypnosis 
may alter neocortical cognition by re-creating a state of interaffectivity similar to 
an infant’s experience of the mother’s influence on affect. 
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Nutritional therapies and Chinese and Indian systemic approaches to 
health address depression, anxiety, disturbing thought, erratic behavior, 
reactivity, and a hyper-adrenal response from a perspective of deficiency, 
imbalance or depletion. The emotional and physical symptoms are viewed as 
symptomatic of what is out of balance in the system. The goal is to rebuild 
system. Joan Larson, Ph. D. (1997), built a treatment program based on 
reloading the essential chemicals which are missing after the brain has been 
altered by drug use. She reports having a 74% success rate, based on a 314 
year follow-up study of 100 patients. Anxiety and depression were significantly 
reduced or eliminated within weeks of beginning treatment. The program has 
not been used with heroin addicts, but the principle of being able to rebuild drug 
depleted systems is established. 
Certain types of bodywork, also address the symptoms of anxiety, fear, 
hypervigilence, depression, reactivity, and the body’s memory of trauma. When 
a person has been violated repeatedly the body will show a pattern of insult and 
defense in the organs, muscles, and skeletal structure. These patterns can be 
worked on, emotions and memories released, and the individual can experience 
a new sense of grounding and stabilization. It is often easier for a client to take 
a step in the area of self-care and see and feel results than it is to imagine 
changing defenses, which have helped them to survive. 
Unrecognized or untreated, the emotional and neurochemical loops 
create self-defeating, self-perpetuating cycles of behavior and feelings of failure. 
Triffleman and Marmar (1995) noted that subjects with PTSD had the worst 
functioning on all of their symptom measures and were subject to more suicide 
attempts, more hospitalizations and increased depression and dissociation. 
Hien, Levin, and Brady (1994) observed that untreated PTSD in chemically 
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dependent clients created complications and hindered treatment response. This 
study also supports the correlation between PTSD, shame and treatment 
outcome. Together, this study along with other these studies on chemical 
dependency and co-existing suggest that a comprehensive treatment program 
which addresses symptoms and conditions of both PTSD and chemical 
dependency could make significant differences in treatment outcome. 
A challenge for clinicians and treatment centers that recognized that both 
chemical dependency and a continuum of trauma exist, is to find ways to 
differentiate symptomatology and diagnoses. The clinicians must learn howto 
monitor and discern the ways in which the symptoms and behaviors of chemical 
dependency are paralleled, mirrored and masked by manifestations of PTSD 
and internalized shame symptoms and behaviors. 
Internalized shame, for example, has been identified in this study as an 
integral aspect of several conditions: chemical dependency, PTSD and trauma- 
both in childhood and adult life. For this reason, its diagnosis and treatment 
require several discriminating considerations. Shame needs to be carefully 
reviewed and understood in its different contexts, which include it’s etiology and 
how it is manifested in various ways at differing treatment intervals. One might 
ask: when is internalized shame a symptom of trauma and when is it a symptom 
of chemical dependency? Other symptoms also require careful consideration 
and discernment and are presented in the following table. 
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Table 16. Symptoms 
Later Stage Abstinence or 
Chemical Withdrawal PTSD Shame 
Dependency 
Anxiety Anxiety Anxiety Anxiety 
Depression Depression Depression Depression 
Isolation Isolation Agoraphobia Avoidance 
Withdrawal Withdrawal Avoidant Isolation 
Misdirected Anger: Angry Suppressed Angry Outburst 
Toward self Outbursts Rage Anger Toward 
Toward others Blaming Others 
Outbursts Self Annihilation 
Paranoid Paranoia Phobia Narcissistic 
Psychotic Hallucinations Dissociations Tendencies 
Features 
Sleep Disturbance Sleep Disturbance Sleep Disturbance Sleep Disturbance 
The following questions remain: What part of the client profile is 
chemistry, brought on by chemical dependency and what part is the result of 
trauma? Which symptoms and dynamics are related to deficiencies, caused by 
the various aspects of chemical dependency and which are aspects of PTSD, 
internalized shame or other traumas? 
Another challenge in the diagnosis and treatment, then, is to determine 
which symptoms in methadone treated clients are a result of changed or 
deficient chemistry that cannot be restored and those that can be resolved or 
reduced in therapy. Some of the symptoms, which are the result of emotional 
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distress patterns and biochemical stress can be altered by therapies and by 
other health restoring and stress management disciplines. 
If distinctions are determined, appropriate referrals could be made. 
Comprehensive programs could be designed to address the need to rebuild 
body chemistry, along with learning skills to manage affect and changed 
behavioral patterns. 
Rebuilding this chemistry depends on several conditions. Among the 
questions needed to assess an individual’s biochemical status are: How severe 
and for how long was the original neglect and/or abuse perpetuated and at what 
age of development? Were there any supports or learned skills around coping 
with emotional pain? How have the individual’s lifestyle and choices fed into the 
learned cycle of over or under-response? How has lifestyle continued to deplete 
the system through repeated patterns of stress responses and the need for an 
opiate response? Did the individual then choose certain drugs and stimulants to 
substitute for the deficient opiates? Are there compulsive behaviors which 
perpetuate the cycle of deficiency? These types of questions begin the process 
of differentiating between chemical dependency symptoms and trauma 
symptoms. Without this differentiation in treatment, Hien’s (1994) research 
reminds us that the treatment is often prolonged and the risk of the client’s 
withdrawal from treatment is high.. 
Another way to approach the process of differentiating symptoms is to 
look at treatment intervals, which identify times when internalized shame or 
PTSD symptoms often emerge or are heightened. Progress in treatment is 
marked by changing levels of drug use and by changes in behaviors. The 
cessation of street drug use is one milestone. A long period of time without 
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street drug use or infrequent dirty urines is another indication of progress. 
Lowered methadone doses also indicates progress. 
A change from one level to another could signal or contribute to the 
emergence of various symptoms. A lower dose of methadone may no longer 
effectively suppresses the trauma and shame experiences. Any of the 
uncomfortable feelings associated with these experiences could move a client to 
numb these feelings with drugs, more medication or compulsive behavior. 
Another time when addressing and treating these issues could make a 
difference in progress is when clients are on high doses of methadone. The test 
results show that 68% of clients in the high dose range experience PTSD. In 
this situation, clinicians could be pro-active, asking questions and helping clients 
to identify the source of their feelings. They could help the client learn to keep 
him/herself safe and help him/her to avoid retraumatization. The naming and 
acknowledgement of a client’s struggle can “normalize” the underlying anxieties, 
fears and rage which the client may feel compelled to medicate. Just by being 
aware of the possibility that the feelings of toxic shame or the expression of 
trauma material could surface at therapeutic intervals could help the clinician to 
better prepare the client by helping the client to name and learn to manage 
his/her experiences. 
In another situation someone who has been free of street drugs for a 
period of time can relapse to using street drugs. There are several reasons why 
a relapse will occur. There may be an additional stressor in the person’s life 
with which he or she is not able to cope. Relapse may occur because an 
individual is not using his or her recovery tools and program enough. 
Decreased participation in treatment, creates less support and direction for 
coping with stressors. 
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A relapse may also signal the retriggering of trauma and the emergence 
of overwhelming trauma material, regardless of one’s treatment status. Life 
events can trigger trauma symptoms at any time. The resulting shame cycle can 
be immobilizing. The urge to numb the emotional pain is strong. The risk of 
relapsing when trauma material is triggered is high. The added shame that 
results from relapsing prolongs drug use if it isn’t addressed. 
If clinicians were trained to spot these occurrences and to address the 
surfacing material, treatment could more effectively support continued progress. 
Clinicians could be trained and prepared to ask questions around issues and 
feelings, which surface when there is a change or an anticipated change in the 
level of treatment. When clients are unable to take a step or progress to the 
next level in their programs, clinicians could explore issues of internalized 
shame or other symptoms relating to PTSD. Talking about shame breaks the 
isolating silence that internalized shame causes. Once the shame is exposed in 
an environment of acceptance and modeled compassion, it can no longer hold 
the client captive. By processing feelings and events around the internalized 
shame, the interpersonal bridge begins to be rebuilt. 
In addition, an understanding of the biochemical effects of both trauma 
and heroin dependency could help clinicians evaluate these effects and assess 
their possible impact on the client’s abilities to proceed in treatment. Such 
knowledge could be very helpful when formulating a treatment plan, protocol, 
and prognosis for methadone clients. Current research on the brain, trauma and 
chemical dependency describe how the feedback loops which are the result of 
the original insult of abuse and neglect are perpetuated. The following 
paragraphs describe how these loops can be interrupted. 
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Chemical dependency is described and treated on physical, mental, 
emotional, behavioral and spiritual levels. An intervention on any level helps to 
modify the feedback loop. In treatment, when patterns of thinking and behaving 
are identified and explained in the context of these feedback loops, the client 
can begin to see how these patterns perpetuate undesirable outcomes. It is 
important for clients to understand that the depleted biochemistry of the adrenal 
system can effect how one copes. Angry outbursts, anxiety and depression are 
often the result of a deficiency in the adrenal, opioid, neurotransmitter loop, and 
can lead to angry outbursts, anxiety and depression. Once the client 
understands that adrenal depletion can compromise one’s ability to manage 
affect, some relief from self blame is possible. Negative self-judgement can be 
lifted and the immobilizing experience of internalized shame is lessened. 
Using a biochemical explanation as one aspect of what a client is 
experiencing can help to ground the client so that he/she can take manageable 
steps to create a sense of stability and predictability, for example, in his or her 
ways of communicating in relating. By rebuilding the endocrine system along 
with identifying and addressing patterns that need to be changed the client will 
experience fewer and less severe mood swings along with less reactivity. By 
releasing the perception of being an awful person the client is freer to make 
some of these changes. 
When a client understands that some of the behaviors that hurt others are 
reactive defenses, ways of coping and externalizing painful feelings they can 
begin to experience compassion for themselves and their experiences of abuse. 
They begin to understand that these behaviors and feelings are often 
manifestations of trauma, internalized shame and chemical dependency, which 
are unconscious. The client can then, become conscious of their own self 
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perpetuating, self defeating learned behaviors and feedback loops. Once made 
conscious, that the patterns lose some of their power. The individual is 
empowered by this new knowledge and can learn ways to change these hurtful 
patterns. 
When clients decrease biochemical stressors and begin to rebuild their 
adrenal system, there is less reactivity because there are more biochemicals 
available to cope. When the patterns are identified, they can be changed at 
various points. If an individual learns that his/her brain has been biochemically 
trained and now is structurally changed to hijack their emotions, there is less self 
blame. This creates an opportunity for the individual to take a position of 
responsibility, to learn new ways of coping and to chose different ways to 
redirect learned responses and defenses. 
When an individual understands that his/her chemistry is depleted by 
various substances and emotional and behavioral feedback loops, it is easier to 
develop strategies for replenishing the body and learning new skills. The client 
can see that the drugs have changed his/her ability to handle stress and 
manage affect. Once an individual understands that toxic shame and self 
loathing are at the root of blaming others and of being hypercritical and 
judgmental, then he/she can begin to have compassion for themselves and in 
turn can take responsibility for lashing out or dumping their discomfort with 
themselves on others. Trauma survivors learn how their ‘wiring’ and how 
certain events, tones, and communications may trigger very deep old hurt 
feelings. Rather than treat those they love with malice or by withdrawing, clients 
learn to identify these events, and learn to discern the difference between 
trauma and internalized shame triggers and the present. They can begin to 
learn about projection a release their loved ones from their old wounded places. 
87 
The survivor of trauma learns to identify the feelings, and behaviors, and 
interactions that trigger feelings of that make them feel powerlessness which 
are similar like they to the powerlessness felt when they were children as a child 
victim and victims of others. As treatment and trust progress the client can 
identify the behaviors and reactive defenses which hurt others in ways they were 
hurt. This work is described as identifying the internalized behaviors of the 
abusive person. It is an essential part of the work with survivors to help them to 
recognize how projection and learned hurtful behaviors and defenses can be 
changed. Without this conscious awareness, intimacy is not possible. Once 
they are recognized, the behaviors can be addressed in the eh context of trauma 
and internalized shame. 
Couples work is essential. It could be offered as an aspect of treatment 
to help the client and his/her partner recognize triggers and to establish a 
working allied relationship rather than a combative, blaming relationship where 
little is resolved, leaving the client and family members living in a system where 
there is painful and hurtful interaction or emotional distance.. Family members 
who have been living with a chemically dependent person and/or survivor of 
trauma can find relief,also. Instead of blaming themselves or the client, they can 
begin to understand their own feelings and reactions in the context of 
understanding the effects of chemical dependency and/or trauma on 
relationships and family systems. 
Many abusive and hurtful behaviors in relationships could be addressed 
by understanding the various feedback loops and resultant emotional and 
behavioral patterns. Clients can learn to name their experiences and their 
feelings and begin to talk about how out of control, ashamed and horrible they 
feel instead of acting out on others or themselves. 
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When clients who grew up in neglectful or abusive environments can see 
and understand that they now have the opportunity to learn what they didn’t 
have the opportunity to learn growing up, the internalized shame is lessened. It 
wasn’t his/her fault. The client comes to understand that he/she is not flawed 
and defective. Relationships require skills and skills can be learned. 
When they learn that they have a disease of chemical dependency which 
contributes to their depleted and therefore compromised chemistry and feeling 
states, they learn that they are not bad people and can follow a physically, 
emotionally and spiritually healthy wellness recovery program. 
Intimacy and closeness which can automatically trigger the trauma 
defenses of abandonment, can become a healing journey where individuals can 
now share their experiences and vulnerabilities rather than have the defenses 
erupt from the unconscious and hurt others. 
Identifying internalized shame and PTSD issues would also help 
clinicians identify and address the underlying developmental needs of the client. 
These needs, defenses and reactive formations occur in response to neglect 
and violation. As aspects of PTSD and internalized shame, they must be 
addressed in treatment. Studies (Hien, 1994) suggest that treatment cannot 
otherwise proceed. In fact, if the clinician fails to understand and help the client 
to cope with the traumas of abandonment, neglect or abuse, this omission often 
replicates the original trauma. When an aspect of the original trauma or shame 
are re-enacted in a treatment setting, the client may withdraw from treatment or 
remains in the silence of their own pain and trauma. Therefore, the need to train 
practitioners to identify, differentiate, and address symptoms and struggles that 
could otherwise paralyze a client and sabotage progress in treatment is key. 
Freed from having to hide their shame, clients could be invited to learn what they 
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did not have the opportunity to learn in their families. By normalizing their 
defenses and talking about the feelings of internalized shame, the shame is 
reduced. The implications recognizing and addressing the feelings of 
internalized shame for treatment could change the nature of diagnosis, 
treatment, and goals of methadone treatment programs. 
Tantamount in the decision to use methadone is the controversy around 
using methadone as a long-term treatment option for people addicted to heroin. 
Methadone has a direct effect on biochemistry and symptoms. The discovery 
that there is a feedback loop which decreases the body’s ability to produce 
natural opiates when methadone and other exogenous drugs are introduced can 
be used to argue for and against medicating symptoms. Several 
psychopharmological medications appear to have the ability to restore chemical 
balance in the brain. Methadone is used in treatment to relieve dysphoria 
associated with anger. It reduces anger and feelings of restlessness. Like other 
opiates, it calms, soothes and relaxes the body by supplying opiates to the 
opiate receptors when there is a deficiency. In addiction terms, it also relieves 
the symptoms of withdrawal. 
Zweban (1991) writes about guidelines for treating co-existing 
psychological disorders. Treatment protocol calls for higher doses for those 
clients who exhibit depression, phobic anxiety, paranoia, psychotic features, 
aggression, or somatization. Whether this condition exists from childhood or are 
brought on by chronic heroin use, Dole (1988) and Zweben (1998) promote the 
practice of medicating these deficiencies for the remainder of the client’s life. 
However, the symptoms mentioned above also signal the later stages of 
chemical dependency, and higher dosing may actually speed up the progression 
of this disease. As the disease progresses it is harder to become drug-free. A 
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distinction between the causes of these symptoms would help avoid 
unnecessary medication and inadvertent progression of the disease. 
The use of higher doses for co-existing disorders is viewed as 
counterproductive by Herman, Gelinas, and Miller. Harvard (1998) studies 
support this view by demonstrating the negative effects of continued drug use. 
When laboratory animals were given unlimited amounts of cocaine or heroin and 
then cut off from supplies of drugs, the brain became temporarily insensitive to 
normal signals of reward. No action seemed pleasurable (Harvard, 1998). 
In another study, Glover (1992), reports that emotional numbing as a 
symptom of PTSD can through time, be reversed in veterans when treated with 
the use of opiate antagonists. This experience of depression and lack of 
pleasure response was also duplicated in the Genazzani’s research in (1982) 
when spinal taps showed deficiencies in neurotransmitters after six months of 
abstinence. (Genazzani, 1992). Genazzani also showed that the 
neurotransmitters were replenished through abstinence and recovery over a 
period of six months to two years in most cases. This supports the argument to 
limit the use of methadone for medicating symptoms. Recovery involves a 
commitment to take steps to improve one’s relationship with Self, with others and 
with one’s own understanding of Spirit. This includes eating a healthy diet, self 
care, and efforts to change one’s thinking and behaviors that perpetuate 
compulsivity and ill health. It also addresses and offers the person in recovery 
the opportunity to address the past with forgiveness and compassion and 
provides the opportunity to develop interpersonal skills to repair relationships 
and families. Recovery is a mind, body, spirit wellness program, designed to 
rebuild and renew these aspects of an individual’s life by reducing stressors and 
patterns that diminish and by enhancing skills that promote well-being. 
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Trauma and chemical dependency experts argue that when symptoms are 
over-medicated, the feelings and material that need to be worked on in therapy 
are suppressed. Again, staff who are trained to recognize shame and trauma 
symptoms and who are able to differentiate between symptoms of chemical 
dependency and trauma ares needed. This study has been limited to identifying 
a need for more comprehensive diagnosing, interventions and treatment 
planning. The effects of these changes could be measured in further studies. In 
the next sections further limitations of the study will be discussed, along with 
proposed further study. 
Limitations 
Early on in the study, issues were raised about the translation of the 
MMPI PTSD survey, at the first site. Dissent and resistance were voiced. 
Counselors stated that the translations were poor and that clients could not 
complete them in the allotted time. It was stated that it was taking clients up to 
an hour to complete a ten to twenty minute task. 
There were several possibilities to explore in terms of the survey. Could 
the research company which professionally and nationally distributes Spanish 
translations be using a form of Spanish which was not accessible to this 
population? This researcher consulted with a Latino colleague and another 
colleague who tested a family with the survey. Both stated that though some 
wording was different, it was possible to determine the itended meaning and 
complete the survey within the prescribed time. 
Given that one of the common features of chemical dependency is 
alexythymia or the inability to identify feelings, it was explained that answering 
several questions which ask about feelings would be difficult. It was explained 
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that this feature would be factored in the test results. This researcher is left with 
two questions: Do these quetionnaires take the challenges of their subjects into 
consideration? How will the clients’ inability to understand the questions due to 
their limitations arouond accessing feelings affect test results? 
Another consideration is the fact that the people who were tested are drug 
affected. In addition to methadone, individuals are not required to stop their use 
of alcohol. When symptoms are medicated by drug use, a true picture of the 
presence and intensity of feelings or symptoms is compromised. As a result of 
their chemical dependency, clients report information from a drug affected 
perspective. Memory is impaired, and the reporting of experiences and feelings 
is altered by their drug use as well as the progression of the chemical 
dependency. In addition, it is important to remember that methadone is an 
opiate which replaces the naturally occurring opiates. The administration of 
methadone affects brain chemistry in other ways. While methadone stabilizes 
neurochemistry, it is unclear as to whether or not the resultant medication of 
symptoms actually suppresses underlying emotions and issues that could 
otherwise be addressed and resolved in therapy. If methadone does suppress 
feelings and emotional experience, then the questionnaire results would be 
skewed toward lower scores. The use of street drugs would also lower scores, 
thus lowering the correlation between PTSD, internalized shame and treatment 
outcome variables. 
In addition, while the study looked for correlations between treatment 
outcomes, PTSD, and internalized shame, the study was not designed to look 
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carefully at the nature of trauma in each client’s life. In order to realistically 
determine and track the impact of trauma and the effects of treatment in a 
chemically dependent population, it would be necessary to gather much more 
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information about an individual’s experiences of both physical and emotional 
abuse as well as nd his or her exposure to violence. 
Psychosocial histories contain some history pertaining to childhood and 
relational abuse experiences. Trauma, such as witnessing and/or participating 
in violent events, is also experienced as a result of living as an addict. However, 
this type of information gathering is not at present a mandatory part of intake at 
the clinics. At clinics, general questions relating to the experiences and 
symptoms of trauma are frequently not asked. 
Clients who suffer from toxic shame, trauma, or PTSD often don’t recall 
their experiences or they withhold information to avoid re-experiencing painful 
feelings. If the questions are not asked, the experiences of PTSD, trauma and 
internalized shame often go undetected. Further studies could address 
therapeutic outcomes in clinics where these issues are thoroughly assessed and 
addressed from the time of initial clinical contact. Variables such as the nature 
of treatment and the improvement of symptoms could be measured and tracked 
as a means to better understand how treatment affects subjects’ experiences. 
Topic sentence ?? This study was also limited by not including client interviews, 
which would have captured more information about an individual’s history and 
experiences of PTSD and internalized shame. In addition, the client’s subjective 
report of his or her progression in treatment was not obtained. 
Limitations of the study also result from the way in which treatment is 
framed, leaving a number of questions still unresolved. Are the clients coming to 
methadone treatment for the sole purpose of discontinuing their heroin use? Are 
they coming to address chemical dependency? Are they looking to merely 
substitute their drug use? Are they coming to address other symptoms or 
chemical dependency alone? Are they aware of their PTSD diagnosis? Are 
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they being treated for two distinct conditions, or are their symptoms framed as 
general anxiety, paranoia or depression? What are the goals of treatment? 
How is progress measured? What conditions are being addressed? What is 
understood about the nature of the individual’s condition, both chemically and 
psychologically? 
Another limitation of this study, is its inability to address the confounding 
variables which are presented in current debates around the use of methadone 
and the treatment of trauma. 
In the following section, the neurochemistry of heroin addiction will be 
described along with a review of the neurochemical changes involved in trauma. 
The goal of these presentations is to demonstrate how these two conditions 
parallel, mirror, and mask one another. An understanding of both, at the levels 
of chemistry and psychological dynamics helps to further understand the 
feedback loops which may make it difficult for clients to proceed int treatment 
and lay the framework for future studies. 
Further Studies 
Along with the studies that measure treatment outcomes when different 
therapies are used to address PTSD and internalized shame, further studies 
should address the controversies that are central to methadone treatment. 
Questions that address these issues are: What role does methadone play in 
stabilizing an individual’s chemical dependency? At the same time, what role 
does it play in medicating PTSD and shame symptoms? How do the methadone 
treatment goals of changing one’s lifestyle, building supports, and counseling, 
impact PTSD symptomology? What role does methadone play in possibly 
masking symptoms that could be and should be addressed more directly in 
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therapy? Does the use of methadone bias research results? Is there a way to 
explore and measure the effects that medicating symptoms have on the 
relationships between chemical dependency and shame or PTSD? 
Further studies could address therapeutic outcomes in clinics where 
these issues are thoroughly assessed and addressed from the time of initial 
clinical contact. Variables such as the nature of treatment and the improvement 
of symptoms could be measured and tracked as a means to better understand 
how treatment affects subjects’ experiences 
In future research, studies could use a multivariate diagnosis that would 
facilitate a more comprehensive study of outcomes. Other studies have 
identified anxiety, depression, paranoia,and personality disorders in people who 
have the disease of chemical dependency. However, when these symptoms are 
viewed as components of posttraumatic stress, treatment protocol would need to 
be modified. New steps in treatment would need to be measured in terms of 
these newly anticipated outcomes. Theoretically, by identifying PTSD symptoms 
along with internalized shame in the methadone population, comprehensive 
treatment would facilitate more healing and progress in methadone programs. 
Outcome studies could then better address the complexities of treating chemical 
dependency, PTSD and internalized shame. 
In Summary 
The inter-correlations in this study strengthen the existing evidence that 
internalized shame, PTSD and chemical dependency are all intertwined. This 
study suggests that internalized shame, PTSD, and chemical dependency each, 
significantly effects brain chemistry and, consequently the individual’s Thus each 
of these three factors appears to have an effect on the ability of the client to 
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progress in treatment. The study suggests that while PTSD is found to be 
prevalent in methadone and other chemically dependent populations, generally 
it goes untreated. Several studies that were reviewed in this research also 
suggest that when left untreated, symptoms worsen and treatment is prolonged. 
This study found the prevalence of PTSD and internalized shame to be 
high in this methadone population, ten to twelve times higher than in the general 
population and two and a half time higher than in other chemically dependent 
populations. The inter-correlations in this study strengthen the existing evidence 
that internalized shame, PTSD and chemical dependency are ail intertwined. 
Correlations between PTSD, internalized shame and the treatment outcome 
variables of drug use frequency and methadone dose levels were statistically 
significant. The analyses indicate that clients who continue to use street drugs 
greater than 20% of the time and those who are on higher doses of methadone 
also experience a higher percentage of PTSD. This suggests that changes in 
how these conditions are addressed could change outcome results. 
Research in the literature review suggests that internalized shame, PTSD, 
and chemical dependency each, significantly effects brain chemistry and 
consequently affects an individual’s capacity to manage affect and behaviors 
that result from these conditions. Each of these three factors appears to have 
an effect on the ability of the client to progress in treatment. The study supports 
the idea that the co-existing condition of PTSD corresponds with higher doses of 
methadone and more frequent drug use in this methadone population. The 
study suggests that while PTSD behaviors and emotional symptoms are found to 
be prevalent in this methadone population, the actual rate of PTSD diagnosis for 
these symptoms is it is low. Several studies that were reviewed in this research 
also suggest that when left untreated, symptoms worsen and treatment is 
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prolonged. This implies that changes in how PTSD is addressed and treated 
could change treatment outcomes. Due to the high correlation between PTSD 
and internalized shame, outcomes could also be affected by addressing 
internalized shame which is an integral component of PTSD, as well as other 
trauma and chemical dependency. 
The literature emphasizes the importance of viewing clients as dually or 
multiply diagnosed when evaluating treatment progress. Studies on chemical 
dependency and PTSD suggest that a more comprehensive understanding 
about these co-existing conditions is essential for improved outcomes. Because 
PTSD, internalized shame and chemical dependency can parallel, mirror and 
mask one another, training the staff to increase their abilities to correctly discern 
between these conditions, could make a significant difference in treatment 
strategies and outcomes.Training the staff, increasing their abilities to correctly 
discern between the symptoms and conditions of PTSD, internalized shame, and 
chemical dependency which can parallel, mirror and mask one another in 
treatment could make a significant difference. Diagnoses and treatment, 
informed by these differentiations could change the direction and treatment 
efficacy of treatment for methadone and other chemically dependent 
populations. 
The roles that PTSD and internalized shame play in treatment outcomes 
is yet unmeasured. However, this study supports the findings that progress in 
treatment is compromised when there is a diagnosis of PTSD in a client. The 
relationship between the outcome variables of drug use and methadone dose is 
strong. Although the variable of internalized shame was not statistically 
significant in the two way analyses, its high correlation with PTSD in this study, 
substantiate a relationship between PTSD and internalized shame. According to 
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literature, the effects of internalized shame are profound and its treatment could 
facilitate marked improvement in outcomes. Thus, future outcome studies could 
be designed to more accurately measure its effects on treatment outcomes are 
effected by PTSD and internalized shame. 
Research reviewed in this study supports the understanding that there is 
the potential for clients to remain stuck in biochemical, emotional and behavioral 
feedback loops, if PTSD and internalized shame are not explored and addressed 
in treatment. The study discusses how self-defeating behaviors, biochemical 
deficiency, a lack of biochemical support for changing and modulating affect, as 
well as and the self-annihilating effects of retriggered trauma and internalized 
shame tend to slow down the process of healing when they are not properly 
addressed. 
Hopefully, this study will begin to build a bridge between conventional 
methadone treatment- which uses behavioral modification and drug 
replacement therapies—with the exciting new findings in neurobiochemistry. 
The long-term neurochemical effects of trauma, internalized shame and drug use 
present a full range of concerns for the person who is on methadone 
maintenance. 
In the emerging fields of psychoneurobiology, behavioral, neurochemical, 
and wholistic approaches for opiate dependency can compliment one another 
and increase the client’s capacity for success and healing. The potential for a 
more comprehensive, scientific and effective treatment is increased by 
integrating these modalities with current research. This new way of thinking 
holds profound implications for treating and working with approaching the 
treatment of people who are on methadone maintenance and other chemical 
dependency programs. 
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Hopefully, this study will begin to build a bridge between conventional 
methadone treatment- which uses behavioral modification and drug 
replacement therapies—with the exciting new findings in neurobiochemistry 
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CONSENT FORM 
I am asking you to participate in a study that is looking at methadone treatment. I 
am looking at concerns and issues that might be addressed when they are identified in 
treatment. I am asking you to complete two questionnaires. These questionnaires are 
part of a research study I am conducting to complete my doctoral work at the University 
of Massachusetts, Amherst The information gathered from this interview will be used 
initially in a doctoral thesis. The same information may, at a later date, be used in articles 
or papers 
One hundred and fifty people will be filling out these surveys and the information 
will be grouped together. No information about you will leave the clinic. In addition to 
filling out the surveys which will be given to you by your case manager, I am asking your 
permission to record data from your MIS intake form and to record drug screen data. 
Again, your anonymity is assured. The following safeguards will be used when 
information is collected for this study: all information will be recorded anonymously. A 
number code will be used to identify each questionnaire. No individually identifiable 
information will be used. Confidentiality is guaranteed. 
Participation in this study is voluntary. 
There will be no monetary compensation for participation. 
There is no anticipated risk in participation. 
I will be pleased to share the results of this study with you at its conclusion. Please make 
requests at the methadone clinic office. 
I have read and understood this consent form. I am willing to participate in the 
study. 
Date: Signature: 
Please print your name: 
Thank you for your time! 
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Hoja de Consentmriento 
Le estoy pidiendo que participe en un estudio que examina el tratamiento con Metadona. 
Estoy examinando aspectos y asuntos que se podrian discutir una vez identificados en 
tratamieno. Le estoy piendo que complete dos cuestionarios. Estos cuestionaiios son 
parte de un estudio investigativo que estoy conduciendo para completar un grado doctoral 
en la Universidad de Massachusetts en Amherst La informacion que se recogera en esta 
entrevista se usara inicialmente para una tesis doctoral. La misma informacion podra 
tambien ser utilizada en el futuro para publicaciones profesionales. 
Ciento cincuenta personas completaran la encuesta y la informacion se agrupara. 
Ninguna informacion sobre listed saldra de la clinica. Ademas de llenar la encuesta que 
le dara su consejero/ra, le estoy pidiendo su permiso de recopilar informacion de su 
formulario MIS y de recopilar data de sus examenes de drogas. De nuevo, su anonimidad 
esta garantizada. Por su seguridad, los siguientes procedimientos seran udlizados al 
recopilar informacion: toda informacion sera documentada anonimamente. Un numero 
de codigo sera usado para identificar cada cuestionario. No se utilizara informacion 
alguna que la/lo identifique. Se garantizara su confidencialidad. 
Participation en este estudio es voluntario. 
No habra compensation economica por participar. 
No se anticipa riesgo alguno por participar. 
Con mucho gusto compartire los resultados de este estudio con usted al concluir el 
mismo. De ser asi, por favor, notifique la oficina en la clinica de metadona. 
He leido y entendido esta hoja de consentimiento. Estoy de acuerdo en participar en el 
estudio. 
Fecha_ 
Firma: 
Favor escribir su nombre en letra de 
molde:__ 
Gracias por su tiempo! 
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APPENDIX B 
DEMOGRAPHIC SURVEY 
105 
C/3 02 
CJ 
> 
ee: 
u 
co 
02 
C/3 
=) 
02 
O 
2 
£ 
ca 
3 
co 
CL 
a 
C/3 
CO 
< 
H 
CSC 
< 
c. 
£ 
M 
> 
X 
E P 
Z 
cc 
i 
□ □ 
LI □ □ □ □ □ □ 
CO 
CO 
2 
C£ 
□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ 0 i m □ □ □ □ 
I 
£ 
3 
c 
l = 
■g *» 
«^ 
S ; 
c s 
•ft 
w> 
E 
B 
2 
"ill 
sdD St s 
a 
i !□!□ 
i !□!□ 
□ □□□ □ □ □ □ □ □ □ □ 
2 O 
o 
O' 
© 
B 
I 
a 
a 
o 
' _ o 
;□ l 
-a 
CJ 
M 
3 
O 
£ 
3 
I 
u 
3 
J£ O — 
£ 5 E 
*3 00*3 
< < < 
— « c • c 
8 
LL 
5 ^ >— 
o —• 
2 
SIDP 
CJ 
x- 
£ E 2 w 
12 — O — ^ 
2 c c 
a « — t ; 
“ ~ ■« ~ ® 
= o i «. s 
O0 •” 
^ X5 C. 
»*“ J——I »- o 
?□ ? I ~ o 
-= c_ 
.=* E ^ = 
= W Q CJ 
Q O 
o 
£ 
— <M 
106 
?(1
5M
 
•
 
S/
IM
 
-
 
PO
60
34
 
I 
APPENDIX C 
SCALES 
107 
SURVEY I 
This inventory consists of numbered statements. Read each statement and decide 
whether it is true as applied to you or false as applied to you. 
If a statement is true or mostly true, as applied to you, circle the T. If a statement is 
false or not usually true, as applied to you, circle F. If a statement does not apply to you 
or if it is something that you don’t know about, make no mark on the answer sheet But 
try to give a response to every statement 
Remember to give your own opinion of yourself. 
1. T F 
2. T F 
3. T F 
4. T F 
5. T F 
6. T F 
7. T F 
8. T F 
9. T F 
10. T F 
11. T F 
12. T F 
13. T F 
14. T F 
I have a good appetite. 
I wake up fresh and rested most mornings. 
My daily life is full of things that keep me interested. 
Once in awhile I think of things too bad to talk about. 
I am sure I get a raw deal from life. 
At times I have very much wanted to leave home. 
No one seems to understand me 
At times I have fits of laughing and crying that I 
can not control. 
I have nightmares every few nights. 
I find it hard to keep my mind on a task or job. 
I have had very peculiar and strange experiences. 
At times I feel like smashing things. 
I have had periods of days, weeks, or months when I couldn't take 
care of things because I couldn't "get going." 
My sleep is fitful and disturbed. 
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15. T F 
16. T F 
17. T F 
18. T F 
19. T F 
20. T F 
21. T F 
22 T F 
23. T F 
24. T F 
25. T F 
26 T F 
27 T F 
28. T F 
29. T F 
30. T F 
31. T F 
32. T F 
33. T F 
34. T F 
Once a week or oftener I suddenly feel hot all over, for no real 
reason. 
I am in just as good physical health as most of my fiiends. 
Most anytime I would rather sit and daydream than do anything 
else 
I am a very sociable person. 
I have not lived the right kind of life. 
I wish I could be as happy as others seem to be 
I am troubled by discomfort in the pit of my stomach every few 
days or oftener. 
Most of the time I feel blue. 
I usually feel that life is worthwhile. 
I do many things which I regret afterwards (I regret 
things more than others seem to). 
At times I have a strong urge to do something harmful or shocking. 
I don’t seem to care what happens to me. 
Much of the time I feel as if I have done something wrong or evil. 
I am happy most of the time. 
Often I feel as if there is a tight band around my head. 
Often I can’t understand why I have been so irritable and grouchy. 
I believe that my home life is as pleasant as that of most people I 
know. 
I have often lost out on things because I couldn’t make up my 
mind soon enough. 
Most nights I go to sleep without thought or ideas bothering me. 
During the past few years I have been well most of the time 
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35. T 
36. T 
37. T 
38. T 
39. T 
40. T 
41. T 
42. T 
43. T 
44. T 
45. T 
46. T 
47. T 
48. T 
49. T 
50. T 
51. T 
52. T 
53. T 
54. T 
55. T 
56. T 
F I feel that I have often been punished without cause. 
F Sometimes I feel as if I must injure either myself or someone else. 
F My memory seems to be all right 
F I have had periods in winch I carried on activities without knowing 
later what I had been doing. 
F I am afraid of losing my mind. 
F There is something wrong with my mind. 
F I frequently find myself worrying about something. 
F I hardly ever notice my heart pounding and I am seldom short of 
breath. 
F I have periods of such great restlessness that I cannot sit long in a 
chair. 
F I dream frequently about things that are best kept to myself. 
F I believe I am no more nervous than most others. 
F Life is a strain for me much of the time. 
F I am so touchy on some subjects that I can’t talk about them. 
F Even when I am with people I feel lonely much of the time. 
F I seem to make friends about as quickly as others do. 
F I cannot keep my mind on one thing. 
F I feel anxiety about something or someone almost all the time. 
F I easily become impatient with people. 
F Most of the time I wish I were dead. 
F Sometimes I become so excited that I find it hard to get to sleep. 
F I have certainly had more than my share of things to worry about. 
F I often feel as if things are not real. 
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y/. 1 F I have strange and peculiar thoughts. 
58. T F I hear strange things when I am alone. 
59. T F I have more trouble concentrating than others seem to have. 
60. T F Bad words, often terrible words, come into my mind and I 
can ot get rid of them. 
61. T F Sometimes some unimportant thought will run through 
my mind and bother me for days. 
62. T F I have sometimes felt that difficulties were piling up so high that I 
could not overcome them. 
63. T F It makes me feel like a failure when I hear of the success of 
someone I know well. 
64. T F I am never happier than when alone. 
65. T F Whenever possible I avoid being in a crowd. 
66. T F I am not easily angered. 
67. T F I am not happy with myself the way I am. 
68, T F I have sometimes stayed away from another person because 
I feared doing or saying something that I might regret afterwards. 
69. T F Often, even though everything is going fine for me, I feel that I 
don’t care about anything. 
70. T F I am usually calm and not easily upset. 
71. T F Several times a week I feel as if something dreadful is about to 
happen. 
72. T F I feel tired a good deal of the time. 
73. T F I sometimes feel that I am about to go to pieces. 
74. T F I have often been frightened in the middle of the night. 
75. T F Often I get confused and forget what I want to say. 
Ill 
76. T F Some people think it’s hard to get to know me. 
77. T F I am never happier than when I am by myself. 
78. T F My life is empty and meaningless. 
79. T F I almost never lose self-control. 
80. T F It takes a great deal of effort for me to remember what people tell 
me these days. 
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iiscala 1 
Este cuestionario consta de oraciones o proposiciones enumeradas. Lea cada una y 
decida si, en su caso, es cierta o falsa. Queda por sobre entendido que listed respondera a 
las preguntas de acuerdo a su sexo. 
Si la oracion es cierta, o mas o menos cierta en su caso, marquela letra C(Cierto). Si la 
oracion es falsa, o mas o menos falsa en su caso, marque con la letra F (Falso). Si la 
oracion no se aplica a listed, o si se trata de algo que desconoce, no haga • 
marca alguna en la hoja de contestaciones. Pero trate de dar una respuesta 
a cada oracion. 
Recuerde dar su opinion propia acerca de usted mismo. 
1. C F 
2. C F 
3. * C F 
4. C F 
5. C F 
6. C F 
7. C F 
8. C F 
9. C F 
10. C F 
11. C F 
12. C F 
13. C F 
14. C F 
Tengo buen apetito. 
Me despierto fresco(a) y descansado(a) casi todas las mananas. 
Mi vida diaria esta llena de cosas que me mantienen interesado(a). 
De vez en cuando pienso en cosas demasiado malas como para 
hablar de ellas. 
Estoy seguro(a) que la vida me trata mal. 
A veces he sentido muchisimos deseos de abandonar mi hogar. 
Nadie parece comprenderme. 
A veces me d£n ataques de risa y llanto que no puedo controlar. 
Me dan pesadillas una que otra noche. 
Me cuesta concentrarme en una tarea o trabajo. 
He tenido experiencias muy o extranas. 
A veces me dan ganas de destrozar cosas. 
He tenido periodos de dias, semanas, o meses en los cuales no 
podia ocuparme de nada por no tener el animo para hacerlo. 
Mi sueno es sobresaltado e intranquilo. 
15. C F 
16. C F 
Una vez por semana o con mas frecuencia, siento de pronto calor 
por todo el cuerpo sin razon aparente. 
Me encuentro en tan buenas condiciones de salud ffsica como la 
mayona de mis amigos. 
17. C F En cualquier momento dado preferina sentarme a sonar 
despierto(a) que hacer cualquier otra cosa. 
18. C F Soy una persona muy sociable. 
19. C F No he vivido un tipo de vida propio y correcto. 
20. C F Quisiera poder ser tan feliz como otros parecen serlo. 
21. C F Sufro de malestares en la boca del estomago varias veces a la 
semana o con mas frecuencia. 
22. C F 
23. * C F 
24. C F 
25. C F 
26. C F 
27. C F 
Casi siempre me siento triste. 
Por lo general siento que la vida vale la pena. 
Hago muchas cosas de las que despues me anepiento (me 
arrepiento mas que los demas de las cosas). 
^ # *• 
A veces siento un fiierte impulso de hacer algo danino o chocante. 
No parece importarme lo que me suceda. 
La mayor parte del tiempo me siento como si hubiera hecho algo 
main o inalvado. 
28. C F Soy feliz la mayor parte del tiempo. 
29. C F A menudo siento como si tuviera una presion alrededor de 
mi cabeza. 
30. C F 
31. C F 
32. C F 
A menudo no puedo comprender por que he estado tan 
malhumorado(a) e irritable. 
Creo que mi vida de hogar es tan agradable como la de la mayoria 
de las personas que conozco. 
Confrecuencia he perdido oportunidades porque no he podido 
decidirme a tiempo. 
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33. C F 
34. • C F 
35. C F 
36. C F 
Casi to das las noches me voy a dormir sin pensamientos o ideas 
que me causen molestia. 
✓ 
Durante los ultimos anos he estado bien la mayor parte del tiempo. 
Siento que frecuentemente he sido castigado/castigada sin motivo. 
Algunas veces siento como si tuviera que herirme a mi mismo(a) o 
a otra persona. 
37. C F Mi memoria parece estar bien. 
38. C F He tenido penodos en los cuales he realizado actividades sin saber 
mas tarde lo que he estado haciendo. 
39. C F Tengo miedo de perder el juicio. 
40. C F Hay algo que no anda bien en mi mente. 
41. C F 
42. C F 
43. C F 
44. C F 
45. C F 
46. C F 
47. C F 
48. C F 
49. C F 
50. C F 
51. C F 
Frecuentemente me encuentro preocupado(a) por algo. 
Raras veces noto mi corazon palpitar y muy pocas veces me falta 
la respiration. 
Tengo penodos de tanta intranquilidad que no puedo permanecer 
sentado(a) en una silla por mucho tiempo. 
Sueno frecuentemente con cosas que mejor las reservo para mi. 
Creo que no soy mas neivioso(a) que la mayona de las personas. 
La mayor parte del tiempo la vida es una carga pesada para mi. 
Soy tan quisquilloso(a) acerca de algunos asuntos que ni siquiera 
puedo hablar de ellos. 
Aun cuando estoy acompanado(a), me siento solo(a) la mayor 
parte del tiempo. 
Me parece que hago amistades tan rapidamente como los demas. 
No puedo concentrarme en una sola cosa. 
Siento ansiedad por algo o por alguien casi todo el tiempo. 
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52. C 
53. C 
54. C 
55. C 
56. C 
57. C 
58. C 
59. C 
F Me impaciento facilmente con la gente. 
F La mayor parte del tiempo quisiera estar muerto(a). 
F Algimas veces me excito tanto que me cuesta doimiime. 
F Sin duda alguna, en cuanto a preocupaciones, he tenido mas de la 
cuenta. 
F A menudo siento como si las cosa no fueran reales. 
F Tengo pensamientos extranos y peculiares. 
F Oigo cosas extranas cuando estoy solo(a). 
F Tengo mas .dificultad para concentrarme que la que parecen tener 
los demas. 
60. C F Mai as palabras, a menudo palabras horribles, vienen a mi mente y 
no puedo librarme de ellas. 
61. • C F Algunas veces algun pensamiento sin importancia me viene a la 
mente y me molesta por dias. 
62. C F Algunas veces he sentido que las dificultades se acumulaban de tal 
modo que no podia vencerlas. 
63. C F Me siento un(a) fracasado(a) cuando oigo hablar del exito de 
alguien a quien conozco bien. 
64. C F Nunca me siento mas feliz que cuando estoy solo(a). 
65. C F Siempre que me es posible, evito encontranne en una multitud. 
66. C F 
67. C F 
68. C F 
69. C F 
70. C F 
No me enojo con facilidad. 
No estoy contento(a) conmigo mismo(a) de la manera que soy. 
A veces me he mantenido alejado(a) de otra persona porque he 
temido hacer o decir algo de lo que pudiera arrepentirme despues. 
Con firecuencia, aun cuando todo me va bien, siento que nada me 
importa. 
Por lo general soy una persona tranquila y no me altero facilmente. 
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71. C F 
72. C F 
73. C F 
74. C F 
75. C F 
76. C F 
77. C F 
78. C F 
79. C F 
80. C F 
Varias veces por semana siento como si algo espantoso fiiera a 
suceder. 
Me siento cansado(a) una buena parte del tiempo. 
Algunas veces me siento a punto de derrumbarme. 
Con frecuencia he sentido miedo en el medio de la noche. 
A menudo me siento confundido(a) y olvido lo que quiero decir. 
Cierta gente cree que es dificil llegar a conocerme. 
Nunca me siento mas feliz que cuando estoy solo(a). 
Mi vida es vacia y carece de sentido. 
Casi nunca pierdo el control. 
Hoy en dia me toma mucho esfuerzo recordar lo que me dicen. 
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Appendix C 
Internalized Shame Scale 
Below is a list of statements describing feelings or experiences that you may have from time to time or that 
are familiar to you because you have had these feelings and experiences for a long time. Most of these 
statements describe feelings and experiences that are generally painful or negative in some way. Some 
people will seldom or never have had many of these feelings. Everyone has had some of these feelings at 
some time, but if you find that these statements describe the way you feel a good deal of the time, it can be 
painful just reading them. Try to be as honest as you can in responding. 
Read each statement carefully and circle the number to the right of the item that indicates the 
frequency with which you find yourself feeling or experiencing what is described in the 
statement. 
In each case, answer according to how you are feeling RIGHT NOW. Use the scale below. 
SCALE 
0 1 2 3 4 
Never Seldom Sometimes Often Almost Always 
1.1 feel like I am never quite good enough. 
2.1 feel somehow left out 
3.1 think dial people look down on me. 
4. All in all, I am inclined to feel that I 
am a success. 
5.1 scold myself and put myself down. 
6.1 feel insecure about others opinions of me. 
7. Compared to other people, I feel like I 
somehow never measure up. 
8.1 see myself as being veiy small 
and insignificant 
9.1 feel I have much to be proud of. 
10.1 feel intensely inadequate and 
full of self-doubt 
11.1 feel as if I am somehow defective as a 
person like there is something basically 
wrong with me. 
12. When I compare myself to others I am just 
not as important. 
13.1 have an overpowering dread that my faults 
will be revealed in front of others. 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
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14. 0 1 2 3 4 Siento que tengo muchas cuaidades buenas. 
15. 0 1 2 3 4 Me veo esforzandome para que todo saiga perfecto y nunca lo 
logro. 
16. 0 1 2 3 4 Pienso que todos pueden ver mis defectos. 
17. 0 1 2 3 4 Cada vez que cometo un error podria golpearme a mi 
misma/o. 
18. 0 1 2 3 4 En general, estoy complacida/o conmigo misma/o. 
19. 0 1 2 3 4 Me gustaria desaparecer cada vez que cometo un error. 
20. 0 1 2 3 4 Sigo pensando una y otra vez en mi mente sobre hechos 
dolorosos hasta que me abrumo. 
21. 0 1 2 4 Me siento que soy una persona con valor, por lo menos en 
igual piano que otras personas. 
22. 0 1 2 3 4 A veces siento que voy a explotar en mil pedazos. 
23. 0 1 2 3 4 Siento que he perdido el control sobre las funciones de mi 
cuerpoymis senrimientos. 
24. 0 1 2 3 4 A veces me siento a nivel del suelo. 
25. 0 1 2 3 4 A veces me siento tan expuesta/o que quisiera que me tragara 
la tierra. 
26. 0 1 2 3 4 Tengo este vacio doloroso dentro de mi que no he podido 
llenar. 
27. 0 1 2 3 4 Me siento vacia/o y frustrada/o. 
28. 0 1 2 3 4 Tomo una actitud positiva hacia mi. 
29. 0 1 2 4 Mi soledad es como un vacio. 
30. 0 1 2 4 Siento como que algo hace falta. 
GRACIA !! 
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Escalall 
La siguiente es una lista de oraciones que describen sendmientos o 
experiencias que podemos sentir ea ocasiones o que nos son familiares 
porque hemos senddo estos sendmientos y experiencias durante mucho 
tiempo. 
La mayoria de estas oraciones describen sendmientos y experiencias que por 
lo general son de alguna forma dolorosos/as o negativos/as. Algunas 
personas casi nunca o nunca han experimentado muchos de estos 
sendmientos. 
Todos hemos senddo estos sendmientos en algun momento, pero si siente que 
estas oraciones describen como usted se siente gran parte 
del dempo, puede causarle dolor el solo leerlas. 
Trate de ser lo mas sincero posible al contestar. 
Lea cada ora cion cuidadosamente y ponga un circulo alrededor del numero a 
la derecha de la frase que describe con que frecuencia usted siente o 
experimenta lo que describe la oracion correspondiente. En cada una, 
conteste de acuerdo a como se siente EN ESTE MOMENTO. 
Use la siguiente escala: 
ESCALA 
0 1 2 
Nunca Casi Nunca A Veces Frecuentemente 
4 
Casi Siempre 
1. 0 1 2 3 
2. 0 1 2 3 
3. 0 1 2 3 
4. 0 1 2 3 
5. 0 1 2 3 
6. 0 1 2 3 
7. 0 1 2 3 
8. 0 1 2 3 
9. 0 1 2 3 
10. 0 1 2 3 
11. 0 1 2 3 
12. 0 1 2 3 
13. 0 1 2 3 
4 Me sienro que nuca soy lo suficientemente buena/o. 
4 Me sienro de cierta man era excluida/o. 
4 Pienso que la gente me desprecia. 
4 En general, me inclino a pensar que soy un/a triunfador/a. 
4 Me llamo la atencion y me reprimo a mi misma/o. 
4 Me siento insegura/o de la opinion que tienen la gente de mi. 
4 Comparandome con otras personas, siento que nunca sere lo 
suficientemente buena/o. 
4 Me considero inferior e insignificante. 
4 Siento que tengo mucho de que senrinne orgullosa/o. 
4 Me siento sumamente inadecuada/o y llena/o de desconfianza 
en mi misma/o. 
4 Siento que de cierta forma estoy defectuosa/o como persona, 
como que hay algo malo conmigo. 
4 Cuando me comparo con otras personas no me veo tan 
importante como ellas. 
4 Tenso un temor abrumador de que mis faltas se revelaran 
frente a otras personas. 
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14.1 feel I have a number of good qualities. 
15.1 see myself striving for perfection only to 
continually fell short 
16.1 think others are able to see my defects. 
0 12 3 4 
0 12 3 4 
0 12 3 4 
17.1 could beat myself over the head with a 
club when I make a mistake. 0 12 3 4 
18. On the whole, I am satisfied with myself 0 12 3 4 
19.1 would like to shrink away when I make 
a mistake. 0 12 3 4 
20.1 replay painful events over and over in my 
mind until I am overwhelmed. 
'll. I feel I am a person of worth at least on an 
equal plane with others. 
22. At times I feel like I will break into a 
thousand pieces. 
23.1 feel as if I have lost control over my body 
functions and feelings. 
24. Sometimes I feel no bigger than a pea. 
25. At times I feel so exposed that I wish the 
earth would open up and swallow me. 
26.1 have this painful gap within me that I 
have not been able to fill. 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
0 12 3 4 
27.1 feel empty and unfulfilled. 
28.1 take a positive attitude toward myself. 
29. My loneliness is more like emptiness. 
30.1 feel like there is something missing. 
0 
0 
0 
0 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
final draft 
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Summary of Demographic Characteristics 
Table I presents the demographic characteristics of the participants in this study. Overall, the 
demographics represent a range of characteristics. 
Table 1 
Months in 
Treatment Count CumCnt Percent CumPct 
Age 
Count CumCnt Pet CumPct 
6 10 10 8.33 8.33 20-29 7 7 5.83 5.83 
7-24 29 39 24.17 32.50 30-39 59 66 49.17 55.00 
25-36 38 77 31.67 64.17 40-49 43 109 35.83 90.83 
37-48 33 110 27.50 91.67 50+ 11 120 9.17 100.00 
49-60 7 117 5.83 97.50 N= 120 
60+ 
N= 120 
3 120 2.50 100.00 
Sex Race 
Count CumCnt Percent CumPct Count CumCnt Percent CumPct 
Male 63 63 52.50 52.50 Caucasian 1 21 21 17.50 17.50 
Female 2 57 120 47.50 Af ro-Amer 2 18 39 15.00 32.50 
N= 120 Latino 3 68 107 56.67 89.17 
Other 
N= 120 
13 120 10.83 100.00 
Puerto Rican Grade 
Count CumCnt Percent CumPct Count CumCnt Percent CumPc 
no 55 55 45.83 45.83 <9th 17 17 14.66 14.66 
yes 65 120 54.17 100.00 9-llth 41 58 35.34 50.00 
N= 120 12th 37 95 31.90 81.90 
12th + 21 116 18.10 100.00 
N= 116 
★ — 4 
Residence Marital 
Count CumCnt Percent CumPct Status Count CumCnt Percent CumPct 
City 117 117 97.50 97.50 Never 61 61 52.14 52.14 
Rural 3 120 2.50 100.00 Married 25 86 21.37 73.50 
N= 120 Separated 11 97 9.40 82.91 
Divorced 17 114 14.53 97.44 
Widowed 3 117 2.56 100.00 
N= 117 
*= 3 
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s, 
Employment Income 
Count CumCnt Perc CumPct No. CumCnt Perc 
Not Working 85 85 72.65 72.65 0 34 34 29 
Looking 21 106 17.95 90.60 <$2,000 4 38 3 
Part Time 6 112 5.13 95.73 $2-4,000 21 59 18 
Full Time 5 117 4.27 100.00 $4-8,000 36 95 30.25 
N= 117 $8-10,000 17 112 14.29 
*= 3 $10-15,000 5 117 4.20 
>$15,000 
N= 119 
*= 1 
2 119 1.68 
Housing 
Count CumCnt Percent CumPct 
Children 
under 6 
Count CumCnt Percent CumPct 
Apt 113 113 94.17 94.17 0 68 68 65.38 65.38 
Insti- 2 115 1.67 95.83 1 25 93 24.04 89.4 
tution 
Group 2 117 1.67 97.50 2 10 103 9.62 99.04 
Home 3 120 2.50 100.00 3 3 1 104 0.96 100.00 
N= 120 N= 104 
16 
Children between Children over 
ages 6-18 Count CumCnt Pet CumPct 18 years No. CumCnt Pet 1 CumPct 
0 52 52 50.00 50.00 0 77 77 74.04 74.04 
1 20 72 19.23 69.23 1 11 88 10.58 84.62 
2 19 91 18.27 87.50 2 10 98 9.62 94.23 
3 9 100 8.65 96.15 3 2 100 1.92 96.15 
4 4 104 3.85 100.00 4 2 102 1.92 98.08 
N= 104 5 2 104 1.92 100.00 
★ — 16 N= 104 ★ — 16 
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Children in categories and Totals 
< 6 years 6-18 years 
Count CumCnt Percent CumPct Count CumCnt Percent CumPct 
None 68 68 65.38 65.38 None 52 52 50.00 50.00 
1+ 36 104 34.62 100.00 1+ 52 104 50.00 100.00 
N= 104 N= 104 
★ — 16 ★ — 16 
18 years Total no. 
Count CumCnt Percent CumPct children Count CumCnt Pet CumPct 
None 77 77 74.04 74.04 0 27 27 26.21 26.21 
1+ 27 104 25.96 100.00 1 20 47 19.42 45.63 
N= 104 2 23 70 22.33 67.96 
16 3 15 85 14.56 82.52 
4 9 94 8.74 91.26 
5 4 98 3.88 95.15 
6 2 100 1.94 97.09 
7 3 103 2.91 100.00 
N= 103 ★ — 17 
Living Situation Public 
Count CumCnt Pet Assisstance Count CumCnt Pet 
Alone 22 22 18 None 14 14 12 
Child<18 8 30 6 AFDC 15 29 12. 93 
Child>18 3 33 3 Welfare 27 56 23. 28 
Partner 26 59 22 SSI 49 105 42.. 24 
Parents 20 79 16.81 Unemploy 4 109 3. 45 
Other Rel 6 85 5.04 Other 7 116 6. 03 
Roomate 11 96 9.24 N= 116 
Spouse & 23 119 19.33 ★ — 4 
N= ★ — 
119 
1 
No Prior 
Treatment 
No. CumCnt Percent CumPct 
none 114 114 95.80 95.80 
*=6 
No Treatment 
But Obvious Problem 
No. CumCnt Percent CumPct 
none 108 108 91.53 91.53 
one 10 118 8.47 100.00 
N= 118 
★ — 2 
Outpatient Counseling One previous 
No. of No. Percent CumPct No 
Of Times 
0 97 82.20 82.20 none 109 
1 117 16.95 99.15 one 9 
2 1 0.85 100.00 N= 118 
N= 118 
+r — 2 
Hospitalization 
CumCnt Percent CumPct 
109 92.37 92.37 
118 7.63 100.00 
2 
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More than one Hospitalization Detoxes 
Count CumCnt Percent CumPct Number Count Percent CumPct 
No. Of Of Times 
Times 
None 113 113 94.96 94.96 0 57 47.90 47.90 
1 6 119 5.04 100.00 1 30 25.21 73.11 
N= . 119 2 6 5.04 78.15 
*= 1 3 5 4.20 82.35 
4 9 7.56 89.92 
5 4 3.36 93.28 
6 2 1.68 94.96 
7 1 0.84 95.80 
8 2 1.68 97.48 
9 1 0.84 98.32 
10 2 1.68 100.00 
N= 119 
★ — 1 
Residential Treatment 
Percent CumPct 
Out Patient Treatment 
Number Count Percent CumPct Number Count 
Of Times 
0 95 
1 20 
2 2 
3 1 
4 1 
N= 119 
79.83 79.83 
16.81 96.64 
1.68 98.32 
0.84 99.16 
0.84 100.00 
Of Times 
0 88 
1 23 
2 7 
3 1 
N= 119 
73.95 73.95 
19.33 93.28 
5.88 99.16 
0.84 100.00 
Previous Methadone Treatment DUIs 
Number Count Percent CumPct Number Count Percent CumPct 
Of Times Of Times 
0 40 33.61 33.61 0 117 98.32 98.32 
1 47 39.50 73.11 1 2 1.68 100.00 
2 25 21.01 94.12 N= 119 
3 4 3.36 97.48 ★ — 1 
4 2 1.68 99.16 
7 1 0.84 100.00 
N= 119 
*= 1 
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Age of First Methadone Treatment 
First Count Percent CumPct Count Percent CumPct 
Use 
5 1 0.84 0.84 no 41 36.94 36.94 
8 1 0.84 1.68 yes 69 62.16 99.10 
9 2 1.68 3.36 
10 3 2.52 5.88 N= 110 
11 6 5.04 10.92 ★ = 10 
12 15 12.61 23.53 
13 14 11.76 35.29 
14 12 10.08 45.38 
15 14 11.76 57.14 
16 13 10.92 68.07 
17 5 4.20 72.27 
18 8 6.72 78.99 
19 4 3.36 82.35 
20 6 5.04 87.39 
21 3 2.52 89.92 
22 1 0.84 90.76 
23 1 0.84 91.60 
24 2 1.68 93.28 
25 1 0.84 94.12 
26 2 1.68 95.80 
27 1 0.84 96.64 
28 1 0.84 97.48 
34 2 1.68 99.16 
40 1 0.84 100.00 
N= 119 
Primary Drug 
Of Choice 
Count Percent CumPct 
Administration 
of Drug 
Count Percent CumPct 
Cocaine 6 .00 5.00 Smoke 5 4.27 4.27 
Crack 1 0.83 5.83 Inhale 32 27.35 31.62 
Marijuana 1 0.83 6.67 Inject 77 65.81 97.44 
Heroin 112 93.33 100.00 Other 117 2.56 100.00 
N= 120 
Second Drug 
Of Choice 
Count Percent CumPct 
N= 117 
Third Drug 
of Choice 
Count Percent CumPct 
None 1 0.88 0.88 None 1 1.39 1.39 
Alcohol 19 16.81 17.70 Alcohol 1 40.28 41.67 
Cocaine 55 48.67 66.37 Cocaine 16 22.22 63.89 
Crack 8 7.08 73.45 Crack 8 11.11 75.00 
Marijuanal 6 14.16 87.61 Marijuana 11 15.28 90.28 
Heroin 5 4.42 92.04 Heroin 1 1.39 91.67 
Opiates 3 2.65 94.69 Methadone 1 1.39 93.06 
Amphet- 1 0.88 95.58 Opiates 1 1.39 94.44 
amines 
Benzos 3 2.65 98.23 Stimlants 1 1.39 95.83 
Other 2 1.77 100.00 Benzos 1 1.39 97.22 
N= 113 
*= 7 
Tranquilizers 
N= 72 
2 2.78 100.00 
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Methadone Dose Non-compliance 
Levels 
Count Percent CumPct Count Percent CumPct 
Low 12 10.08 10.08 Compliant 83 69.75 69.75 
Maintenance 2 45.38 55.46 Non-compliant 36 30.25 100.00 
High 42 35.29 90.76 N= 119 
Very High 4 9.24 100.00 *= 1 
N= 119 
*= 1 
Opiate Use Cocaine Use 
Count Percent CumPct Count Percent CumPct 
None 53 44.17 44.17 None 53 44.17 44.17 
Used 67 55.83 100.00 Used 67 55.83 100.00 
N= 120 N= 120 
Barbituates Benzodiazapines 
Count Percent CumPct Count Percent CumPct 
None 107 90.68 90.68 None 82 69.49 69.49 
Used 11 9.32 100.00 Used 36 30.51 : 100.00 
N= 118 N= 118 
★ — 2 ★ — 2 
Categorized by Frequency of Drug Use 
Count Percent CumPct 
0 22 28.82 18.64 
1-20 12 10.17 28.81 
21-50 20 16.95 45.76 
51-100 64 54.24 100.00 
N= 118 
Needles Count Percent CumPct Shame Scale Count Percent CumPct 
None 57 50.44 50.44 None 67 56.78 56.78 
Use 56 49.56 100.00 Sig. Shame 87 16.95 73.73 
N= 113 Severe Shame 31 26.27 100.00 
*= 7 N= 118 
PS Scale Count Percent CumPct PK Scale Count Percent CumPct 
None 45 37.50 37.50 None 44 36.67 36.67 
PTSD 29 24.17 61.67 PTSD 38 31.67 68.33 
Severe 
N= 120 
46 38.33 100.00 Severe 
N= 120 
38 31.67 100.00 
Self Esteem 
Count Percent CumPct 
Sufficient 30 25.86 25.86 
Self Esteem 
Low Self Esteem 86 74.14 100.00 
N= 116 
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Descriptive Statistics with Number and Means 
Variable N N* Mean Median TrMean St Dev 
Time 1 0 21.7 18.50 20.24 14.15 
Age 120 0 39.417 38.000 38.991 7.87 
Grade 116 4 10.595 11.000 10.808 3.14 
Income 119 1 2.210 3.000 2.121 1.73 
TllAgel 119 1 15.933 15.000 15.477 5.20 
PrimS ub 120 0 4.825 5.000 4.97 0.68 
Firstuse 118 2 23.339 23.000 23.09 7.20 
>12 119 1 2.481 2.000 1.74 4.40 
CurMeth 119 1 66.70 65.00 66.31 25.27 
Mlclean 120 0 42.98 33.00 42.20 39.07 
MlOP 120 0 24.98 12.50 22.44 30.69 
MICoc 120 0 27.68 8.50 25.20 35.39 
MIBen 118 2 14.58 0.00 10.91 
MIBarb 118 2 2.39 0.000 0.43 9.62 
PerRelap 118 2 55.20 64.00 55.79 39.53 
SelfE 116 4 14.02 15.000 14.12 5.28 
Shame 116 4 42.67 44.00 42.38 24.-68 
PSScale 120 0 30.20 30.50 30.31 14.74 
PKScale 120 0 22.89 23.00 22.89 11.63 
Variable SE Mean Minimum Maximum Q1 Q3 
Time 1.29 6.00 91.00 10.25 30.00 
Age 0.719 24.000 63.000 33.250 44.00 
Grade 0.292 0.000 18.000 9.000 12.00 
Income 0.159 0.000 8.000 0.000 3.00 
TllAgel 0.477 5.000 40.000 13.000 18. -00 
PrimS ub 0.0622 2.0000 5.0000 5.0000 
5.000 
Firstuse 0.664 10.000 41.000 17.750 28.00 
>12 0.404 0.000 30.000 0.000 3.00 
CurMeth 2.32 7.00 140.00 50.00 83.00 
Mlclean 3.57 0.00 100.00 0.00 85.25 
MlOP 2.80 0.00 100.00 0.00 43.75 
MICoc 3.23 0.00 100.00 0.00 45.75 
MIBen 2.61 0.00 100.00 0.00 14.00 
MIBarb 0.886 0.000 64.000 0.000 0.00 
PerRelap 3.64 0.00 100.00 10.75 100.00 
SelfE 0.491 0.000 24.000 11.000 18.00 
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Shame 2.29 0.00 103.00 21.00 60.00 
PSScale 1.35 2.00 56.00 17.50 43.00 
PKScale .06 1.00 57.00 14.00 33.00 
* 
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I. Correlations for Scales and Outcome Variables 
Time Meth Dose Drug Use 
Frequency 
SelfE Shame PS Scale 
Meth Dose 0.215 
0.019 
Drug Use 
Frequency 
0.006 
0.952 
0.207 
0.025 
Self 
Esteem 
0.037 
0.695 
-0.002 
0.980 
-0.026 
0.785 
Shame 0.045 
0.634 
0.081 
0.389 
0.190 
0.043 
•0.327 
0.000 
PS Scale 0.028 
0.758 
-0.048 
0.605 
0.134 
0.149 
•0.231 
0.013 
0.719 
0.000 
PK Scale 0.073 
0.425 
0.021 
0.820 
0.178 
0.054 
0.210 
0.024 
0.701 
0.000 
0.939 
0.000 
Cell Contents: Correlation 
P-Value 
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II. Correlations for Scales and Other Variables 
Time Meth Dose Drug Use Needle Sexual Age Self Shame 
Frequency Use Abuse Esteem 
Meth Dose 0.215 
0.019 
Drug Use 
Frequency 
0.006 
0.952 
0.207 
0.025 
Needle 
Use 
0.085 
0.372 
0.215 
0.023 
0.071 
0.459 
Sexual 
Abuse 
0.020 
0.850 
0.057 
0.594 
-0.021 
0.844 
0.107 
0.327 
Age 
1st Use 
-0.075 
0.416 
-0.043 
0.645 
-0.125 
0.181 
-0.124 
0.193 
-0.184 
0.082 
Self 
Esteem 
0.037 
0.695 
-0.002 
0.980 
-0.026 
0.785 
-0.001 
0.990 
-0.134 
0.212 
0.175 
0.062 
Shame 0.045 
0.634 
0.081 
0.389 
0.190 
0.043 
0.203 
0.034 
0.248 
0.020 
-0.173 
0.065 
-0.327 
0.000 
PS Scale 0.028 
0.758 
-0.048 
0.605 
0.134 
0.149 
0.131 
0.168 
0.177 
0.095 
-0.213 
0.020 
-0.231 
0.013 
0.719 
0.000 
PK Scale 0.073 
0.425 
0.021 
0.820 
0.178 
0.054 
0.117 
0.216 
0.205 
0.053 
-0.251 
0.006 
-0.210 
0.024 
0.701 
0.000 
PS Scale 
PK Scale 0.939 
0.000 
Cell Contents: Correlation 
P-Value 
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III. Correlations for Scales and Specific Drugs 
SelfE 
Esteem 
Shame PS Scale PK Scale Refused 
Testing 
Opiate 
Use 
Cocaine 
Use 
Benzo 
Use 
Shame -0.327 
0.000 
PS Scale -0.231 
0.013 
0.719 
0.000 
PK Scale -0.210 
0.024 
0.701 
0.000 
0.939 
0.000 
Refused 
Testing 
-0,095 
0.310 
0 .-078 
0.409 
0.115 
0.213 
0.162 
0.079 
Opiate 
Use 
-0.058 
0.535 
0.133 
0.153 
-0.009 
0.922 
0.020 
0.829 
0.027 
0.773 
Cocaine 
Use 
-0.028 
0.762 
0.053 
0.575 
0.015 
0.875 
0.074 
0.420 
0.049 
0.600 
0.282 
0.002 
Benzodia- 
zapine Use 
0.001 
0.988 
0.121 
0.201 
0.155 
0.094 
0.129 
0.164 
0.040 
0.665 
0.014 
0.883 
-0.140 
0.131 
Barbitu¬ 
rate Use 
0.063 
0.503 
-0.027 
0.777 
0.015 
0.876 
-0.015 
0.875 
0.274 
0.003 
0.177 
0.056 
-0.039 
0.673 
0.364 
0.000 
Cell Contents: Correlation 
P-Value 
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v 
IV. Correlations for Outcome Variables and Specific Drugs 
Time Meth Dose Drug Use 
Frequency 
Refused 
Test 
Opiate 
Use 
Cocaine 
Use 
Benzodiazapines 
Use 
Meth Dose 0.215 
0.019 
Drug Use 
Frequency 
0.006 
0.952 
0.207 
0.025 
Refused 
Test 
0.063 
0.493 
0.216 
0.019 
0.361 
0.000 
Opiate 
Use 
-0.141 
0.124 
0.277 
0.002 
0.543 
0.000 
0.027 
0.773 
Cocaine 
Use 
-0.086 
0.353 
0.037 
0.689 
0.611 
0.000 
0.049 
0.600 
0.282 
0.002 
Benzo- 
diazapine 
Use 
0.101 
0.276 
0.196 
0.034 
0.358 
0.000 
0.040 
0.665 
0.014 
0.883 
-0.140 
0.131 
Barbitur¬ 
ate Use 
0.025 
0.791 
0.226 
0.014 
0.179 
0.055 
0 f 274 
0.003 
0.177 
0.056 
-0.039 
0.673 
0.364 
0.000 
Cell Contents: Correlation 
P-Value 
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V. Correlations for Scales and Age of First Drug Use 
Age of 1st Self Shame PS Scale 
Use 
Self 0.175 
Esteem 0.062 
Shame -0.173 ■0.327 
0.065 0.000 
PS Scale -0.213 ■0.231 0.719 
0.020 0.013 0.000 
PK Scale -0.251 0.210 0.701 0.939 
0.006 0.024 0.000 0.000 
Cell Contents: Correlation 
P-Value 
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I. Two Sample T-Tests For Drug Use Frequency and Significant Variables 
A. Two Sample T-Test for Drug Use Frequency and PK Scale 
Two sample T for PK Scale 
Drug 
Use 
N Mean StDev SE Mean 
0 35 18.9 11.5 1.9 
1 83 24.7 11.2 1.2 
95% Cl for mu (0) - mu (1) : ( -10.4, -1.2) 
T-Test mu (0) = mu (1) (vs not =): T = -2.52 P = 0.014 DF = 62 
B. Two Sample T-Test for Drug Use Frequency and PS Scale 
Two sample T for PS Scale 
Drug 
Use 
N Mean StDev SE Mean 
0 35 26.1 14.6 2.5 
1 83 32.0 14.3 1.6 
95% Cl for mu (0) - mu (1) : ( -11.7, 0.0) 
T-Test mu (0) = mu (1) (vs not =): T = -2.00 P = 0.050 DF = 62 
C Two Sample T-Test for Drug Use Frequency and Shame 
Two sample T for Shame 
Drug 
Use 
N Mean StDev SE Mean 
0 34 36.0 28.1 4.8 
1 80 45.4 23.0 2.6 
95% Cl for mu (0) - mu (1) : ( -20.3, 1.6) 
T-Test mu (0) = mu (1) (vs not =): T = -1.71 P = 0.093 DF = 52 
D. Two Sample T-Test for Drug Use Frequency and Methadone Dose Level 
Two sample T for Methadone Dose Level 
Drug 
Use 
N Mean StDev SE Mean 
0 35 58.1 22.2 3.8 
1 82 70.1 25.9 2.9 
95% Cl for mu (0) - mu (1) : ( -21.4, -2.6) 
T-Test mu (0) = mu (1) (vs not =): T = -2.54 0.013 DF 74 
146 
E. Two Sample T-Test for Frequency of Drug Use and Length of Time in Treatment 
Two sample T for Time 
Use N Mean StDev SE Mean 
0 35 22.8 10.7 1.8 
1 83 21.4 15.5 1.7 
95% Cl for mu (0) - mu (1) : ( -3.5, 6.4) 
T-Test mu (0) = mu (1) (vs not =): T = 0.57 0.57 DF = 91 
F. Two Sample T-Test for Frequency of Drug Use and Age of First Drug Use 
Two sample T for TllAgel 
use 
0 
1 
N Mean 
35 16.86 
82 15.49 
StDev SE Mean 
6.06 1.0 
4.82 0.53 
95% Cl for mu (0) - mu 
T-Test mu (0) = mu (1) 
(1): ( -0.9, 3.69) 
(vs not =): T = 1.19 P 0.24 DF = 53 
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II. ANOVAS for Race and Scales 
A. One-way Analysis of Race and Shame 
Analysis of Variance for Shame 
Source DF SS MS 
Race 3 4358 1453 
Error 112 65715 587 
Total 115 70074 
Level N Mean StDev 
1 20 43.20 27.55 
2 18 33.28 20.34 
3 66 47.09 25.56 
4 12 31.58 12.80 
Pooled StDev = 24.22 
F P 
2.48 0.065 
Individual 95% CIs For Mean 
Based on Pooled StDev 
-+-+-+--f- 
( * ) 
(-* ) 
(-*-) 
( *-) 
-H-1--1-(-- 
20 30 40 50 
B. One-way Analysis of Race and the PS ScaleVariance 
Analysis of Variance for PSScale 
Source DF SS MS p P 
Race 3 1542 514 2.45 0.067 
Error 116 24327 210 
Total 119 25869 
Individual 95% CIs For Mean 
Based on Pooled StDev 
Level N Mean StDev 
21 29.14 17.95 (- -) 
2 18 26.56 11.99 (- 
3 68 32.96 14.37 (- — *-) 
4 13 22.54 11.59 (- -) 
--i— 
Pooled StDev = 14.48 18.0 24.0 30.0 36.0 
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III. T-Tests Shame Scale, PK Scale, Sexual Abuse and Needle Use 
A. Two sample T- test for Shame and Sexual Abuse 
sexA N 
0=no abuse 64 
l=sexual abuse 24 
Mean StDev SE Mean 
39.4 22.9 2.9 
52.5 23.8 4.9 
95% Cl for mu (0) - mu (1): ( -24.5, -1.7) 
T-Test mu (0) = mu (1) (vs not =): T = -2.33 P = 0.025 DF = 39 
B. Two Sample T-Test for PK Scale and Sexual Abuse 
sexA N Mean StDev SE Mean 
0=no abuse 65 21.3 11.4 1.4 
l=sexual abuse 25 26.40 9.75 1.9 
95% Cl for mu (0) - mu (1): ( -9. 9, -0.2) 
T-Test mu (0) = mu (1) (vs not =) : T = -2. 10 P = DF = 50 
C. Two Sample T-Test for PK Scale and Needle Use 
Needles N 
0=no needles 57 
l=needle use 56 
Mean StDev SE Mean 
21.4 11.5 1.5 
24.1 11.3 1.5 
95% Cl for mu (0) - mu 
T-Test mu (0) = mu (1) 
(1) : ( -6.9, 1.6) 
(vs not =): T = -1.24 P 0.22 DF = 110 
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IV. Chi Square Analysis for Cocaine Use and Other Variables 
A. Cocaine Use and Gender 
Cocaine Use 
Gender 
0=no drug 
use 
l=cocaine 
use 
Totals 
l=males 
33 
27.82 
30 
35.18 
63 
63.00 
count 
expected frequency 
2=females 
20 
25.17 
37 
31.82 
e;-7 
57.00 
count 
expected frequency 
Totals 
53 
53.00 
67 
67.00 
120 
120.00 
Chi-Square = 3.629, DF = 1, P-Value = 0.057 
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B. Cocaine and Opiate Use 
Cocaine Use 
Opiate Use 
0=no use l=cocaine 
use 
Totals 
0=no use 53 
23.41 
0 
29.59 
53 
53.00 
count 
expected frequency 
l=opiate 
use 
0 
29.59 
67 
37.41 
67 
67.00 
count 
expected frequency 
Totals 53 
53.00 
67 
67.00 
120 
120.00 
Chi-Square = 120.000, DF = 1, P-Value = 0.000 
C. Cocaine and Barbiturate Use 
Cocaine Use 
0=no use l=cocaine 
use 
Totals 
Barbituates 
0=no use 48 
48.06 
59 
58.94 
107 
107.00 
count 
expected frequency 
l=barb 
use 
5 
4.94 
6 
6.06 
1 1 
mlm -l. 
11.00 
count 
expected frequency 
Totals 53 
53.00 
65 
65.00 
118 
118.00 
Chi-Square = 0.001, DF = 1, P-Value = 0.970 
1 cells with expected counts less than 5.0 
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The LOGISTIC Procedure 
Model Fitting Information and Testing Global Null Hypothesis BETA=0 
Criterion 
Intercept 
Only 
Intercept 
and 
Covariates Chi-Square for Covariates 
AIC 139.505 132.306 
SC 142.223 140.461 • 
-2 LOG L 137.505 126.306 11.199 with 2 OF (p=0.0037) 
Score • • 10.556 with 2 DF (p=0.0051) 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr > Standardized Odds Variable 
Variable DF Estimate Error Chi-Square Chi-Square Estimate Ratio Label 
INTERCPT 1 -1.4155 0.7530 3.5334 0.0601 m Intercept 
CURMETH 1 0.0188 0.00950 3.9276 0.0475 0.251217 1.019 CURMETH 
PKSCALE 1 0.0481 0.0196 6.0559 0.0139 0.308329 1 .049 PKSCALE 
Association of Predicted Probabilities and Observed Responses 
Concordant = 68.8% Somers ' D = 0.380 
Discordant = 30.8% Gamma = 0.382 
Tied = 0.4% Tau-a = 0.162 
(2652 pairs) c = 0.690 
Residual Chi-Square = 3.0104 with 3 DF 
o
 
o
 
CT>
 
CO
 
O
 
II
 
C
L
 
Analysis of Variables Not in the Model 
Score Pr > Variable 
Variable Chi-Square Chi-Square Label 
TIME 2.3295 0.1269 TIME 
T11AGE1 0.5910 0.4420 T11AGE1 
SHAME 0.0007 0.9784 SHAME 
NOTE: No (additional) variables met the 0.1 significance level for entry into the model. 
The SAS System 
The LOGISTIC Procedure 
Summary of Stepwise Procedure 
Variable Number Score Wald Pr > Variable 
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The SAS System 
The LOGISTIC Procedure 
Step 1. Variable PKSCALE entered: 
Model Fitting Information and Testing Global Null Hypothesis BETA=0 
Intercept 
Intercept and 
Criterion Only Covariates • Chi-Square for Covariates 
AIC 139.505 134.467 
SC 142.223 139.904 • 
-2 LOG L 137.505 130.467 7.037 with 1 OF (p=0.0080) 
Score • • 6.832 with 1 DF (p=0.0090) 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr > Standardized Odds Variable 
Variable DF Estimate Error Chi-Square Chi-Square Estimate Ratio Label 
INTERCPT 1 -0.2530 0.4550 0.3092 0.5782 . . Intercept 
PKSCALE 1 0.0492 0.0193 6.4976 0.0108 0.315155 1.050 PKSCALE 
Association of Predicted Probabilities and Observed Responses 
Concordant = 64.8% Somers 1 D = 0.313 
Discordant = 33.5% Gamma = 0.318 
Tied 1.7% Tau-a = 0.134 
(2652 pairs) c = 0.656 
Residual Chi-Square = 7.0477 with 4 DF (p=0.1334) 
Analysis of Variables Not in the Model 
Score Pr > Variable 
Variable Chi -Square Chi-Square Label 
TIME 1.7695 0.1834 TIME 
T11AGE1 0.5770 0.4475 T11AGE1 
CURMETH 4.0796 0.0434 CURMETH 
SHAME 0.0317 0.8588 SHAME 
Step 2. Variable CURMETH entered: 
The SAS System 
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Step Entered Removed In Chi-Square Chi-Square Chi-Square Label 
1 PKSCALE 1 6.8322 0.0090 PKSCALE 
2 CURMETH 2 4.0796 0.0434 CURMETH 
Conditional Odds Ratios and 95% Confidence Intervals 
Wald 
Confidence Limits 
Odds 
Variable Unit Ratio Lower Upper 
CURMETH 1.0000 1.019 1.000 1.038 
PKSCALE 1.0000 1.049 1 .010 1.090 
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Table 17. 
Profiles for Opiates(68 clients) 
Demographics Percentages 
Time 
6-12 months in treatment 13% 
1-2 years 54% 
2-4 years 29% 
Age 
30-39 years of age 54% 
40-49 years of age 29% 
Race 
Latino 51% 
Afro American 29% 
Caucasian 16% 
Other 12% 
Sex 
Men 57% 
Women 48% 
>12 months Abstinence 
No abstinence 32% 
1.5+ years abstinence 68% 
Age of First Use 
< 13 years of age 41% 
<16 years of age 72% 
<18 years of age 85% 
Physical Abuse 28% 
Sexual Abuse 28% 
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Current Methadone Dose 
Low 9% 
Maintenance 59% 
High 32% 
Relapse Percentages 
>20% relapsing 91% 
>50% 80% 
Opiates Relapsing 00% 
Cocaine 75% 
Benzodiazapines 30% 
Barbiturates 15% 
Needles 48% 
Shame 46% 27% severe 
PS Scale 68% 44% severe 
PK Scale 67% 37% 
Self-esteem 83% 
Fifty seven percent of the population did relapse with opiates. Thirty 
two percent of the subjects who were relapsing on opiates reported having no 
success in stopping the use of any of their drugs. Eighty percent of these 68 
clients relapsed >50% of the time with opiates. Seventy five percent of this 
population also relapsed with cocaine. Forty eight percent reported using 
needles and 28% reported sexual abuse in their histories. There were no 
significant differences around race, age, sex or time in the program. Shame 
scores were significant for 46% the population and high for twenty six 
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percent The PTSD scores were significant for 68% of the population on both 
tests, scoring high for 37 and 44% of the clients, while self esteem was rated 
low for eighty three percent 
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Table 18. 
Profiles for Sexual Abuse (25 clients) 
Demographics Percentages 
Age 
30-39 years of age 64% 
40-49 years of age 28% 
Race 
Latinos 44% 
Afro Americans 24% 
Caucasians 24% 
Sex 
Men 24% 
Women 76% 
>12 months Abstinence 
No abstinence 32% 
1.5+ years 68% 
Age of First Use 
<13 years of age 40% 
<16 years of age 84% 
<18 years of age 96% 
Physical Abuse 
Sexual Abuse 
Relapse Percentages 
75% 33% of relapses 
Opiates >23% 35% 
Cocaine >29% 52% 
Benzodiazapines >25% 20% 
Barbiturates >64% 04% 
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Shame 45% 
PS Scale 72% 
PK Scale 72% 
Self-esteem 75% 
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Table 19. 
Profiles for Latinos (68 clients) 
Demographics Percentages 
Age 
30-39 years of age 51% 
40+ years of age 36% 
Sex 
Men 59% 
Women 41% 
>12 months Abstinence 
None 41% 
1+ years for one or more drugs 59% 
Age of First Use 
<13 years of age 38% 
<16 years of age 62% 
<18 years of age 75% 
Physical Abuse 20% 
Sexual Abuse 20% 
Current Methadone Dose 
Low 8% 
Maintenance 59% 
High 32% 
Relapse Percentages 
>29% 66% 
>50% 49% 
Opiates 51% 
Cocaine 53% 
Benzodiazapines 23% 
Barbiturates 08% 
Needles 50% 
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Shame 55% 
PS Scale 67% 
PK Scale 70% 
Self-esteem 76% 
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Table 20. 
Profiles for Caucasians (21 clients) 
Demographics Percentages 
>12 months Abstinence 
None 33% 
1.5+ years for one or more drugs 67% 
Age of First Use 
<13 years of age 20% 
<16 years of age 75% 
<18 years of age 85% 
Sexual Abuse 38% 
Physical Abuse 19% 
Current Methadone Dose 
Low 14% 
Maintenance 10% 
High 74% 
Relapse Percentages 
>23% 74% 
Opiates 52% 
Cocaine 52% 
Benzodiazapines 57% 
Barbiturates 10% 
Needles 48% 
Shame 40% 
PS Scale 62% 
PK Scale 57% 
Self-esteem 75% 
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Table 21. 
Profiles for Afro Americans (18) 
Demographics___Percentages 
>12 months Abstinence 
None 41% 
1+ years for one or more drugs 69% 
Age of First Use 
<13 years of age 17% 
<16 years of age 78% 
<18 years of age 83% 
Physical Abuse 40% 
Sexual Abuse 40% 
Relapse Percentages 
>33% 
Opiates 
Cocaine 
Benzodiazapines 
Barbiturates 
Needles 
Shame 
PS Scale 
PK Scale 
Self-esteem 
Methadone Dose 
89% 
78% 
83% 
33% 
11% 
41% 
28% 
61% 
50% 
61% 
35% Maintenance 
47% High Dose 
A higher percent of blacks are maintained on high doses. 
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Table 22. 
Profiles for Current Methadone 0-34 mg. (12 clients) 
Demographics_Percentages 
Age 
30-39 years of age 50% 
40+ years of age 41% 
>12 months Abstinence 
Never abstinent 50% 
1.5 or more years 50% 
Race 
Latino 50% 
Sex 
Men 33% 
Women 67% 
Age of First Use 
<13 years of age 25% 
<16 years of age 67% 
Physical Abuse 22% 
Sexual Abuse 33% 
Relapse Percentages 
>20% 39% 
90-100% - 05% 
Opiates 25% 
Cocaine 42% 
Benzodiazapines 42% 
Barbiturates 0% 
Needles 25% 
Shame 38% 
PS Scale 38% 
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PK Scale 58% 
Self-esteem 50% 
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Table 23. 
Profiles for Current Methadone of 70-1 OOmg. (46 subjects') 
Demographics Percentages 
Time 
1-2 years 57% 
2-4 years 39% 
Age 
30-40- years old 50% 
30-50 years old 39% 
Sex 
Men 61% 
Women 39% 
Race 
Latino 46% 
Caucasian 30% 
Afro-American 13% 
>12 months Abstinence 
None 36% 
1+ years 64% 
Age of First Use 
<13 years of age 32% 
<16 years of age 67% 
<18 years of age 80% 
Sexual Abuse 26% 
Physical Abuse 21% 
Relapse Percentages 
>20% 75% 
Opiates 43% @ >27% + 
Cocaine 37% @ >29% + 
Benzodiazapines 29% @ >22% + 
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Barbiturates 02% @ >35%+ 
Needles 62% 
Shame 46% 30% high range 
PS Scale 65% 46% high range 
PK Scale 65% 37% high range 
Self-esteem 76% 
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Table 24. 
Profiles for Current Methadone lOOmg. (8 clients) 
Demographics_Percentages 
Time 
1- 2 years 38% 
2- 4 years 38% 
Age 
30-39 years 
40-49 years 
50+ years 
63% 
25% 
13% 
Sex 
Men 25% 
Women 75% 
Race (evenly distributed) 
>12 months Abstinence 
0 50% 
1.75+ years 50% 
Age of First Use 
<16 years of age 86% 
Physical Abuse 0 
Sexual Abuse 1 
Relapse Percentages 
100% 75% 
Opiates 
Cocaine 
Benzodiazapines 
Barbiturates 
75% @ 23% + 
75% @ 25% + 
50% @ 55%+ 
25% @ 50% + 
Needles 50% 
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Shame 57% 14% high range 
PS Scale 75% 12% high range 
PK Scale 72% 12% high range 
Self-esteem 71% 
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Table 25. 
Profiles for Zero Relapses (22) 
Demographics Percentages 
Sex 
Men 54% 
Women 46% 
Marital Status 
Married 30% 
Race 
Caucasian 18% 
Afro-American 9% 
Latino 55% 
>12 months Abstinence 
None 50% 
2+ years 50% 
Age of First Use 
<13 years of age 36% 
<16 years of age 72% 
<18 years of age 77% 
Physical Abuse 14% 
Sexual Abuse 33% 
Current Methadone Dose 
Low 14% 
Maintenance 50% 
High 32% 
Very high 5% 
Relapses 0 
Needles 42% 
Shame 24% all in high range 
PS Scale 53% 27% in high range 
PK Scale 40% 23% in high range 
Self-esteem 62% 
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Table 26. 
Profiles for 100% Relapsing 
Demographics Percentages 
Sex 
Men 38% 
Women 62% 
Marital status 
Married 20% 
Race 
Caucasian 13% 
Afro-American 28% 
Latino 47% 
>12 months Abstinence 
None 32% 
1.5+ years 68% 
Age of First Use 
<13 years of age 47% 
<16 years of age 78% 
<18 years of age 84% 
Physical Abuse 
Sexual Abuse 36% 
Current Methadone Dose 
Low 6% 
Maintenance 38% 
High 38% 
Very high 19% 
Relapse Percentages 
Opiates 44% 
Cocaine 75% 
Benzodiazapines 32% 
Barbiturates 12% 
Needles 53% 
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Shame 
PS Scale 
PK Scale 
Self-esteem 
51% 23% severe range 
74% 40% high range 
76% 38% high range 
83% 
There is a higher percentage of Afro-Americans relapsing in this category. 
Shame and PTSD scores are high in a large portion of this group. 
175 
REFERENCES 
Addiction and the Brain - Part I. (1998). The Harvard Mental Health Letter 
14(121 1-3. “ 1 
Addiction and the Brain - Part II. (1998). The Harvard Mental Health Letter 
15(1). 1-3. 1 
Akashi, A. (1994). Investigation of attachmnt, shame, and pspychological stress 
in outpatient psychotherapy clients. Doctoral dissertation, Ohio State 
University. 
Alan, S.; Gilbert, P.; & Goss, K. (1994). An exploration of shame measures: II. 
Psychopathology. Personality and Individual Differences. 17(5). 719-722. 
Andreasen, N. (1984). The Broken Brain. New York: Harper & Row. 
Attia, P. (1988). Dual Diagnosis: Definition and Treatment. Alcoholism 
Treatment Quarterly. 5(3/4). 53-63. 
Bailey, R. C.; Hser, Y.; Hsien, S.; Anglin, D. ((1994). Influences affecting 
Maintenance and cessation of narcotics addiction. Journal of Drug Issues. 
24(1-2), 249-272. 
Bean, E. D. (1994). Compulsive Overeating: An Internalized Shame Response 
to Externally Imposed Artificial Standard of Beauty. A Quasi-experimental 
Study, Smith College. 
Bianchi, E.; Maremmani, I.; Melene, D. (1992). Controlled use of heroin in 
patients on methadone maintenance treatment. Journal of Substance 
Abuse Treatment. 9(4), 383-387. 
Blaszczynski, A. P. (1984). Endorphins and psychiatry. Australian & New 
Zealand Journal of Psychiatry, 18(2). 111-112. 
Blume, E. (1990). Secret Survivors: Uncovering Incest and Its Aftereffects in 
Women. New York: Wiley & Sons. 
176 
Blume, S. (1989). Dual diagnosis: Psychoactive substance dependence and 
the personality disorders. Journal of Psvchoactive Drugs. 21f2l 139-143. 
Bollerud, K. (1990). A model for the treatment of trauma-related syndromes 
among chemically dependent inpatient women. Journal of Substance 
Treatment. 7(2\. 83-87. 
Bradshaw, J. (1988). Healing the Shame that Binds You. Deerfield Beach, FL: 
Health Communications. 
Brady, K. T.; Killeen, T.; Saladin, M. E.; Dansky, B.; etal. (1994), Comorbid 
substance abuse and posttraumatic stress disorder. American Journal on 
Addictions. 3(2V 160-164. 
Brown, P.; & Mueller, T. (1996). Posttraumatic stress disorder and substance 
abuse relapse among women: A pilot study. Psychology of Addictive 
Behaviors. 10(2). 124-128. 
Brown, P., & Stout, R. (1996). Posttraumatic Stress Disorder and Substance 
Abuse Relapse Among Women: A Pilot Study. Psychology of Addictive 
Behaviors. 10(2), 124-127. 
Brown, P. J., & Wolfe, J. (1994). Substance abuse and post-traumatic stress 
disorder comorbidity. Drug and Alcohol Dependence. 35(1). 51-59. 
Cagnon, M. E. (1992). Mid-life women and shame: The importance of 
connection, Smith College. 
Calsyn, D. A.; Roszell, D. K.; Chaney, E. F. (1989). Validation of MMPI profile 
subtypes among opioid addicts who are beginning methadone 
maintenance treatment. Journal of Clinical Psychology. 45(6). 991-998. 
Capleton, J. R., & Batey, R. G. (1992). Maintenance in Australia. Journal of 
Drug Issues. 22(3). 661-678. 
Cook, D. R. (1991). Shame, attachment, and addictions: Implications for family 
therapists. Contemporary Family Therapy An International Journal. 13(5). 
405-419. 
Cook, D. R.; Wong, M. (1992). Shame and its contribution to PTSD. Journal 
Of Traumatic Stress. 5(4). 557-562. 
r Cook, D. R. (1993). The Internalized Shame Scale Manual. Menominee, Wl: 
Channel. 
177 
Craig, R. J.; Olson, R. E.; & Shalaton, G. (1990). Improvement in psychological 
functioning among drug abusers. Journal of Substance Abuse Treatment 
ZOl 11-19. " —* 
Dansky, B.; Brady, K.; Saladin, M.; Killeen, T.; Becker, S.; & Roitzsch, J. (1996). 
Victimization and PTSD in Individuals with Substance Use Disorders: 
Gender and Racial Differences. American Journal of Drug Alcohol 
Abuse. 22m. 75-93. 
Darke, S.; Swift, W.; Hall, W. (1994). Prevalence, severity and correlates of 
psychological morbidity among methadone maintenance clients. 
Addiction. 89(2). 211-217. 
de Leon, G. (1993). What psychologists can learn from addiction treatment 
research. Psychology of Addictive Behaviors. 7(2). 103-109. 
Decker, K. P., & Ries, R. K. (1993). Differential diagnosis and 
psychopharmacology of dual disorders. Psychiatric Clinics of North 
America. 16(4). 703-718. 
Drake, R., & Wallach, M. (1989). Substance abuse among the chronic mentally 
ill. Hospital and community Psychiatry, 40(10). 1041-1046. 
Druschel, D. (1993). The relationship between internalized shame and suicide 
probability. Masters paper, University of Wisconsin-Stout. 
El-Guebaly, N. (1990). Substance abuse and mental disorders: The Dual 
diagnoses concept. Canadian Journal of Psychiatry. 35. 261-267. 
Ellen, P.; & Kammen, D. (1990). The Biological findings in post-traumatic stress 
disorder: A Review. Journal of Applied Social Psychology. 20. 1789- 
1821. 
Elson, M. (1977). The Kohut Seminars, New York: W. W. Norton & Company. 
Emery, O.; Emery, P.: Delek, S.; Quiana, N.; Jassani, A. (1991). Predisposing 
Variables in PTSD Patients. Journal of Traumatic Stress. 4(3), 325-343. 
Fenichel, Otto. (1994). Dynamics of addiction [Chapter]. Levin, D.; Weiss, R.; 
et al., (Eds.). The Dynamics and Treatment of Alcoholism: Essential 
Papers. Northville, NJ: Jason Aronson. 
178 
Field, T. M. (1985). Attachment as psychobiological attunement: Being on the 
same wavelength. In M. Reite & T. M. Fields (Eds.), The Psychobiology 
of Attachment and Separation. 
Firestone, L. (1991) The Firestone Voice Scale for self-destructive behavior 
Investigating the scale’s validity and reliability. Doctoral dissertation, 
California School of Professional Psychology, Los Angeles. 
Galvan, J. A. (1994). Shame and social phobia: Perspectives from object 
relations, Smith College. 
Gelinas, D. J. (1983). The persistent negative effects of incest. Psychiatry. 46. 
312-332. 
Genazzani, A. R., et al. (1982). Central deficiency of beta-endorphin in alcohol 
addicts. Journal of Clinical Endocrinology and Metabolism. Vol. 55. 583- 
586. 
Glover, H. (1992). Emotional numbing: A possible endorphin mediated 
phenomenon associated with post-traumatic stress disorders and other 
allied psychopathologic states. Journal of Traumatic Stress. 5(4), 
643-675. 
Glover, H. (1995). A Different Opinion Regarding the Use of Opiate Antagonists 
in PTSD: Comments on “An Unusual Reaction to Opioid Blockade with 
Naltrexone in a Case of Post-Traumatic Stress Disorder”. Journal of 
Traumatic Stress. 8(3), 483-489. 
Goodwin, J.; Cheeves, K.; & Connell, V. (1988). Defining a syndrome of severe 
symptoms in survivors of severe incestuous abuse. Dissociation 
Progress in the Dissociative Disorders, 1(4). 11-16. 
Goss, K,; Gilbert, P.; & Allan, S. (1994). An exploration of shame measures: I. 
The other as shame scale. Personality and Individual Differences. 17(5). 
713-717. 
Gossop, M., & Grant, M. (1991). A six country survey of the content and 
structure of heroin treatment programs using methadone. British Journal 
of Addiction. 86(01 1151-1160. 
Graziano, R. (1992). Treating women incest survivors: A bridge between 
"cumulative trauma" and "post-traumatic stress." Social Work in Health 
Care. 17(1). 69-85. 
179 
Hall, N., Altman, F., & Blumenthal, S., (Eds.). (1996). Mind-Body Interactions 
and Disease and Psvchoneuroimmunoloaical Aspects of Health and 
Disease. Health Dateline Press. 
Hazelton, S. E. (1986). Shame Faced. Hazelton Educational Materials. 
Helzer, J. E.; Robins, L. N.; & McEvoy, L. (1987). Post-traumatic stress disorder 
in the general population: Findings of the Epidemiologic Catchment Area 
survey. New England Journal of Medicine. 31 (26V 1630-1634. 
Hermann, J. (1992). Trauma and Recovery. New York: Basic Books. 
Hien, D., & Levin, F. (1994), Trauma and trauma-related disorders for women 
on methadone: Prevalence and treatment considerations. Journal of 
Psvchoactive Drugs. 26(41. 421 -429. 
Hudson, C. J. (1990). Anxiety disorders and substance abuse. Journal of 
Chemical Dependency Treatment, 3(2). 119-138. 
Ibarra, P.; Bruehl, S.; McCubbin, J.; Carlson, C.; Wilson, J.; Norton, J.; & 
Montgomery, T. (1994). An Unusual Reaction to Opioid Blockade with 
Naltrexone in a Case of Post-Traumatic Stress Disorder. Journal of 
Traumatic Stress. 7(2). 303-309. 
Joe, G. W.; Simpson, D. D.; & Hubbard, R. L. (1991). Treatment predictors of 
tenure in methadone maintenance. Journal of Substance Abuse. 3(1). 
73-84. 
Joe, G. W.; Simpson, D. D.; & Sells, S. B. (1994). Treatment process and 
relapse to opioid use during methadone maintenance. American Journal 
of Drug and Alcohol Abuse. 20(2), 173-197. 
Kahn, R. B. (1992). Methadone maintenance treatment: Impact of its politics 
on staff and patients. Journal of Psvchoactive Drugs, 24(3). 281-283. 
Kardiner, A. (1941). The Traumatic Neuroses of War. New York: Hoeber. 
Kaufman, E. (1989). The Psychotherapy of dually diagnosed patients. Journal 
of Substance Abuse Treatment. 6. 9-18. 
Kaufman, G. (1989). The psychology of shame: Theory and treatment of 
shame-based syndromes. New York: Springer. 
180 
Kaufman, J. (1992). Shame: The Power of Carina. Cambridge, MA: 
Schenkman. ' 
Kaufman, J. (1998). Overview of Opioid Pharmacotherapy: The Science of 
narcotic treatment. Heroin Addiction and Recovery Conference, 
Marlboro, MA. 
Keane, T. M., & Wolfe, J. (1990). Comorbidity in posttraumatic stress disorder: 
An analysis of community and clinical studies. Journal of Applied Social 
Psychology. 20(21), 1776-1788. 
Kendell, R. E. (1968). The classifications of depressive ilnesses. London, 
New York: Oxford Press. 
Kendell, R. E. (1991). The major functional psychoses: Are they independent 
entities or part of a continuum? Philosophical and conceptual issues 
underlying the debate. [Chapter] Kerr, A.; et al. (Ed.), Concepts of 
Mental Dissorder: A Continuing Debate. London, England: 
Gaskell/Royal College of Psychiatrists. 
Kenderdine, S. K.; Phillips, E. J.; & Scurfield, R. M. (1992). Comparison of the 
MMPI-PTSD subscale with PTSD and substance abuse patient 
populations. Journal of Clinical Psychology. 48fh. 136-139. 
Kemberg, Otto, (1984). Severe Personality Disorders: Psychotherapeutic 
Strategies. New Haven: Yale University Press. 
Kemberg, Otto, (1990). An ego psychology object relations theory approach 
to transference. (Chapter). Esman, A. (Ed.). Emotion. Psychopathology, 
and Psychotherapy. San Diego: Academic Press, Inc. 
Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: 
Focus on heroin and cocaine dependence. American Journal of 
Psychiatry, 142. 1259-1264. 
Khantzian, E.; & Shaffer, H. (1981). A Contemporary Psychoanalytic View of 
Addiction Theory and Treatment. In J. Lowinson and P. Ruiz (Eds.). 
Substance Abuse: Clinical Problems. Baltimore, MD: Williams & Wilkins 
Khantzian, E. J.; Halliday, K. S.; & McAuliffe, W. E. (1990). Addiction and the 
vulnerable self: Modified dynamic group therapy for substance abusers. 
New York: Guilford Press. 
181 
Kleber, H. D. (1989). Treatment of drug dependence: What works. Special 
Issue: Psychiatry and the addictions. International Review of Psvchiatrv 
1M-2). 81 -99. - 
Kofoed, L.; Friedman, M. J.; & Peck, R. (1993). Alcoholism and drug abuse in 
patients with PTSD. Psychiatric Quarterly. 64(21 151-171 
Kofoed, L.; Kania, J.; Walsh, T.; & Atkinson, R. (1986). Outpatient Treatment of 
Patients with Substance Abuse and Coexisting Psychiatric Disorders. 
American Journal of Psvchiatrv. 143(71 867-872. 
Kohut, H. (1972). Thoughts on narcissism and narcissistic rage. 
Psychoanalytic Study of the Child. 27. 360-400. 
Kohut, H. (1977). The Restoration of the Self, New York: International 
University Press. 
Koretsky, J. (1990). Leading the Recovery. Holmes Beach Florida: Learning 
Publications. 
Kosten, T. A; Bianchi, M. S.; & Kosten, T. R. (1992). The predictive validity of 
the dependence syndrome in opiate abusers. American Journal of Drug 
and Alcohol Abuse. 18(2V 145-156. 
Kosten, T. R.; Wahby, V.; Giller, E. L.; & Mason, J. W. (1990). The 
dexamethasone suppression test and thyrotropin-releasing hormone 
stimulation test in posttraumatic stress disorder. Biological Psvchiatrv. 
28(8), 657-664. 
Kugler, K., & Jones, W. H. (1992). On conceptualizing and assessing guilt. 
Journal of Personality and Social Psychology. 62(2L 318-327. 
Krystal, H.; & Raskin, H. (1994). Affect tolerance. The dynamics and treatment 
of alcoholism: Essential papers. Northvale, NJ: Jason Aronson (pp. 158- 
175). 
Krystal, H.; & Raskin, H. A. (1970). Drug dependence: Aspects of ego 
functions. Detroit: Wayne State University Press. 
Krystal, J. H. (1994). Alcohol dependence may be the missing link between 
posttraumatic stress disorder and panic. Archives of General Psvchiatrv. 
51 (5), 430. 
182 
Larson, J. (1997). Seven Weeks to Sobriety: The Proven Program to Fight 
Alcoholism Through Nutrition. New York, NY: Fawcett Columbine Book 
Group. 
Linn, L. S. (1972). Physician characteristics and attitudes toward legitimate use 
of psychotherapeutic drugs. Conference Paper. New York: AMS Press. 
Litz, B. T.; Penk, W. E.; Walsh, S.; Hyer, L.; et al. (1991). Similarities and 
differences between MMPI and MMPI-2 applications to the assessment of 
posttraumatic stress disorder. Journal of Personality Assessment. 57(2). 
238-253. 
Lynd, H. (1959). On Shame and the Search for Identity. Harcourt Press. 
Maddux, J. F., & Desmond, D. P. (1992). Methadone maintenance and 
recovery from opioid dependence. American Journal of Drug and Alcohol 
Abuse. 18(1). 63-74. 
Maddux, J. F., & Desmond, D. P. (1992). Ten-year follow-up after admission to 
methadone maintenance. American Journal of Drug and Alcohol Abuse. 
18(3). 289-303. 
Maremanni, L; Nardini, R.; Zolesi, O.; & Castrogiovanni, P. (1994). Methadone 
dosages and therapeutic compliance during methadone maintenance 
programs. Drug and Alcohol Dependence. 34(2), 163-166. 
McLellan, A.; Luborsky, L.; Woody, G.; Druley, K.; & O'Brien, C. P. (1983). 
Predicting response to alcohol and drug abuse treatments: Role 
psychiatric severity. Archives in General Psychiatry. 40. 620-625. 
McLellan, A. T. (1986). Psychiatric Severity As a Predictor of Outcome from 
Substance Abuse Treatments: Psychopathology and Addictive Disorders. 
New York: Guilford. 
Miller, D. (1994). Women Who Hurt Themselves: A Book of Hope and 
Understanding. New York, NY: Basic Books. 
Miller, L. (1994). Neuropsychodynamics of alcoholism and addiction: 
Personality, psychopathology, and cognitive style. Journal of Substance 
Abuse Treatment. 7(1). 31-49. 
Millman, R. 1986). Considerations on the psychotherapy of the substance 
abuser. Journal of Substance Abuse Treatment. 3. 103-109. 
183 
Minkoff, K. (1989). An integrated treatment model for dual diagnosis of 
psychosis and addiction. Hospital and Community Psvchiatrv 40(10) 
1031-1036. — 
Moolchan, E. T., & Hoffman, J. A. (1994). Phases of treatment: A practical 
approach to methadone maintenance treatment. International Journal of 
the Addictions. 29(21 135-160. 
Mulinski, P. (1989). Dual diagnosis in alcoholic clients: Clinical implications. 
Social Casework. 70(61 333-339. 
Nathanson, D. (1987). A timetable for shame. In D,. L. Nathanson (Ed.). 
The many faces of shame. New York: Guildord. 
Nathanson, D. (1988). Affect, affective resonance and a new theory for 
hypnosis. Psychopathology, 21(2-31 126-137. 
Nathanson, D. L. (1989). Understanding what is hidden: Shame in sexual 
abuse. Psychiatric Clinics of North America. 12(2) 381-388. 
Nathanson, D. L. (1992). The nature of therapeutic impasse. Psychiatric 
Annals. 22(10). 509-513. 
Nathanson, D. L. (1992). Shame and pride: Affect, sex and the birth of the self. 
New York: Norton. 
Nathanson, D. L. (1993). About emotion. Psychiatric Annals. 23(102). 543-555. 
Nathanson, D. L. (1993). Affect theory and psychopharmacology. Psychiatric 
Annals. 23(10). 584-593. 
Nathanson, D. L. (1994). Shame, compassion, and the "borderline" personality. 
Psychiatric Clinics of North America. 17(4). 785-810. 
Nathanson, D. L. (1994). Shame Transactions. Transactional Analysis Journal, 
24(2). 121-129. 
Neal, L. A.; Busuttil, W.; Rollins, J.; Herepath, R.; et al. (1994). Convergent 
validity of measures of post-traumatic stress disorder in a mixed military 
and civilian population. Journal of Traumatic Stress. 7(3). 447-455. 
Nebelkopf, E. (1989). Innovations in drug treatment and the therapeutic 
community. International Journal of Therapeutic Communities. 10(1), 
39-52. 
184 
O’Malley, S. S.; Kosten, T. R.; & Renner, J. A. (1990). Dual diagnoses: 
Substance abuse and personality disorders. New Directions for Mental 
Health Services. 47. (Fain. 115-137. 
Osher, F.f & Kofoed, L. (1989). Treatment of patients with psychiatric and 
psychoactive substance abuse disorders. Hospital and Community 
Psychiatry, 40(101. 1025-1030. 
Payte, J. T. (1991). A brief history of methadone in the treatment of opioid 
dependence: A personal perspective. Journal of Psvchoactive Drugs. 
23(2). 103-107. 
Penk, W. E.; Rabinowitz, R.; Black, J.; Dolan, M. P.; et al. (1989). Co-morbidity: 
Lessons learned about post-traumatic stress Disorder from developing 
PTSD scales for the MMPI. Journal of Clinical Psychology. 45(5. Mono 
Supple). 709-717. 
Perlman, M. (1958). An investigation of anxiety as related to guilt and shame. 
Archives of Neurological Psychiatry. 80. 742-759. 
Potter-Efron, R. T. (1989). Differential diagnosis of physiological, psychiatric 
and sociocultural conditions associated with aggression and substance 
abuse. Journal of Chemical Dependency Treatment. 3(1). 37-59. 
Rawson, R. A., & Ling W. (1991). Opioid addiction treatment modalities and 
some guidelines to their optimal use. Journal of Psvchoactive Drugs. 
23(2). 151-163. 
Reno, R. R.; & Aiken, L. S. (1993). Life activities and life quality of heroin 
addicts in and out of methadone treatment. International Journal of the 
Addictions. 28(3). 211-232. 
Restak, R. (1979). The Brain. New York: Warner Books. 
Reuter, P. (1994). Identifying new policy trade offs. Addictions. 89(7). 806-807. 
Ritchey, M. T. (1991). Object relational aspects of shame internalization, Smith 
College. 
Rosenberg, M. (1965). Society and the adolescent self-image. Princeton, NJ: 
Princeton University Press. 
185 
Rossi, E. (1993). The Psychobiology of Mind-Bodv Healing. New York: W. W. 
Norton & Company. 
Rowan, A. (1993). Post-Traumatic StressDisorder in Child Sexual Abuse 
Survivors: A Literature Review. Journal of Traumatic Stress. 6(1 V 3-2Q. 
Rutherford, M. J.; Cacciola, J. S.; Alterman, A. I. (1994). Relationships of 
personality disorders with problem severity in methadone patients. Drug 
and Alcohol Dependence, 35(h. 60-76. 
Salloway, S.; Southwick, S. M.; & Sadowsky, M. (1990). Opiate withdrawal 
presenting as posttraumatic stress disorder. Hospital and Community 
Psychiatry. 41f6V 666-667 
Saunders, B.; Arata, C., Kilpatrick, D. (1990). Development of a crime-related 
post-traumatic stress disorder scale for women within the symptom 
checklist-90-revised. Journal of Traumatic Stress. 3(31 439-447. 
Saxe, G. N.; Van der Kolk, B. A.; Berkowitz, R;. Chinman, G.; et al. (1993). 
Dissociative disorders in psychiatric inpatients. American Journal of 
Psychiatry, 15Q(7L 1037-1042. 
Schore, A. (1994). Affect Regulation and the Origin of the Self. New Jersey: 
Lawrence Erlbaum Associates. 
Shaffer, H. J., & LaSalvia, T. A. (1992). Patterns of substance use among 
methadone maintenance patients: Indicators of outcome. Journal of 
Substance Abuse Treatment. 9(2). 143-147. 
Shreve, B. W. (1987). Constructing a measure of shame-proneness and its 
Relation to treatment outcome for hospitalized suicidal individuals. 
Doctoral Dissertation, University of Tennessee. 
Silver, S. M., & Salamone-Genovese, L. (1991). A study of the clinical and 
research scales for post-traumatic stress disorder diagnostic utility. 
Journal of Traumatic Stress. 4(4), 533-548. 
Stark, M. J. (1989). A psychoeducational approach to methadone maintenance 
treatment. Journal of Substance Abuse Treatment. 6(3). 169-181. 
Strain, E. C.; Stitzer, M. L.; Liebson I, A.; & Bigelow, G. E. (1993). Methadone 
dose and treatment outcome. 53rd Annual Scientific Meeting of the 
Committee on Problems of Drug Dependence. Drug and Alcohol 
Dependence, 33(2), 105-117. 
186 
Strain, E. C.; Stitzer, M. L; Liebson, I. A.; & Bigelow, G. E. (1994). Outcome 
after methadone treatment: Influence of prior treatment factors and 
current treatment status. Drug and Alcohol Dependence. 35(31 223-230. 
Strain, E. C.; Brooner, R. K.; & Bigelow, G. E. (1991). Clustering of multiple 
substance use and psychiatric diagnoses in opiate addicts. Drug and 
Alcohol Dependence. 27(2\. 127-134. 
Talbert, F. S.; Albrecht, N. N.; Albrecht, J. W.; Boudewyns, P. A.; et al. (1994). 
MMPI profiles in PTSD as a function of comorbidity. Journal of Clinical 
Psychology, 50(41 529-537. 
Tomkins, S. S. (1987). Shame. In D. L. Nathanson (Ed.). The Many Faces of 
Shame. New York: Guilford. 
Tomkins, S. S. (1963). Affect. Imagery. Consciousness: The Negative Affects. 
New York: Springer. 
Triffleman, E., G.; Marmar, C. R.; Delucchi, K.; Ronfeldt, H. (1995). Childhood 
trauma and posttraumatic stress disorder in substance abuse inpatients. 
Journal of Nervous and Mental Disease. 183(3). 172-176. 
Twerski, A. J. (1989). Diagnosing and treating dual disorders. Alcoholism and 
Addiction. 37-40. 
Valliant, G. (1993). Natural History of Alcoholism: Causes. Patterns, and Paths 
to Recovery. Cambridge, MA: Harvard University Press. 
Van der Kolk. (1987). Psychological Trauma. Washington, DC: American 
Psychiatric Press. 
Van der Kolk, B.; McFarlane, A.; & Weisaeth, L. (Ed.). (1996). Traumatic Stress. 
New York: Guilford Press. 
Van der Kolk, B. A.; & Saporta, J. (1993). Biological response to psychic 
trauma. In J. P. Wilson & B. Raphael (Eds.), International Handbook of 
Traumatic Stress Syndromes. New York: Plenum Press. 
Vereby, K. (1978). Endorphins in psychiatry: An overview and a hypothesis. 
Archives of General Psychiatry. 35(7). 877-888. 
Wallace, J. (1985). Alcoholism: New Light on the Disease. Newport: Edgehill 
Publications. 
187 
Wang, D.; Wand, Y.; & Zhang, Y. (1992). The relationship between locus of 
control, depression, shame, and self-esteem, Chinese Mental Health 
Journal. 6(51 207-210. 
Warsaw, M. G.; Fierman, E.; Pratt, L.; Hunt, Molly; et al. (1993). Quality of life 
and dissociation in anxiety disorder patients with histories of trauma or 
PTSD. American Journal of Psychiatry. 150(101 1512-1516. 
Weathers, F.; Litz, B.; Keane, T.; Herman, D.; Steinberg, H.; Huska, J.; & 
Kraemer, H. (1996). The Utility of the SCL-90 for the diagnosis of war- 
zone related post-traumatic stress disorder. Journal of Traumatic Stress, 
9(1). 11-128. 
Weddington, W. W. (1991). Towards a rehabilitation of methadone 
maintenance. International Journal of the Addictions. 25(9A-10A), 
1201-1224. 
Wick, J. (1998, May/June). Medical concerns of heroin users. The Counselor, 
8, 15-19. 
Wilson, K. (1994). Women’s Alcoholism: The Role of Internalized Shame and 
Attitudes toward Female Intoxication, Unpublished doctoral dissertation, 
Smith College. 
Wong, M. R., & Cook, D. (1992). Shame and its contribution to PTSD. Journal 
of Traumatic Stress. 5(4), 557-562. 
Wood, S. (In process). Object relations: Symptoms of psychological distress 
and methadone treatment outcome. Doctoral dissertation, Smith College, 
Massachusetts. 
Woody, G. E.; McLellan, A. T.; Luborsky, L.; & O'Brien, C. P. (1990). 
Psychotherapy and counseling for methadone-maintained opiate addicts: 
Results of research studies. National Institute on Drug Abuse Research 
Monograph Series. Research Mono 140, 9-23. 
Woody, G. C.; Luborsky, L.; Mclellan, A. T.; & O'Brien, C. P. (1988). 
Psychotherapy for substance abuse. 50th Annual Scientific Meeting of 
the Committee on Problems of Drug Dependence. National Institute on 
Drug Abuse Research Monograph Series. Mono 90, 162-167. 
Woody, G.; Luborsky, L.; McLellan, T.; O'Brien, C.; Beck, A.; Blain, J.; Herman, 
L; & Hole, A. (1983). Psychotherapy for opiate addicts. Archives of 
General Psychiatry. 40. 639-645. 
188 
Wurmser, L. (1994). Psychodynamics in compulsive drug use. In J. Levin and 
R. Weiss (Eds.). The dynamics and treatment of alcoholism: Essential 
papers. Northvale, NJ: Jason Aronson, pp. 176-205. 
Wurmser, L. (1981). The Mask of Shame. Baltimore: Johns Hopkins University 
Press. 
Wurmser, L. (1974). Psychoanalytic considerations of the etiology of 
compulsive drug use. Journal of American Association. 22. 820-843. 
Zinberg, N. E. (1975). Addiction and ego function. The Psychoanalytic Study of 
the Child. 30, 567-588. 
Zwebem, J. E. (1998). Opioid maintenance therapy for heroin addiction. The 
Counselor. 8. 31-33. 
Zweben, J. E. (1989). Considerations in using psychotropic medication with 
dual diagnosis patients in recovery. Journal of Psvchoactive Drugs, 
21(2). 221-227. 
Zweben, J. E. (1991). Counseling issues in methadone maintenance treatment. 
Journal of Psvchoactive Drugs. 23(2). 177-190. 
Zweben, J. E.; Smith, D.; & Stewart, P. (1991). Psychotic conditions and 
substance use: Prescribing guidelines and other treatment issues. 
Journal of Psvchoactive Drugs. 23(4). 387-395. 
189 


